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Ageing is the greatest risk factor for most forms of dementia. Variant 
Creutzfeldt-Jakob Disease (vCJD) however is predominantly a disease of 
younger adults and sporadic CJD (sCJD), although a disease of the older 
population, mainly affects those under 80 years of age. The very low age-
specific incidence of both vCJD and sCJD in the oldest age group may, in 
part, be due to case under ascertainment, perhaps due to a lack of familiarity 
with CJD, or atypical clinical presentation of CJD  
 
In the UK, suspect cases of CJD are referred by clinicians to the National CJD 
Research & Surveillance Unit (NCJDRSU) for clinical assessment and 
epidemiological review. Case ascertainment in CJD is important not only for 
appropriate clinical care but also, due to the potential for person-to-person 
transmission of the CJD agent through medical procedures, to help protect 
public health. In this thesis: 
 
1) I describe the clinical and referral characteristics of CJD patients diagnosed 
later in their disease progression and determine if these characteristics differ 
in those diagnosed earlier. A retrospective review of CJD cases referred to 
the NCJDRSU, for vCJD between 1995 and 2015 (n = 177) and for sCJD 
between 2010 and 2015 (n = 584) was undertaken. Age was significantly 
associated with timing of diagnosis, with later diagnoses occurring in older 
patients, and differences in clinical and referral characteristics between these 




2) I also pilot a study of enhanced CJD surveillance in the older population. 
Since January 2016, patients aged 65 years seen in NHS Lothian with a 
diagnosis of non-CJD dementia but with atypical features (e.g. rapid speed of 
progression or focal neurology) have been invited to participate in a study to 
investigate whether atypical CJD might underlie the diagnosis of some 
patients with dementia. For each participant, a clinical examination was 
undertaken, with consent, including Addenbrooke’s Cognitive Examination–III, 
the frontal assessment battery, the hospital anxiety and depression scale, 
Barthel’s Index, and the Edinburgh Motor Assessment Scale. In addition, MRI 
was undertaken (including DWI and FLAIR sequences), a blood sample was 
taken for codon-129 subtyping and patients were consented for donation of 
brain tissue in the event of their death. Ten patients were recruited during the 
initial 6 months of study. Although patients had individual features of CJD 
there was no evidence of CJD clinically. No patients however reached post-
mortem during this initial study period.  Barriers to referral, including clinician 
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Creutzfeldt-Jakob Disease (CJD) is a rare but important form of dementia, not 
least due to its potential for secondary transmission in the healthcare setting. 
All forms of CJD are important, however, variant CJD (vCJD) has specific 
implications due to particular infectivity of tissues outwith the central nervous 
system. Whilst there has been a decline in the number of patients diagnosed 
with vCJD over the last decade, significant public health concerns remain and 
CJD surveillance is as important now as it has ever been.  
 
This thesis will consider CJD with a particular focus on older patients, and 
specifically whether cases of CJD in older patients may be missed by current 
surveillance activities.  
 
1.2 Dementia  
Dementias are generally persistent and, for the majority, progressive 
syndromes commonly associated with neurodegeneration. A number of types 
of dementia (or syndromes) exist, all with the core feature of a decline from 
previous functioning. The Diagnostic and Statistical Manual of Mental 
Disorders – 5th edition (DSM – V) definition of dementia (now termed ‘major 
neurocognitive disorders’) is detailed in Box 1. 
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Box 1:  DSM-V criteria for the diagnosis of major neurocognitive 
disorders (2013) [1] 
 
1. Evidence of significant cognitive decline from a previous level of 
performance in one or more cognitive domains (complex attention, 
executive function, learning and memory, language, perceptual-motor, 
or social cognition) based on: i) concern of the individual, a 
knowledgeable informant, or the clinician that there has been a 
significant decline in cognitive function and ii) a substantial impairment 
in cognitive performance, preferably documented by standardised 
neuropsychological testing or, in its absence, another quantified clinical 
assessment.  
2. The cognitive deficits interfere with independence in everyday activities 
(ie, at a minimum, requiring assistance with complex instrumental 
activities of daily living such as paying bills or managing medications).  
3. The cognitive deficits do not occur exclusively in the context of a 
delirium.  
4. The cognitive deficits are not better explained by another mental 
disorder (eg, major depressive disorder, schizophrenia). 
 
The global prevalence of dementia in 2015 was estimated to be 46.8 million, 
with an estimated overall incidence of 17.3 cases per 1,000 person years in 
those aged 60 years (equating to approximately 9.9 million new cases per 
year) [2]. In the United Kingdom (UK), the overall prevalence and incidence in 
those aged 65 years in 2015 was estimated to be 670,000 and 17.7 per 
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1,000 person years (equating to just under 210,000 new cases per year) 
respectively [3, 4].  
 
The incidence of dementia has been demonstrated to rise with age both in the 
UK and globally (Figure 1) [2, 5]. However, in some less commonly 
encountered dementias this exponential relationship is not seen and a fall in 
age-specific incidence can occur in older patients [6, 7]. It is not clear whether 
this observation is a true epidemiological feature or whether it reflects under-
recognition of dementia, perhaps as a consequence of less thorough 
investigation of cognitive symptoms in older patients.   
 
Figure 1: Estimated age specific incidence of dementia; World Alzheimer 
Report (2015) (permission for use granted) [5] 
 
HIC: High income countries LMIC: lower middle income countries 
 
The global prevalence of dementia is predicted to increase by almost three 
fold by 2050, predominantly due to a rising number of cases in low to middle 
income countries (most likely reflecting global demographic changes) [2]. High 
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income countries (including the UK), however has seen a decline in incidence 
of all cases of dementia in those aged 65 years between 1991 and 2011 [4]; 
reasons for this are not clear, although it may reflect cardiovascular-targeted 
public health measures [2] and improving literacy / educational attainment in 
recent generations [8, 9]. This observed decline should not however 
underestimate the predicted societal impact of dementia in the UK; dementias 
are associated with increased rates of hospital admissions [10] and 
institutional care [11], which, given the UK’s ageing population poses 
significant future economical burden. 
 
1.3 Dementia diagnosis and the older population 
Dementia can be caused by a range of pathologies. These pathologies are 
associated with clinical syndromes. The relative percentage of dementia 
syndromes in all age groups in the UK is demonstrated in Figure 2. In all age 
groups, the most common form of dementia is Alzheimer’s dementia, 
accounting at least in part for 65-70% of all diagnoses [12, 13]. Other 
conditions, driven by differing pathological substrates, also contribute to 
dementia.  Each of these can be diagnosed according to well-established 
consensus diagnostic criteria ([6, 14-17]) and are described in more detail in 
Appendix A. Symptoms affecting patients include memory disturbance but 
also deficits in other cognitive domains including language, behaviour and 
visuospatial functioning.  Discriminating between the causes of dementia is 
challenging with histopathological (or genetic) analysis remaining the gold 
standard.  
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Figure 2: Relative percentage of dementia subtypes in the U.K., all ages 
(2014) [18] 
 
PD – Parkinson’s disease; FTD – frontal temporal dementia; DLB – dementia with Lewy 
Bodies; VD – vascular dementia; AD – Alzheimer’s dementia 
 
Discriminating between the different subtypes of dementia in any age group is 
important; it allows for timely evaluation of potentially reversible conditions 
and for earlier consideration of the potential role for therapeutic interventions. 
Importantly, it also allows for planning with an increased likelihood the patient 
will be able to participate in discussions regarding their own future care.  
 
The diagnosis of a dementia however has its challenges. These include: 1) 
patient recognition of symptoms; 2) the clinical challenge of attributing 





FTD, 2% PD, 2%
Other, 3%
Percentage	of	dementia	subtypes	in	the	U.K.
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daily functioning; and 3) establishing the underlying pathophysiology of 
patients’ deficits. Both these challenges have additional factors to consider in 
the older population. Firstly, approximately 50% of individuals with dementia 
are not registered as such on primary care registries [2, 19, 20]; those who 
are older are more likely to be missed [19, 21, 22]. A number of reasons 
suggested as to why this may be the case are detailed in Box 2.  Even where 
dementia is identified, however, consensus criteria for the pathophysiological 
classification of the dementia often lack utility in clinical practice as criteria are 
generally designed for recruitment to research trials and therefore favour 
specificity over sensitivity. This is of particular relevance in older patients, for 
the following reasons: 
 
1) The relative high prevalence of common dementias.  
In general the more common forms of dementia (i.e. Alzheimer’s dementia) 
are over-diagnosed in older patients and the less common forms, under-
diagnosed [6, 21, 23, 24]  
 
2) The prevalence of mixed pathology in older patients.  
Almost half of older patients with a diagnosis of dementia had evidence of 
multiple pathologies (generally mixed Alzheimer’s pathology and 
atherosclerosis) at post-mortem [25]   
 
3) An increased likelihood of dissociation of pathology and typical phenotype.  
In older patients without a clinical diagnosis of dementia, 49% have been 
found to have pathological changes at post-mortem that fulfilled the diagnostic 
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criteria for Alzheimer’s dementia [26] with 3% found to have Lewy Bodies [27]. 
Conversely, 22% of older patients with a clinical diagnosis of dementia had no 
neuropathological features of dementia at post-mortem [26].  
 
4) The low rate of post-mortem in older patients.  
Confirmation of a diagnosis of a particular cause of dementia can only be 
reached with post-mortem histopathological examination of brain material / a 
brain biopsy in life (or identification of a disease causing genetic mutation). 
The general rate of post-mortem, however, is in decline [28, 29] with <1% of 
deaths now reaching hospital post-mortem in the UK [30]. Post-mortem rates 
are lowest in the elderly [29], making it difficult to establish numbers of cases 
(outwith research cohorts), leading to a limited understanding of both clinical 
features and investigation interpretation in older patients. These problems are 
particularly pertinent in the less commonly encountered types of dementia, 
such as prion disease.  
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Box 2: Possible reasons for missed cases of dementia in the elderly 
 Risk factors for delayed presentation more common in elderly 
(depression / lower socioeconomic status / social isolation [19, 21, 31])  
 Cognitive symptoms may be misattributed to normal ageing [32] 
 Confounding factors more common in elderly (polypharmacy, remote or 
current alcohol excess, or poor nutrition) [22, 33] 
 Physical co-morbidities are common in elderly; these may be given 
priority with time / financial constraints limiting full attention to cognitive 
symptoms [22, 33]. 
 Poor access to healthcare (physical reasons (e.g. transport), co-
morbidities (e.g. pacemaker excluding MRI, anticoagulation limiting 
lumbar puncture etc.), or a lack of awareness of resources in a less 
internet savvy / informed generation) [22, 33]. 
 More likely to be seen by generalists less confident in differentiating 
between abnormal and normal cognitive ageing [22].  
 
 
1.4 The prion hypothesis 
Prion diseases are neurodegenerative and universally fatal conditions. They 
are characterised by a post-translational structural change of the naturally 
occurring prion protein (PrPC) resulting in tissue deposition of an abnormal, 
mis-folded, and partially protease-resistant form (PrPSc).   
 
The normal PrPC is found in most tissues throughout the body however is 
found in highest concentrations in the central nervous system and 
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lymphoreticular system. The prion-only hypothesis states that all that is 
required for propagation of the diseased form of the prion protein is the 
presence of PrPSc and PrPC.  PrPC is recruited as the substrate with 
conformational change to PrPSc in an autocatalytic manner [27].  
 
Prion diseases were originally described in animals (with the prototypic illness 
of scrapie in sheep and goats) with later description in humans. 
 
1.5 Human prion diseases 
Human prion diseases consist of Creutzfeldt-Jakob disease (CJD), the most 
common form, comprising sporadic, genetic, iatrogenic types (including 
variant CJD [vCJD: a much less commonly encountered acquired form], and 
Kuru [a historical disease affecting a small part of Papua New Guinea]) and 
two relatively distinct genetic forms: Gerstmann-Sträussler-Scheinker 
syndrome & Fatal Familial Insomnia. A more recently described form of 
uncertain nosology is Variably Protease Sensitive Prionopathy (VPSPr). This 
review will focus on CJD, and in particular sporadic and variant CJD. 
 
Creutzfeldt-Jakob Disease (CJD) was first described by the neuropathologist, 
Hans Gerhard Creutzfeldt and neurologist, Alfons Jakob in 1920. It is a highly 
heterogeneous disorder categorised according to aetiology with differing 
associated clinicopathological and epidemiological characteristics. There are 
however key commonalities between all forms of CJD: 
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a) Clinical features.  
Common to all forms of CJD is a characteristic, usually rapidly progressive, 
intellectual and multifocal neurological decline converging on a terminal 
akinetic mute stage. In general this is shortest in sporadic and longest in 
variant and some inherited forms.  
 
b) Codon-129 expression.  
Disease susceptibility and phenotypic expression of all forms of CJD are 
mediated by expression of either methionine or valine at codon-129 on the 
prion gene (PRNP) on chromosome 20. A significant excess of methionine 
homozygotes are seen; in the normal UK population, 44.1% are homozygous 
for methionine, however, 61.5 – 67% of sCJD and 99.4% of vCJD cases 
tested were methionine homozygotes [7, 34, 35].   
 
c) Neuropathological appearances.  
Core features include spongiform change, reactive proliferation of astrocytes 
and microglia, neuronal loss, + / - amyloid plaque deposition. The spongiform 
change is seen within the neuronal processes throughout the cerebral cortex, 
and also commonly in other grey matter structures such as the basal ganglia 
and thalamus. Demonstration of the abnormal isoform, PrPSc, by 
immunohistochemistry is also a key diagnostic feature seen in all forms [36].  
 
d) Transmissibility and public health considerations.  
All forms of CJD are potentially transmissible, making them unique amongst 
the neurodegenerative disorders. Further to this, PrPSc is resistant to standard 
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autoclaving and sterilisation procedures of surgical equipment. This combined 
with a lack of a pre-clinical diagnostic / screening test furthers the unique 
implications for public health posed by CJD  
 
1.  Sporadic CJD 
Sporadic CJD (sCJD) is the most common form of CJD, accounting for >80% 
of all cases. It is a disease of older patients, affecting those mostly in their late 
60s and early 70s, with the median age of onset of 67 years. Cases as young 
as 15 years old and as old as 94 years have, however, been reported [7].  
 
The exact aetiology of sCJD is unknown. Theories include the spontaneous 
production of PrPSc via a random (as yet undetermined) event, the somatic 
mutation of the prion gene (PRNP), or exposure to an as yet unidentified 
exogenous source of infection. Given what is known about the epidemiology 
of sCJD, the last of these is unlikely to be the general explanation for sCJD 
cases, however it is difficult to exclude as the cause of at least some cases.   
 
sCJD is characterised by a rapidly progressive dementia associated with 
multifocal neurological decline (including ataxia, visual disturbance, pyramidal 
and extrapyramidal features with later myoclonus and akinetic mutism). The 
median duration of illness is 4 months (range 1 to 74 months). Approximately 
60% of UK patients will die within 6 months of symptom onset [7]. 
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Internationally accepted diagnostic criteria are as detailed in Box 3, and have 
been recently updated to incorporate the CSF prion protein biomarker, RT-
QuIC. 
 
Box 3: Internationally agreed diagnostic criteria for sCJD (as of 31st 
December 2015) [37] 
 
 
Worldwide, the annual mortality rate from sCJD is 1-2 cases/million/year [6]; 
in the UK this increases to 4-5 cases/million/year in those over 65, and then 
declines, with few cases in those 80 years old (Figure 3). These figures are 
comparable to other countries with established CJD surveillance centres. 
Similar to other centres also are the age, sex, codon-129 distribution, and the 
rise seen in the age specific mortality rates of sCJD, particularly in older 
patients [38, 39]. 
 
sCJD 
I Rapidly progressive cognitive impairment 
II A     Myoclonus 
   B Visual or cerebellar problems 
   C Pyramidal or extrapyramidal features 
   D Akinetic mutism 
III Typical EEG 
IV High signal in caudate/putamen on MRI brain scan    
 
DEFINITE:  
Progressive neurological syndrome AND Neuropathologically OR 
immunocytochemically OR biochemically confirmed 
 
PROBABLE: 
I + 2 of II and either typical EEG OR typical MRI brain scan OR positive 14-




I + 2 of II + duration <2 years 
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Figure 3: Age specific mortality rates from sporadic CJD in the UK (1970 
– 2014) - As taken from the NCJDRSU 23rd Annual report (2015) [7] 
  
 
2. Variably protease sensitive prionopathy 
A newly recognised prion disease has been described: variably protease 
sensitive prionopathy (VPSPr) [40]. The nosological status of this disease is 
uncertain however it is most likely a subtype of sporadic CJD.  
 
The frequency of VPSPr in the general population is not known and some 
reported cases are hard to distinguish from more common dementing 
illnesses without neuropathological examination.  
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The literature describing clinical features is limited to small case series 
meaning it is difficult to draw general conclusions, however like other forms of 
CJD, VPSPr presents as a relatively rapid onset dementia with associated 
neuropsychiatric features [40]. Unlike vCJD and sCJD, however, the majority 
of cases are homozygote for valine at codon-129.  
 
3. Genetic prion disease 
Approximately 10-15% of human prion diseases are due to autosomal 
dominantly inherited mutations on PRNP [41].   
 
There are 3 recognised forms of genetic prion disease: genetic (previously 
familial) CJD (gCJD); fatal familial insomnia (FFI) and Gerstmann-Sträussler-
Scheinker disease (GSS) (see Table 1).  
 
There is considerable variability in the frequency of different genetic mutations 
dependent on country of origin and ethnicity, however, overall the most 
common mutation is the point mutation, E200K (which accounts for 70% of 
cases of gCJD in the UK [41]). Like most forms of CJD, all forms of inherited 
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Table 1: Inherited CJD (Adapted from Genetic prion disease: the 
















GSS No 70 30 10 50 
FFI No 90 20 <5 20 
E200K Yes 50 45 70 90 
V210I Yes 10 15 80 95 
 
4. Iatrogenic CJD 
CJD may rarely be attributable to iatrogenic exposure (iCJD). The main 
sources of infection have been past exposure to human growth hormone and 
dura mater grafts. Rarely contaminated neurosurgical instruments, corneal 
grafts and gonadotrophins have been implicated [42]. 
 
In the UK, 85 cases were reported between 1970 and 2015, with the vast 
majority (99% of cases) due to contaminated human growth hormone (hGH) 
(n = 76) and contaminated dura mater grafts (n = 8). Case numbers peaked in 
the late 1990s and have continued to fall since.  
 
In general, patients present with a cerebellar syndrome (or visual disturbance 
in dura mater cases) followed by cognitive and multifocal neurological decline. 
The mean age at death for hGH-derived iCJD in the UK is 35 years old (range 
20 – 51 years) with a mean incubation period of 20 years. Dura mater-derived 
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cases have a later mean age at death of 46.5 years old (range 27 – 78 years) 
with a shorter incubation period of 12 years [42]. 
 
Allele expression at codon-129 influences both disease susceptibility and 
incubation period of iCJD. Those who present earlier are over-represented by 
methionine homozygotes with a later ‘second wave’ of heterozygote cases. 
This is consistent with other acquired forms of prion disease (e.g. Kuru) [43, 
44]. 
 
5.  Variant CJD 
In 1996 the first cases of variant CJD (vCJD) were described in the UK [45]. In 
total 178 cases of vCJD have been reported between 1996 and December 
2017 [6].  The majority of cases have been causally linked to bovine 
spongiform encephalopathy (BSE) epidemiologically and through molecular 
analysis and strain linkage of PrPSc [46, 47]. Three cases have however been 
associated with infection via contaminated non-leucodepleted red blood cells, 
with two further instances of transmission of infection identified in 
asymptomatic recipients of blood/blood products from a donor who 
subsequently developed vCJD [48, 49]. 
 
Variant CJD is characterised by an insidious onset of behavioural change, 
psychiatric symptoms and sensory disturbance, followed by cognitive decline 
and ataxia with later myoclonus and terminal decline into akinetic mutism. 
Internationally accepted diagnostic criteria are as detailed in Box 4. The 
median duration of illness is longer than sCJD at 14 months (range 6 – 114 
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months). Distinct from other human forms of CJD (where infectivity is mostly 
limited to the central nervous system), PrPSc can also be detected within the 
lymphoreticular system posing unique public health concerns with cases, as 
above, transmitted via blood products.  
 
Box 4: Internationally agreed diagnostic criteria for vCJD (as of 31st 
December 2015) [37] 
 
 
Whilst the general pathology of vCJD is similar to other human prion 
diseases, the neuronal loss is particularly severe within the pulvinar region 
I  
A Progressive neuropsychiatric disorder  
B Duration of illness > 6 months 
C Routine investigations do not suggest an alternative diagnosis  
D No history of potential iatrogenic exposure  
E No evidence of a familial form of TSE  
 
II  
A Early psychiatric symptoms 
B Persistent painful sensory 
C Ataxia 
D Myoclonus or chorea or dystonia  
E Dementia  
 
III  
A EEG does not show the typical appearances of sCJD in the early stages of 
illness  
B Bilateral pulvinar high signal on MRI scan  
 
IV Positive tonsil biopsy 
 
DEFINITE: 1A and neuropathological confirmation of vCJD 
 
PROBABLE: I and 4/5 of II and IIIA and IIIB  
Or I and IV A 
 
POSSIBLE: I and 4/5 of II and III A  
The influence of age on case ascertainment in CJD 
 
Chapter 1: Dementia and prion disease in the older population	 18
giving rise to distinct MRI characteristics and possibly the sensory symptoms 
characteristic of vCJD. The pattern of deposition of PrPSc is characteristically 
different to sCJD and highly conserved between cases of vCJD [50].  
 
In general, vCJD is a disease of the young, with the median age of onset 
younger than sCJD at 26 years old (Figure 4) although cases as young as 12 
years old, and older cases, up to 74 years old, have been reported. [7].  
 
Figure 4: Age specific incidence of variant CJD in men and women (1996 
– 2014) - As taken from the NCJDRSU 23rd Annual report (2015) [7] 
 
 
As discussed in iCJD, allele expression at codon-129 influences incubation 
period in acquired cases of prion disease with methionine homozygotes 
generally presenting earlier and a later, ‘second wave’, of heterozygotes. 
There is suggestion of this in vCJD; all cases of probable / definite vCJD 
(tested for codon-129 polymorphism) up until 2009 were methionine 
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homozygotes. In 2009, the first case of possible MV vCJD was diagnosed 
[49], with the first case of pathologically confirmed MV vCJD diagnosed in 
2016 [51]. Both cases were in their 30s and therefore older than the median 
age of onset of vCJD. The case of possible vCJD was more in keeping with 
‘classical vCJD’ and presented with a protracted history over 19 months of 
pain, psychiatric symptoms, cognitive decline and ataxia. The MRI however 
was equivocal for the pulvinar sign and CSF 14-3-3 was positive. The case of 
definite vCJD presented with psychiatric and behavioural disturbance and, 
unusually for vCJD, with visual symptoms. Both disease duration (10 months) 
and MRI findings (hyperintensity greatest of the basal ganglia plus cortical 
ribboning) were atypical for vCJD and more compatible with a diagnosis of 
sCJD. CSF was negative for RT-QuIC and 14-3-3. Whilst this case was 
suggestive of prion disease it is important that the presentation had features 
more in keeping with sCJD, which has a lower post-mortem rate compared to 
vCJD (60% compared to 69% respectively) and different potential public 
health implications.  
 
The number of vCJD cases peaked in 2000 and has been falling since, 
reflecting exposure to BSE (Figure 5). There are currently no known living 
cases of vCJD in the world, however, a prevalence of subclinical prion 
infection has been reported in the UK, with significant implications for public 
health.  In 2013, the ‘Appendix II Study’ was published. This demonstrated a 
prevalence of clinically silent abnormal prion protein amongst those exposed 
to BSE during the 1980s and 1990s, of 1 in 2000 of the UK population [52]. In 
2017 the ‘Appendix III Study’ was published, demonstrating a prevalence of 
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abnormal prion protein in approximately 1 in 4,200 in those who had their 
appendix removed prior to 1980 (that is, prior to the time when BSE was first 
thought to be circulating) and in those born after 1996 (that is, after the final 
restrictions were put in place to remove BSE from the human food chain) [53]. 
Whilst the prevalence in Appendix III is lower compared to the previous 
Appendix study, the difference was not statistically significant. It may therefore 
be that the period of BSE infection exposure was longer than originally 
estimated or that, in fact, the presence of abnormal prion protein does not 
necessarily equate to previous dietary exposure to BSE. At present, this is 
unresolved. 
 
Whilst the two heterozygote cases do not amount to a ‘second wave’ of vCJD, 
and it is not clear the significance of subclinical infection, they both highlight 
the important role of on-going disease surveillance and post-mortem 
confirmation of cases with disease sub-typing.  
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Figure 5: Number of cases of BSE and vCJD in the UK (1987 – 2004): As 
taken from the NCJDRSU 23rd Annual report (2015) [7] 
  
 
1.6 CJD surveillance in the UK 
In 1990, the National CJD Research and Surveillance Unit (NCJDRSU) was 
established in the UK following the BSE epidemic, to ‘..monitor the 
characteristics of all forms of CJD, to identify trends in incidence rates, to 
study risk factors for the development of disease and to contribute to 
improving the quality of care for those with CJD’ [7]. It was through this 
surveillance project that the first cases of variant CJD were detected [45].  
 
Integral to the surveillance system is the referral, by clinicians, of suspected 
CJD cases to the NCJDRSU and their subsequent follow up by the NCJDRSU 
team. Referral may be via: 1) clinicians directly, on clinical suspicion of CJD; 
2) referral for cerebrospinal fluid analysis for markers of CJD; 3) death 
certificates, where CJD has been included as a cause of death; and 4) 
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pathology, if evidence of CJD is demonstrated on biopsy or at post-mortem, 
without a CJD diagnosis in life.  
 
The NCJDRSU also works closely with the National Prion Clinic (NPC) at the 
National Hospital for Neurology and Neurosurgery (NHNN) with clinicians 
encouraged to refer suspected cases to both institutes. This dual referral 
system ensures support is available for the clinical team as well as the patient 
and their family, and facilitates research into prion diseases by both centres.  
 
1.7 Under-ascertainment of CJD 
The above approach allows comprehensive case ascertainment, however no 
case ascertainment system is perfect and it is likely that some cases will be 
missed. In the UK, evidence for this, comes from the following: 
 
1) For sCJD, an increase in mortality over time, particularly in older age 
groups has been reported across all European and other international 
surveillance centres, including the UK (Figure 3). This is thought to reflect 
increased awareness of CJD amongst clinicians and better diagnostic 
methods reflecting improved case ascertainment (as opposed to a true 
increase in incidence). It is likely that at least part of this rise may reflect a 
move towards distinguishing CJD from other forms of dementia and therefore 
is unmasking longstanding under-ascertainment, particularly in older patients.  
 
2) Missed cases (i.e. cases of prion disease diagnosed at post-mortem and 
not suspected in life) are reported as part of national disease surveillance 
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systems. In the UK, approximately 7% of cases of sCJD are referred to the 
NCJDRSU at post-mortem (although it is not clear whether CJD was 
suspected in such cases). 
 
3) As a truly spontaneous protein-related neurodegenerative condition, the 
incidence of sCJD should rise with increasing age, in line with other 
neurodegenerative disorders. As per Figure 3, a fall in age specific mortality is 
seen over the age of 79 years old. It may be that this fall is in part a true 
phenomenon, such that after reaching a certain age the likelihood of 
developing CJD will naturally be less likely due to an innate feature of the 
disease itself or of how the prion protein interacts with the ageing brain. Given 
however the previously noted difficulties in differentiating dementia subtypes 
in older patients (and particularly so with less common dementias) and 
evidence that cases can be missed, missed cases are likely to be at least 
partially responsible. 
 
vCJD, on the other hand, is a disease of younger ages. Although there is 
some evidence of age-related susceptibility to infection [54], the Appendix 
studies have demonstrated that there is a relatively high prevalence of 
abnormal prion protein in the lymphoreticular systems of older patients also 
[43,44]. Again this raises the possibility that some cases in older patients may 
have been missed. 
 
Quantifying the extent of under-ascertainment in the UK surveillance system 
is difficult in the absence of a gold standard against which to compare 
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observed versus expected figures. A number of studies have looked into this. 
In 2002, Hillier et al reviewed all death certificates of those aged 15-45 years 
old who had died of any cause, other than external injury or poisoning, 
between 1985 and 1995 in England and Wales [55].  A total of 12091 
certificates were reviewed, of which 3322 were assigned neuropsychiatric 
causes of death compatible with vCJD and for whom brain material was 
available for review. No cases of CJD were identified. A further similar study 
identified 1537 people aged 15-44 years old at the time of death from 1979 - 
1996 in England. A total of 1473 cases were included. Of these, 705 had 
medical records available for review. In 91% there was sufficient information 
in the medical notes to exclude vCJD and sCJD as a likely cause of death. As 
a result of the review a total of four cases were referred to the NCJDRSU; 
after assessment, no cases were suggestive of CJD [56].   
 
Whilst both studies were primarily undertaken to determine if vCJD was a 
novel condition, they provide a method of assessing the completeness of 
surveillance systems and highlight the inherent difficulties of such studies. 
Death certificates are commonly completed by the most junior member of the 
medical team who may enter details only of the terminal event (e.g. 
respiratory failure) rather than the underlying neurodegenerative condition. 
Indeed, the Office of National Statistics demonstrated that review of 
unselected death certificate lowers the diagnosis of death by respiratory 
disease by 7% [57]. Further to this, until recently most dementia was labelled 
as ‘senile’ dementia or Alzheimer’s dementia with little phenotyping beyond 
this making it difficult to retrospectively review cases. 
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A more recent review of brain donations from 1984 – 2005 to the National 
Alzheimer’s Co-ordinating Center in Washington, USA (Maddox, 2015) 
identified 6000 patients with a clinical diagnosis of dementia and availability of 
neuropathological material. Of these, 21 cases had neuropathological data 
indicating prion disease, of which 19 cases had accompanying clinical data. 
7/19 cases (37%) had not been considered in life. Limited clinical details were 
provided, however cases were at the extremes of age range for sCJD (mean 
age 66 years, range 47 - 88 years) with long disease durations [58]. 
 
In 1995 a neuropathological review was published on the Corsellis Collection; 
a large neuropathological archive collected prospectively from both psychiatric 
and general hospitals since 1964. Brain tissue from a total of 6559 patients 
was available for examination, with over 1000 having been diagnosed in life 
with dementia. 19 cases of CJD were identified. Eight cases (42%) were not 
suspected in life; 6 of which had protracted histories and who would not have 
fulfilled diagnostic criteria based on paucity of clinical features on examination 
[59]. Such cases again were at the extremes of age for sCJD (mean age: 64 
years, range: 40 years to 79 years). 
 
Finally, in 1989, Jellinger undertook a neuropathological review of 675 
consecutive autopsy cases of patients with dementia from three hospitals in 
Vienna over a seven-year period. Nine cases of CJD were identified; six were 
suspected in life. However, it is not clear whether this six were of the nine 
confirmed at post-mortem [58, 60]. 
The influence of age on case ascertainment in CJD 
 
Chapter 1: Dementia and prion disease in the older population	 26
 
The above studies provide insight into missed cases amongst specialist in-
patient settings, where even in such settings cases of CJD may be missed. In 
practice however generalisability is limited; the majority of older patients with 
dementia reside in the community and, as previously noted, post-mortem 
rates in the elderly are low (and a particular rarity in those with a diagnosis of 
dementia) [28, 61]. The presentation of patients included must therefore have 
been unusual enough to warrant admission to specialist units and for post-
mortem to be undertaken, even if prion disease had not specifically been 
raised in life.  
 
Reasons for under ascertainment 
Surveillance sources are limited and neuropathological series have 
demonstrated that cases of CJD can be missed, but it is important to review 
why this might occur. When compared to other, more common, forms of 
dementia in the elderly (as in Appendix A), the rapidity of decline and 
associated neurological features as detailed in section 1.5 should set CJD 
apart easily. One reason is that dementia is not considered as a diagnosis, 
with resons outlined in section 1.2. Even if it were considered, however, 
misclassification due to either lack of familiarity with CJD or because the 
presentation is in some way atypical may be important. A review of these 
factors follows: 
  
1) The clinical features that together comprise the CJD diagnostic criteria and 
distinguish CJD from other more common forms of dementia (i.e. rapid 
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progression and focal neurological features) are not in themselves unique to 
prion diseases.  
 
a) Rapid progression - a number of studies in the united States and Europe 
have reviewed rapidly progressive dementias (RPDs) [62-66]. Whilst there is 
no universal definition of RPD and it is difficult in some to be clear about the 
timing or nature of initial symptoms, most studies have accepted a definition 
of 1-2 years from symptom onset to a diagnosis of dementia as fulfilling this 
concept.  
 
As prion disease is the archetypal form of rapid dementia, the majority of 
studies are based on cohorts of patients referred to national CJD surveillance 
units who were subsequently diagnosed with an alternative underlying 
pathology. Between 12 - 54% of all referrals where CJD has been considered 
are diagnosed with an alternative diagnosis (dependent on the nature of the 
referral patterns and whether referrals include CSF-only referrals in addition to 
clinically suspected cases). A review of non-prion diagnoses from these 
cohorts, in addition to patients with RPD presenting to tertiary referral 
dementia centres [67-70], are presented in Table 2. A total of 13606 
neuropathologically confirmed cases are included.  
 
It is difficult to draw general conclusions due to the heterogeneity of cohorts. It 
is also possible that within these cohorts cases of CJD may have been 
missed by older generation immunohistochemistry techniques with a lower 
specificity for PrPSc detection. General conclusions, however can be drawn; 
Alzheimer’s Disease was the single most common non-prion 
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neurodegenerative condition, likely reflective of the high prevalence of AD in 
the population. A number however presented with RPD secondary to a non-
neurodegenerative condition, most commonly inflammatory disorders, 
highlighting the importance of investigation for treatable neurodegenerative-
mimics. 
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39 31 77 n/a 63 60 37 36 43 95 64
AD 8 5 51 27 40 18 6 21 13 43 9 
FTLD 10 7 3   16 12 4 2 18  
VaD  2 12 9 11 13  12 2 13  
‘Parkinson’s 
plus’  
9 11 2 7 5 15 10 10 10 10 14 
HD   0.3 2     0.4   
MND / MND-
FTD 
   2 2   1 0.1  23 
Mixed / other / 
unknown 
  7  5  6 9 4.5  18 
Secondary 
dementias 
n/a n/a 23 n/a n/a 24 26 n/a 40 n/a n/a
Inflammatory 22 16 6 1.1 5 9 2  11   
Neoplastic  6 8 8 4 7 12 2 8 5   
Infectious 6  5    2 5    
Metabolic/toxic 4  2 6 6 6 8 1 7   
Vascular 4    1   8 8   
Psychiatric 6 12  5  2   6   
Other / 
unknown 
13 32 2 4 15 6 11 11 20.2   
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b) Focal neurological features – A sub-selection of RPD reviews have also 
examined the presence of focal neurological features (common to both vCJD 
and sCJD) in non-prion pathologies. As demonstrated in Table 3, focal 
neurological features were commonly seen in other forms of dementia. No 
studies however provide meaningful comparison between prion and non-prion 
cohorts to determine significant differences between groups. 
 
Table 3: Clinical features of patients with non-prion pathologies 
(percentage of all those with non-prion pathologies: clinical features 
present during illness) 
Clinical features Chitravas et al 
2011 (n = 71) [63] 
Poser et al 
1999 (n = 109) 
[64] 
Sala et al 
2012 (n = 
49) [68] 
Scarmeas et al 
2015 (n = 32) [73] 
Dementia 42 63 100  
Myoclonus 12 43 65 75 
Pyramidal 20   66 
Extrapyramidal 12 41 65  
Cerebellar 
dysfunction 
14 46 31  
Visual 
disturbance 
9 23   
Akinetic mutism 5 14   
Gait disturbance    66 
 
Both reviews demonstrate, that whilst the data are highly selected, the 
majority of patients who presented with RPD with or without focal neurological 
features did not have CJD as a cause for their presentation and instead had 
underlying commonly encountered dementia pathologies (that is AD, FTLD, 
DLB, and VaD). Such features are therefore not unique to CJD and it could be 
that cases of CJD are missed amongst these other common 
neurodegenerative conditions. 
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2) In some cases, CJD may have an atypical presentation or phenotype, with 
evidence to suggest this may be more common in older patients. 
 
a) Missed cases of CJD are generally older 
There is very little available literature regarding risk factors for missed cases 
of CJD. As above, however, the Corsellis collection found that missed cases 
were older (although it is unclear whether they were significantly so) [59] and 
Maddox et al [58] found that missed cases were more likely at the extremes of 
ages for sCJD. A review undertaken by el Tawil et al (2015) of older patients 
with vCJD referred to the NCJDRSU found that 4 out of 6 patients aged 55 
years old at time of symptom onset were not diagnosed in life [23].  
 
b) Older cases of dementia are associated with rapid progression 
Staekenborg et al (2015) reviewed risk factors for RPD in 1623 patients 
referred to the Amsterdam Dementia cohort; older age was found to a risk 
factor for rapid progression of non-prion pathologies [69], potentially 
contributing to diagnostic difficulty in differentiating non-prion RPD from cases 
of CJD in older ages. With age, cognitive reserves reduce, this may also be 
an important factor in the rapidity of progression of older cases [74]. 
 
c) Older cases of CJD may potentially have different features to younger 
cases 
There is little published description of the clinical features of older patients 
with vCJD or sCJD. A summary of available literature follows: 
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sCJD 
In sCJD, there are few reviews of the elderly. Karch et al (2015) recently 
reviewed the clinical presentation of patients aged 75 years old with 
probable or definite sCJD referred to the German CJD Surveillance 
Programme between 2001 and 2012 (n = 73) and compared such 
presentations to those aged <75 years old (n=73).  In the older group, patients 
had a shorter duration of illness and were more likely to present with dementia 
and less likely to have visual symptoms compared to younger patients. 
Cerebral MRI was less likely to be typical with isolated cortical lesions more 
frequently seen in those 75 years [75].  
 
A previous review by Brandel et al (2008) [76] reviewed cases of probable or 
definite sCJD referred to the French CJD surveillance programme. The 
presentation of patients aged 80 years old (n = 136) was compared to those 
<80 years (n = 1171). Similar to Karch, the disease duration in those aged 
80 years was significantly shorter compared to younger patients. Clinical 
features were comparable, however cerebellar features and myoclonus were 
seen less frequently in older patients. In the French group CSF, EEG, and 
MRI findings were comparable between groups. Both the codon-129 
polymorphism and protein subtype were also comparable, potentially 
suggesting that disease subtype is not responsible for differing phenotypes in 
the elderly or indeed for reduced incidence in older patients.  
 
Lastly, a previous review undertaken at the NCJDRSU in Edinburgh identified 
all patients aged 80 years with probable or definite sCJD; 12 cases were 
The influence of age on case ascertainment in CJD 
 
Chapter 1: Dementia and prion disease in the older population	 33
identified and described. The authors observed that their clinical presentation 
and disease duration was typical of sCJD [77], however the study did not 
compare cases to those <80 years old. It is therefore difficult to conclude if 
any significant differences were present.  
 
vCJD 
In vCJD, until recently only a single case report [78] existed reviewing the 
presentation of vCJD in older patients.  A recent review of all cases aged 55 
years old in the UK identified six patients, all of whom had neuropathological 
confirmation of diagnosis. Two of these patients fulfilled the clinical diagnostic 
criteria for probable vCJD and two for possible vCJD. Five patients underwent 
MRI imaging with only one demonstrating diagnostic changes of the medio-
dorsal thalamus. Alternative diagnoses given in life were VaD (n = 1), FTD (n 
= 2), and Wernicke’s encephalopathy (n = 1). Of the two diagnosed in life one 
was a known recipient of a blood transfusion from a case of vCJD. No 
comparison was made of these cases to younger cases (and therefore the 
presence of differences is unknown), however all cases did have clinical 
features that would be unusual for the more commonly encountered 
dementias (for example: ataxic gait, additional movements and sensory 
disturbance) [23].  
 
The literature base is sparse, however, in general, it would appear that older 
patients with variant and sporadic CJD are less likely to have positive features 
on MRI brain imaging and possibly fewer neurological features. This may 
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contribute towards missed diagnoses, however conclusions cannot be drawn 
as this association has not been specifically reviewed.  
 
Overall, it is difficult to draw conclusions, however it would appear that older 
age is a possible risk factor for missed diagnosis in CJD. This is important as, 
although surveillance is important in all ages it is particularly so in older 
patients because, as a group, older patients are more likely than the young to 
require surgical interventions (including blood transfusions) putting 
themselves and subsequent patients at risk of iCJD (indeed one of the only 
three blood transfusion associated cases was 65 years old).  
 
1.8 Discussion  
CJD disease surveillance continues to be a relevant measure to protect public 
health and the elderly are an important group who require particular 
consideration. 
 
This section has demonstrated that cases of CJD may be missed, and whilst 
CJD has a distinct and rapid multifocal neuropsychiatric decline, these 
features are not unique. Missed cases may be seen in older patients, possibly 
due to atypical presentation, however a robust review of risk factors for 
missed diagnosis is lacking. Missed cases have implications not only for 
appropriate clinical management but also for public health. 
 
The aim of this thesis is to review the ascertainment of CJD in the older 
population, to investigate age as a risk factor for missed diagnosis in CJD, to 
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describe the characteristics of CJD in older patients, and to detail and trial 
methods for prospective study of enhanced surveillance of CJD in older 
patients. It will do this by first investigating age as a risk factor for missed 
diagnosis in CJD and describing the clinical and referral characteristics of 
older patients, separately for variant CJD (chapter 2) and sporadic CJD 
(chapter 3). A case definition tool for screening patients in whom CJD may be 
missed will be developed with a protocol for the feasibility stage of an 
enhanced surveillance project detailed in chapter 4. This will also include a 
description of the first 10 patients referred to the enhanced surveillance 
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Chapter 1 discussed the possibility that diagnoses of CJD may be missed, 
particularly in older patients. Literature review demonstrated that missed 
cases do occur, with age appearing to be a possible risk factor for this. 
Further evidence comes from the epidemiological characteristics of vCJD and 
sCJD: a) in sCJD, there has been an increase in observed cases over time, 
particularly in older ages; b) late diagnoses (i.e. those not diagnosed in life) do 
occur; and c) the association between age and age specific mortality is not 
linear with a fall in age specific mortality seen in vCJD and sCJD after 29 
years and 79 years old respectively. 
 
The reasons for these epidemiological characteristics are not clear but, as 
previously explored, may include: a) missed cases are in some way atypical 
for CJD (e.g. in the way they present, progress or in their investigation 
findings); b) cases of CJD are typical but are overlooked; or c) cases of sCJD 
are genuinely rising (although as previously discussed, this would seem less 
likely). 
 
In this chapter cases of vCJD will be reviewed to provide some understanding 
of the clinical and referral characteristics that may be associated with timing of 
referral. This will be done by comparing cases recognised as CJD diagnosed 
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late in the disease process or after death and comparing them with cases 
diagnosed earlier.  
 
2.2 Background 
Between 1995 and 1996, the National CJD Research and Surveillance Unit 
(NCJDRSU) reviewed 10 cases of CJD with a younger age of onset, atypical 
but stereotyped clinical features and a longer duration of illness. 
Neuropathological changes were unusual for sCJD and, similar to clinical 
features, were strikingly similar between cases. The condition was termed 
‘new variant CJD’ (now ‘variant CJD’) [45], and a causal link to the BSE agent 
in cattle was later established. 
 
2.21 Clinical features of variant CJD 
Variant CJD (vCJD) presents in the majority of cases with early isolated 
behavioural change or psychiatric symptoms (predominantly mood changes 
and social withdrawal, although psychosis can occur). In approximately 20% 
however, cognitive disturbance or pain may also be seen as early / presenting 
features. Intellectual decline, ataxia, and slurred speech follow in the majority 
within 6 months, with persistent painful sensory disturbance seen in up to half 
of patients. In the later stages, pyramidal features, abnormal movements 
(inclusive of myoclonus, dystonia and chorea), and agitation are seen. As per 
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2.22 Biomarkers of vCJD 
Cerebral MRI demonstrates high signal of the dorsomedial thalamus (the 
‘pulvinar sign’) on fluid-attenuated inversion recovery (FLAIR) and diffusion 
weighted imaging (DWI) sequences. This feature is not specific for vCJD, 
however, in the correct clinical context it is extremely helpful with 91% of 
patients with vCJD demonstrating this sign [80]. Non-specific markers of 
neuronal damage may be seen on CSF (14-3-3 is present in approximately 
50% [7]) and EEG (slow waves but, in the vast majority, without the typical 
changes of sCJD). CSF and EEG do not have the same diagnostic role in 
vCJD as they do in sCJD and are generally more helpful in excluding other 
conditions. As PrPSc is also seen within the lymphoreticular system, biopsies 
of lymphoid tissue (that is, tonsil biopsy) offer a definitive means of diagnosis 
in life.   
 
Patients are classified as possible, probable, or definite according to 
internationally agreed diagnostic criteria (Box 4). Overall, the specificity of the 
clinical diagnostic criteria is 100% with sensitivity of 83% within the UK [80].   
 
2.23 Epidemiology of vCJD: UK and worldwide 
vCJD is a disease of the young and although has a longer duration of illness 
compared to the classical/sporadic form of CJD it is still a rapidly progressive 
condition. There is a slight excess of cases in males [82]. Cases of vCJD 
have been reported in a number of countries, however the majority of vCJD 
cases reported world-wide were UK residents at the time of illness onset (77% 
of cases, including 3 cases of secondary transmissions via blood transfusion). 
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One additional case was a temporary resident during the BSE outbreak in the 
U.K [38, 39]. Almost all (99.4%) of UK cases have been homozygous for 
methionine at codon-129, with all tested cases outwith the UK also 
homozygotes. 
 
2.24 NCJDRSU referral system 
As per chapter 1, the NCJDRSU was established in the UK to monitor for 
changes in epidemiological and clinical trends, which may suggest cross-
species transmission of BSE to humans. It continues to monitor incidence 
rates, study risk factors for disease, and assist local care providers to improve 
the quality of care for those with CJD.  
 
The NCJDRSU receives referrals of suspected cases from various sources 
(as detailed in section 1.6). When patients are referred, an NCJDRSU 
clinician collects details over the telephone on the patient’s illness including 
risk factors for CJD (e.g. family history / known iatrogenic exposure). Advice is 
provided regarding investigations to improve the diagnostic certainty 
(generally speaking cerebral MRI with DWI/FLAIR sequences, CSF for 14-3-3 
and RT-QuIC, and EEG). Contact continues with the clinicians until either an 
alternative diagnosis is reached or CJD becomes the most likely diagnosis, in 
which case a visit is arranged to meet with the patient and their next of kin 
within 5 working days of referral. 
 
During the visit the NCJDRSU clinician, who is usually accompanied by a 
member of the NCJDRSU nursing care team, collects data from the family 
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(and occasionally the patient if able) on clinical and epidemiological features 
using a standardised format questionnaire (inclusive of details such as first 
symptom/sign, and the development of specific features during the illness). A 
description is also taken of the evolution of illness. The patient is examined, 
using a standardised protocol for neurological examination. The medical notes 
are reviewed by the NCJDRSU clinician and details such as the onset of 
objective signs, and results of cognitive / neurological examinations and 
investigations are documented to supplement the history provided by the 
family / patient. Cerebral MRI is reviewed if available.  
 
After the visit, all details collected are then entered manually onto a secure 
electronic database held at the University of Edinburgh. Correspondence files 
are also retained in paper format for future reference. Requests are sent for 
copies of medical notes, cerebral MRI scans (with subsequent review and 
coding by Dr David Summers, NCJDRSU consultant neuroradiologist), and a 
representative page from the patient’s EEG (coded by Professors Will and 
Knight, NCJDRSU consultant neurologists). After a patient’s death, a request 
is sent to access GP notes. Data entries are updated where information is 
available to include any subsequent clinical features documented in GP / 
hospital notes that occurred after the NCJDRSU visit.  
 
Occasionally a patient is not seen during life, either because CJD was not 
suspected in life (and only diagnosed at post-mortem) or the patient died prior 
to review. In such instances the patient’s next of kin is contacted to invite 
them for later review during which the same clinical and epidemiological data 
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are documented with supplementation of the clinical features from review of 




2.31 Population and setting  
A retrospective review of vCJD diagnoses in the UK was undertaken. All work 
was undertaken by the author, unless stated otherwise. All patients referred to 
the NCJDRSU between 1st May 1990 and 31st December 2015, resident in 
the UK at time of onset and classified as probable or definite (according to the 
above mentioned criteria, as of 31st December 2015) were included (n = 177).  
 
Data were extracted from the NCJDRSU database with this first pass of data 
collection undertaken by Ms Jan Mackenzie (NCJDRSU surveillance co-
ordinator) and Mr Nick Attwood (NCJDRSU database manager). A database 
was created in Excel (version 14.7.7). All data were then transferred to SPSS 
(version 22) (the ‘thesis database’) and analysed with the aim of looking for 
factors associated with missed diagnoses of CJD. 
 
2.32 Data processing 
Cases of vCJD have been referred over an extended period of time and 
therefore the clinical and epidemiological review questionnaire used for 
assessing cases of vCJD has evolved. The iteration with features common to 
all versions was therefore used as the standardised form (in use from 2002 – 
2009). For data collected prior to and after this time (approximately 70% of 
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case notes) all correspondence and medical notes were individually reviewed 
and entered onto this common format if this had not already occurred.  
 
The following data were recorded: 
1) Basic characteristics and demographic details. Sex and age at time of 
onset of illness were documented and an index of multiple deprivation (IMD) 
was calculated based on the patient’s postcode of residence at the time of 
referral. This was then grouped into quintiles.  
 
The IMD is the most widely used socioeconomic scale. It is derived nationally 
for all four nations, however, with limitations, can be applied UK wide. Scales 
are updated after each census; the data used for the purposes of this study 
was calculated from the 2001 census in Scotland and in England and the 
2003 census in Wales and in Northern Ireland. These years are the closest to 
the peak of vCJD cases in 2000. 
 
2) Referral characteristics  
a) Source of referral. The speciality of the clinician referring the patient to the 
NCJDRSU was categorised as neurology, psychiatry, pathology, general 
medicine, other 
 
b) Type of referring hospital. Hospitals were classified as regional 
neurosciences centre or other based on data from www.nhs.uk (extracted 
01.04.16); where neuroscience services had migrated in an area or a hospital 
had since closed, the status of the hospital at the time of referral was used 
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c) Time to review by neurology / psychiatry and time to referral to the 
NCJDRSU. Timings were calculated from onset of first symptom  
 
d) Region of referral. The UK was divided into North UK (Scotland, North 
East, North West, Yorkshire and Humberside) and South UK (Wales, East 
Midlands, West Midlands, South West, South East, London, East of England) 
according to the patient’s area of residency at the time of referral to the 
NCJDRSU. 
 
3) Clinical features 
The following clinical features were extracted: 
a) Presenting features. Presenting symptoms were grouped into the following 
themes: i) behaviour / personality change (consisting of any change which 
was not attributable to mood change), ii) sensory disturbance (consisting of all 
sensory modalities including pain), iii) mood disturbance or psychiatric 
features (consisting of delusions, anxiety, and depression), iv) rapid cognitive 
decline (any change in cognition), and v) unsteadiness (consisting of gait 
change or incoordination). These features were enquired about from a family 
member (i.e. what was the first symptom the patient complained of or the first 
sign they noticed). Where this was not possible, GP or hospital records were 
used to determine first symptom the patient sought medical attention for. 
 
b) Signs and symptoms occurring during the course of a patient’s illness. 
Where available, the presence of specific signs and symptoms occurring after 
initial symptom onset were extracted.  
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c) Time to onset of clinical features: Timing of symptoms was calculated using 
time from first symptom to time to development of each subsequent symptom 
/ sign. Where symptoms were present prior to the date of illness onset these 
symptom dates were excluded (e.g. some patients had long-standing mood 
disturbance), unless there was clear worsening or evolution of these clinical 
features during the patient’s illness. If deterioration was documented, the point 
of change was taken as the ‘time of onset’. If the exact date of onset was 
unavailable, the date was standardised to the 15th of the month.  
 
Some features were grouped: depression, anxiety, aggression, and delusions 
were grouped under one symptom heading of ‘psychiatric symptoms’; chorea 
and dystonia were grouped under ‘other movements’; ataxia, nystagmus and 
cerebellar signs were grouped under ‘cerebellar’. The earliest feature that 
developed after the onset of the illness was used in these variables.  
 
d) Duration of illness: This was calculated from first symptom to time of death. 
 
4) Investigation results were documented: 
a) Cerebral MRI was documented as either positive (the presence of medio-
dorsal thalamic restricted diffusion: the ‘pulvinar sign’) or negative (all other 
changes including normal) 
 
b) CSF was documented as either positive (the presence of 14-3-3) or 
negative. Equivocal results were excluded from analysis 
The influence of age on case ascertainment in CJD 
 
Chapter 2: Factors associated with late referral of variant CJD 45
 
c) EEG was documented as typical (the presence of periodic generalised 
synchronised triphasic sharp wave complexes at 1-1.5Hz), atypical (all other 
changes), or normal 
 
d) Codon-129 polymorphism was documented 
 
5) Diagnostic criteria 
Whilst it is important to consider whether specific signs and symptoms are 
associated with timing of referral outcomes, it is also important to consider the 
overall clinical picture and whether missed referrals were missed because 
they perhaps did not fulfil clinical diagnostic criteria in life. All patients were 
therefore categorised as either ‘fulfils diagnostic clinical criteria’ or ‘does not 
fulfil diagnostic clinical criteria’ based on their clinical features alone. The 
presence of signs / symptoms documented throughout the patient’s illness 
was reviewed for each case, and, if they had sufficient features (that is a >6 
month history of a progressive neuropsychiatric disorder with 4 out of 5 
associated clinical features – as detailed in Box 4, page 16) to fulfil the 
diagnostic criteria for ‘possible vCJD’, they were coded as ‘fulfils diagnostic 
clinical criteria’.   
 
6) Diagnosis in life 
Case notes (inclusive of death certificates) from all patients referred on or 
after the date of death were reviewed to determine a) the referring clinician’s 
working diagnosis at time of death and b) whether CJD (and the subtype 
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thereof) had been considered in life. All notes of those referred later in the 
disease process (see page 45) were also reviewed for the working diagnosis 
prior to the patient’s eventual diagnosis of vCJD. 
 
2.33 Data review  
Once data were entered onto the thesis database, variables were checked for 
completeness to ensure cases had not been overlooked during the first pass 
of case review (that is, that no cases had missing information) Variables were 
checked for validity and consistency (e.g. there were no variables with 
negative time to onset of symptoms etc.). If data were missing, notes were re-
reviewed and any further available variables were entered at this stage.  
 
Missing data.  
Where data were not available, it was not possible to make data assumptions 
and missing entries were therefore classified as ‘missing’ with entry fields left 
blank on the thesis database to ensure they were not included in statistical 
analysis. 
 
2.34 Analysis approach 
a) Outcome variables 
The primary outcome variable was to determine the characteristics of patients 
not referred to the NCJDRSU in life (referred to from here as ‘missed 
referrals’) as a proxy measure of missed cases of CJD. It was however 
expected that this group would be small with analysis therefore limited. A 
further subgroup of those referred later in the course of their illness (referred 
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to from here as ‘later referrals’) was therefore added. The rationale for this 
later group was to review whether there were any atypical features that might 
help to inform an understanding of possible risk factors for a missed referral / 
diagnosis in life.  
 
With regards time cut-off points for later referrals, various time points were 
considered, trying to provide a balance between adequate numbers and 
duration. Thirty days prior to death was chosen as this represented 
approximately the last 10% of illness. It might be expected that patients would 
be at a palliative phase by this stage with further diagnostic investigation less 
likely. 
 
b) Explanatory variables included demographic, referral and clinical 
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Table 4: Explanatory variables (vCJD) 




Age Median years + IQR n/a 177 (100) 
Sex % male n/a 177 (100) 
IMD n/a 1-5 174 (98)  
Duration of illness (time from 1st symptom 
to time of death) 
Median months + IQR n/a 177 (100) 
Time to diagnosis (time from 1st symptom 
to time of diagnosis) 
Median months + IQR n/a 177 (100) 
Time to diagnosis excluding those 
referred after death 
Median months + IQR n/a 177 (100) 
Source of referral Neurology, psychiatry, pathology, general medicine, 
other 
n/a 177 (100) 
Fulfilled diagnostic criteria in life Yes/no n/a 177 (100) 
Reviewed by neurology Yes/no n/a 176 (99.4) 
Time to neurology review Median months + IQR  174 (98.3) 
Reviewed by psychiatry Yes/no n/a 171 (96.6) 
Time to psychiatry review  Median months + IQR n/a 80 (45.2) 
Referred from neurosciences centre Yes/no n/a 175 (98.9) 
Region of referral North U.K. / South U.K. n/a 177 (100)  
Presenting feature Behaviour / personality change, sensory disturbance, 
mood disturbance or psychiatric features, rapid 
cognitive decline, and unsteadiness 
n/a 177 (100) 
Signs / symptoms occurring during illness  Feature present since onset of illness Yes/no See Tables 8 and 13 
Cerebral MRI Presence of pulvinar sign Positive/negative 170 (96) 
CSF  Presence of 14-3-3 Positive/negative 129 (72.9) 
EEG  Periodic generalised slow synchronised triphasic sharp 
wave complexes  
Positive/negative 168 (94.9) 
Codon-129  Polymorphism recorded MM / MV / VV 160 (90.4) 
The influence of age on case ascertainment in CJD 
 
Chapter 2: Factors associated with late referral of variant CJD 49
c) Analysis 
Later and missed referrals were identified and described.  
 
Results of explanatory variables for later and missed referrals are as 
compared to those referred before (referred to as ‘early’) and after these 
respective cut-offs. A univariable comparison was initially undertaken. For 
continuous variables (i.e. age, duration of illness, time to onset of clinical 
features and time to review by neurology / psychiatry) due to small numbers 
with a non-parametric spread of data the Mann-Whitney test for association 
was used. For all, time to onset is stated in median months with interquartile 
range (IQR) provided.  
 
Pearson’s 𝒳2 exact test (2-sided) was used to cross-tabulate categorical data 
(i.e. sex, IMD, source of referral, presenting feature, region of referral, 
presence of specific clinical features / positive investigations, review by 
psychiatry and neurology, and referral from neurosciences centre). This 
particular test was used due to the potential for small numbers in categories 
and to minimise data assumptions. Statistical significance was set at p <0.05. 
Risk was also calculated using odds ratio (using the odds ratio Chi-Square 
test) with 95% confidence intervals provided. 
 
In order to determine the relationship between factors identified as associated 
with referral timing a multivariate analysis was undertaken. A binary logistic 
regression model was built using missed or later referral as the constant 
variable and all statistically significant factors from the univariate analysis as 
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the dependent variables. From both univariable and multivariable analysis age 
was highly significantly associated with late / missed referral. Further analysis 
was undertaken to determine whether it was age itself that was important (e.g. 
those who are older are less likely to have clinical features documented or be 
investigated as thoroughly) or was it due to a confounding factor (such as 
investigation findings, presenting complaint, or source of referral, etc.). Ideally, 
a multivariable analysis would have been undertaken of all explanatory 
variables, however, due to small numbers, this was not possible and 
therefore, a separate analysis was undertaken, re-defining age as the 
outcome. 
  
For the purposes of this analysis, patients were classified as ‘older adults’ if 
they were aged 65 years old at the time of onset of first symptoms. 65 years 
old separates young-onset dementia from late-onset dementia; this age 
separation reflects not only a difference in the probability of the underlying 
causative pathology but also reflects typical referral pathways for those with 
dementia (with services generally divided into those <65 years old and 65 
years old). vCJD, however, as previously stated, is a disease of the young 
and therefore expected numbers 65 years old would be small. A further sub-
group analysis was undertaken on the oldest 10% of cases (those aged 45 
years old); this, similar to timing of referral was chosen as a balance between 
clinical significance and adequate numbers to undertake statistical analyses. 
Explanatory variables were then run against those aged 65 years old 
compared to those <65 and similarly, 45 years old compared to those <45 
years old using the same statistical tests stated above.  
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2.41 All cases vCJD  
Overall, 177 patients were included who fulfilled internationally accepted 
surveillance criteria for probable or definite vCJD. Of these, 122 patients 
(69%) were definite cases.  
 
a) Basic characteristics (all patients) 
101 patients were male (57%). The median age of onset of 26 years (IQR: 21 
– 33 years). The median IMD quintile was 3 (1 – 5). Patients had a long 
median time to diagnosis of 11 months (8 – 13 months, excluding those 
referred after death) compared to a median disease duration of 14 months (11 
– 18 months). 169 patients (96%) fulfilled the clinical diagnostic criteria for 
vCJD. In all the rest, the reason for failure to fulfil criteria was a lack of 
documented psychiatric features.  
 
b) Referral characteristics (all patients) 
The majority of patients were referred from a clinician in neurology (155 
(87.6%) patients). All but one patient (99.4%) were reviewed by neurology 
during their illness with a smaller number reviewed by psychiatry (91 (51.4%) 
patients). Over half (103 (58.2%) patients) were under the care of a tertiary 
neurosciences centre at the point of referral.  
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c) Clinical characteristics (all patients) 
Almost 75% of patients presented with either mood disturbance / psychiatric 
features or sensory disturbance, although the most frequently encountered 
clinical features during the illness were cognitive or cerebellar, present in 
almost all patients. Cerebral MRI (when reviewed by the NCJDRSU research 
neuroradiologist) was the most useful investigation to detect the changes of 
vCJD (positive in 91%). 
 
When reviewing the time to onset of symptoms, as expected, given the 
presenting symptoms, pain and sensory disturbance occurred early at 1 and 2 
months respectively. Cognitive, cerebellar and psychiatric features all 
occurred around the same time after at 3 months. Myoclonus occurred last at 
5 months, which, as a late sign in all forms of CJD, was to be expected.  
 
2.42 Late / missed referrals 
a) Basic characteristics (late / missed referrals) 
A total of 13 patients were referred within 30 days of death or after (7.3% of all 
cases of definite / probable vCJD) with six patients referred on or after the 
date of death (3.4% of cases). A description of cases can be found in Table 5. 
In 4/5 missed referrals in whom information was available, CJD was 
considered in life, however, in all cases sCJD was considered the most likely 
subtype. 
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Later / missed referrals were significantly older compared to earlier referrals 
(p = 0.002 for later referrals and 0.004 for missed referrals). All missed 
referrals were male (p = 0.03). The duration of illness was shorter, however, 
as expected, the time to diagnosis significantly longer (Table 6).  
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Table 5: Description of later and missed referrals (vCJD) 









Presenting features Classification 
in life 
MRI Other investigations 
to support a 






prior to death 
1  18 8 Behaviour / personality 
change 
Probable Positive EEG – atypical Insufficient 
information 
Yes – type not 
mentioned 
2*  19 13 Mood / psychiatric 
symptoms 
 
Probable Positive EEG – atypical Rapid onset 
dementia 
Yes – type not 
mentioned 
3  34 14 Mood / psychiatric 
symptoms  
Probable Positive CSF 14-3-3 positive, 
EEG – atypical 
vCJD Yes – sporadic 
(prior to brain 
biopsy result) 
4*  41 7 Rapid cognitive decline Probable Positive EEG – atypical  Encephalopathy  Yes - sporadic 
5  50 11 Unsteady Possible Negative CSF 14-3-3 negative, 
EEG – normal 
sCJD Yes - sporadic 
6  37 12 Behaviour / personality 
change 
Probable Positive CSF 14-3-3 negative, 
EEG – atypical 
vCJD Yes - variant 




8  21 16 Mood / psychiatric 
symptoms 




9  47 11 Mood / psychiatric 
symptoms 




10  35 15 Mood / psychiatric 
symptoms 
Probable Positive EEG – normal vCJD Unclear (vCJD 
after brain 
biopsy result) 
11*  68 13 Mood / psychiatric 
symptoms 




Yes – sporadic 
12*  59 33  Rapid cognitive decline Possible Negative EEG – atypical. CSF 
no info 
Korsakoff’s Yes - sporadic 
13*  56 40 Rapid cognitive decline Did not fulfil 
criteria  
Negative Insufficient information FTD Yes - sporadic 
1Year removed to protect patient confidentiality  *Referred after death; n/a = not available 
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Table 6: Basic demographics - later / missed referrals (vCJD) 
Patient characteristics  Later (referred 30 
days of death) 
Early (referred 
> 30 days of 




(referred on or 






Median age: years^ 41 (28 - 58) 26 (20 – 33) 0.002** n/a 58 (36 - 70) 26 (21 – 33) 0.004** n/a 










96/171 (56.1%) 0.03* 0.56 
(0.49-
0.64) 
Median Index of Multiple 
Deprivation 
3 3 0.61 n/a 3 3 0.94 n/a 
Median duration of 
illness: months^ 
11 (11 - 15) 14 (11 – 18) 0.22 n/a 13 (7 - 35) 14 (11 – 18) 0.82 n/a 
Time to diagnosis: 
months^ 
8.4 (6.5 – 10.0) 6.2 (4.8 – 7.9) 0.008** n/a 9.7 (7.7 – 28.3) 6.3 (4.8 – 7.9) 0.007**  
Fulfilled diagnostic 
criteria in life 
12/13 (92%) 157/164 (96%) 0.46 0.5 (0.06-
4.7) 
5/6 (83%) 164/171 (96%) 0.15 0.2 (0.02-
2.1) 
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b) Referral characteristics (late / missed referrals) 
As expected in this group, there was an excess of patients referred from 
pathology with fewer referred by neurology. There was no difference however 
in the number seen by a neurologist in life (Table 7).  
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( 30 days prior 
to death or 
after) 
Early referrals 




(referred on or 




date of death) 
 
 %  % p-value O.R. 
(95% CI) 





























































































Neurology: n /N 




4 (4-6)  4 (0-16)  0.08 n/a 4 (4-7)  4 (3-5)  0.61 n/a 
Reviewed by 
Psychiatry: n /N  




4 (4-5)  4 (0-15)  0.69 n/a 4 (2-13)  4 (3-6)  0.96 n/a 
Neurosciences 
centre (at point of 
referral): n /N 








































n = number with feature N = number documented *Significant p <0.05 **Highly significant p <0.01  ^Median + IQR 1 For North region 2If referral at PM, neurosciences centre 
determined by hospital referring for PM 
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c) Clinical characteristics (later / missed referrals) 
When compared to earlier referrals, there was a strongly significant 
association with presenting feature and whether referrals were late in the 
disease process (p = 0.02) or missed (p <0.001). In both this was due to an 
excess of patients presenting with rapid cognitive decline and none presenting 
with sensory disturbance (Table 8). With regards clinical features developing 
during illness in both later and missed referrals, there was an excess of 
features associated with end stage vCJD (myoclonus and akinetic mutism) 
with fewer complaining of sensory disturbance. The type of psychiatric 
features also differed between later and earlier referrals; delusions and 
hallucinations were more likely in later and missed referrals with mood 
disturbance described more frequently in earlier referrals.  
 
As expected, given the presenting features in Table 8, there was a shorter 
time to onset of forgetfulness with a longer time to onset of sensory 
symptoms. MRI, which as above, is the most sensitive investigation in vCJD, 
was less likely to be positive in both groups, particularly in missed referrals (p 
= 0.004) (Table 9). 
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( 30 days 
prior to death 
or after) 
Early referrals 




(referred on or 
after date of 
death) 
Referred in life  
n (of 
N1) 




7/13 54 82/164  50 
1 0.57 (0.1 – 4.6) 
2/6  33 87171  51 
1 0.9 (0.8-0.9) 
Sensory 
disturbance 
0/13 0 38/164 23 
0.07 0.8 (0.7 – 0.8) 
0/6  0 38/171  22 
0.3 0.8 (0.7 – 0.8) 
Behaviour / 
personality change 
1/13  8 21/164  13 
1 1.2 (0.4 – 3.6) 
0/6  0 22/171  13 
0.4 0.5 (0.09 - 2.7) 
Rapid cognitive 
decline 
4/13 31 11/164  7 
0.02* 6.2 (1.7 – 23.3) 
4/6  67 11/171  6 
<0.001** 29 (4.8 – 177) 
Unsteadiness 1/13 8 12/164  7 
1 1.1 (0.1 – 8.8) 
0/6  0 13/171  8 
1 1 (0.9 – 1) 





13/13 100 151/156 96.8 1 0.97 (0.94-1) 6/6 100 158/163 96.9 1 n/a 
Cerebellar 12/12 100 154/157 98.1 1 0.98 (0.96-1) 6/6 100 160/163 98.2 1 n/a 
Visual signs 1/13 7.7 20/147 13.6 0.70 0.53 (0.07-4.3) 0/6 0 21/154 13.6 0.60 n/a 
Oculomotor  4/12 33.3 61/146 41.8 0.76 0.7 (0.2-2.4) 1/5 20 64/153 41.8 0.41 0.3 (0.04-3.2) 
Pyramidal 9/12 75 106/153 69.3 1 1.3 (0.3-5.1) 3/5 60 112/160 70 1 0.6 (0.1-4.0) 
Extrapyramidal 1/12 8.3 18/143 12.6 1 0.6  (0.08-5.2) 0/5 0 19/150 12.7 0.63 n/a 
Primitive reflexes 7/10 70 67/139 48.2 0.21 2.5 (0.6-10.1) 2/5 40 72/144 50 1 0.7 (0.1-4.1) 
Seizures 1/11 9.1 8/157 5.1 0.47 1.9 (0.2-16.4) 0/6 0 9/162 5.6 1 n/a 
Myoclonus 10/11 90.9 98/148 66.2 0.11 5.1 (0.6-41.0) 4/4 100 104/155 67.1 0.21 n/a 
Other involuntary 
movements 
8/13 61.5 97/146 66.4 0.76 0.8 (0.3-2.6)  4/6 66.7 101/153 66.0 1 1.0 (0.2-5.8) 
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Presence of symptom 
Pain 5/12 41.7 85/155 54.8 0.55 0.59 (0.18-1.9) 1/5 20 89/162 54.9 0.18 0.2 (0.02-1.9) 
Other sensory 
disturbance 
6/13 46.2 89/149 59.7 0.39 0.58 (0.2-1.8) 3/6 50 92/156 59.0 0.69 0.7 (0.1-3.6) 
Muscle wasting 1/9 11.1 2/152 1.3 0.16 9.4 (0.8-114.6) 0/4 0 3/157 1.9 1 n/a 
Akinetic mutism 4/12 33.3 9/143 6.3 0.01** 7.4 (1.9-29.5) 2/5 40 11/150 7.3 0.06 8.4 (1.2-55.9) 
Gait disturbance 13/13 100 160/164 97.6 1 1 (1-1) 6/6 100 167/171 97.7 1 n/a 
Speech 
disturbance 
11/13 84.6 129/156 82.7 1 1.2 (0.2-5.5) 5/6 83.3 135/163 82.8 1 1.0 (0.1-9.2) 
Visual disturbance 3/11 27.3 46/148 31.1 1 0.83 (0.2-3.3) 2/6 33.3 47/153 30.7 1 1.1 (0.2-6.4) 
Forgetfulness 13/13 100 159/163 97.5 1 1 (1-1) 6/6 100 166/170 97.6 1 n/a 
Clinical depression 7/12 58.3 85/132 64.4 0.76 0.77 (0.2-2.6) 3/5 60 89/139 64.0 1 0.8 (0.1-5.2) 
Social withdrawal 9/10 90 102/130 78.5 0.69 2.5 (0.3-20.3) 4/5 80 107/135 79.3 1 1.0 (0.1-9.7) 
Apathy 7/11 63.6 90/137 65.7 1 0.91 (0.3-3.3) 2/4 50 95/144 66.0 0.61 0.5 (0.07-3.8) 
Anxiety 6/10 60 80/139 57.6 1 1.1 (0.3-4.1) 1/3 33.3 85/146 58.2 0.57 0.4 (0.03-4.0) 
Delusions 7/11 63.6 50/143 35.0 0.1 3.3 (0.9-11.7) 3/4 75 54/150 36 0.14 5.3 (0.54-52.5) 
Hallucinations 7/13 53.8 51/142 35.9 0.24 2.1 (0.7-6.5) 4/6 66.7 54/149 36.2 0.20 3.5 (0.6-19.8) 
Aggression 7/12 58.3 66/146 45.2 0.55 1.7 (0.5-5.6) 2/5 40 71/153 46.4 1 0.7 (0.1-4.7) 




3 (1-5) n/a 3 (2-5) n/a 0.65 n/a 3 (0-10) n/a 3 (2-5) n/a 0.42 n/a 
Forgetful 2 (0-3) n/a 3 (1-4) n/a 0.21 n/a 1.5 (0-5) n/a 3 (1-4) n/a 0.20 n/a 
Cerebellar 4 (4-6) n/a 4 (2-6) n/a 0.16 n/a 5 (3-16) n/a 4 (2-6) n/a 0.22 n/a 
Unsteadiness 3.5 (2-5) n/a 3 (2-4) n/a 0.37 n/a 2 (2-17) n/a 3 (2-4) n/a 0.59 n/a 
Sensory 
disturbance 
4 (1-9) n/a 2 (1-4) n/a 0.28 n/a 5 (0-n/a) n/a 2 (1-4) n/a 0.43 n/a 
Pain 4 (3-4) n/a 1 (0-4) n/a 0.09 n/a 3 (3-3) n/a 1 (0-4) n/a 0.66 n/a 
Myoclonus 6 (5-7) n/a 5 (3-6) n/a 0.15 n/a 6 (2-n/a) n/a 5 (4-6) n/a 0.51 n/a 
Other movement  5 (3-12) n/a 4 (2-6) n/a 0.25 n/a 8.5 (2-
18) 
n/a 4 (2-6) n/a 0.45 n/a 
Psychiatric 
symptoms 
4 (2-7) n/a 3 (1-7) n/a 0.71 n/a 4 (3-n/a) n/a 3 (1-7) n/a 0.33 n/a 
1N = Number documented *Significant p <0.05 **Highly significant p <0.01 ^Median months + IQR 
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Table 9: Investigation results - later referrals (vCJD) 
Investigation 
Later referrals 
( 30 days prior to 
death or after) 
Early referrals 
(>30 days prior to 
death) 
 Missed (referred 
on or after date 
of death) 
Referred in life  
 n (of N 
patients) 





(95% CI) n (of N 
patients) 








9/12 75 147/158 93.0 0.06 0.2 (0.05-
1) 
2/5 40 154/165 93.3 0.004** 0.05 
(0.007-0.3) 
Typical EEG2 
0/11 0 0/157 0 n/a n/a 0/4 0 0/164 0 n/a n/a 
Positive CSF 
14-3-32 
3/5 60 51/124 41.1 0.65 2.1 (0.3-
13.3) 
Nil done n/a 107/135 79.3 n/a n/a 
Codon-129 
genotype  
MM – 12/12 
MV – 0/12 




MM – 148/148 
MV – 0/148 




1 n/a MM – 6/6 
MV – 0/6 




MM – 154/154 
MV – 0/154 





1N = of number documented  2As defined in table 4 
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d) Multivariate analysis (later / missed referrals) 
An independent association in those referred later was retained only for 
akinetic mutism (p = 0.004, O.R. 7.4 (1.9 – 29.5)). All other findings were due 
to the confounding effect of age. Due to the small numbers in missed 
referrals, a multivariate analysis could not be undertaken.  
 
2.43 Older adults 
a) Basic characteristics (older adults) 
Three patients aged 65 years old were identified (2% of all cases of definite / 
probable vCJD). One case was linked to a blood transfusion. 18 patients aged 
45 years old were identified (10% of all included cases). A description of 
patient characteristics is detailed in Table 10.  
 
Those over 65 years old were more likely to be male (Table 11). In both older 
groups there was a shorter duration of illness but a longer time to diagnosis. 
Older patients were less likely to fulfil diagnostic criteria. 
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Table 10: Description of older cases (vCJD) 







Presenting features Classification 
in life2 
MRI Other investigations 




1  48 29 Rapid cognitive decline Probable Positive EEG negative vCJD 
2  52 11 Mood / psychiatric symptoms Probable Positive 14-3-3 positive, EEG 
negative 
vCJD 
3  51 11 Behaviour / personality change Possible Negative 14-3-3 / EEG negative Insufficient info 
4  53 15 Mood / psychiatric symptoms Probable Positive 14-3-3 / EEG negative vCJD 
5  50 11 Unsteadiness Probable Positive 14-3-3 / EEG negative Insufficient info 
6  74 7 Rapid cognitive decline Possible N/A N/A vCJD (blood 
transfusion) 
7  47 11 Mood / psychiatric symptoms Probable Positive 14-3-3 positive, EEG – 
negative 
Insufficient info 
8  51 13 Rapid cognitive decline Probable Positive 14-3-3 / EEG negative vCJD 
9  49 17 Mood / psychiatric symptoms  Probable Positive 14-3-3 / EEG negative vCJD 
10  62 8 Mood / psychiatric symptoms  Probable Positive 14-3-3 / EEG negative vCJD 
11  68 13 Mood / psychiatric symptoms  Possible Negative EEG negative Insufficient info 
12  54 15 Mood / psychiatric symptoms  Probable Positive 14-3-3 positive, EEG 
negative 
vCJD 
13  74 11 Rapid cognitive decline Did not fulfil 
criteria 
Negative EEG negative vCJD 
14  47 45 Sensory disturbance Possible Positive EEG negative  vCJD 
15  53 10 Rapid cognitive decline Possible Negative 14-3-3 positive, EEG 
negative 
vCJD 
16  59 33 Rapid cognitive decline Possible Negative EEG negative Insufficient info 
17  56 40 Rapid cognitive decline Did not fulfil 
criteria 
Negative No details Insufficient info 
18  46 12 Behaviour / personality change Probable Positive 14-3-3 + EEG negative vCJD 
1Year removed to protect patient confidentiality 2 As defined on page 43 
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Table 11: Basic demographics  – older adults (vCJD) 
Patient characteristics  65 years 
old  
(n = 3) 
<65 years old 
(n = 174) 
p-
value 
O.R (95% CI) 45 years old 
(n = 18) 
<45 years old 
(n = 159) 
p-
value 
O.R (95% CI) 
Median age: years (median, 
IQR) 
74 (68-74) 26 (21-33) n/a n/a 53 (49-60) 25 (20-31) n/a n/a 
Male: n of N documented (%) 3 (100%) 99 (57%) 0.26 n/a 10 (56%) 92 (58%) 1 n/a 
Median Index of Multiple 
Deprivation 
3 3 0.5 n/a 3 3 0.1 n/a 
Median duration of illness: 
months^ 
11 (7-11) 14 (11-18) 0.019* n/a 13 (11-20) 14 (11-18) 0.71 n/a 
Time to diagnosis (months)^ 8.7 (4.6 – n/a) 6.3 (4.8 – 8) 0.42 n/a 7.7 (6.1 – 10.6) 6.2 (4.8 – 7.9) 0.025* n/a 
Fulfilled diagnostic criteria in 
life 
2/3 (67%) 167/174 (96%) 0.13 0.08 (0.07-1.04) 16/18 (89%) 153/159 (96%) 0.19 0.31 (0.07-1.6) 
^Median months + IQR *Significant p <0.05 **Highly significant p <0.01 
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Table 12: Referral characteristics – older adults (vCJD) 
Referral characteristic  65 years old  <65 years old  45 years old <45 years old  
  %  % p-value O.R.  %  % p-value O.R. 
Source of referral (n) Neuro – 2 




Path – 6 
Psych – 6 
General – 4 















Psych – 6 
Path – 4 
General – 4 










Reviewed by Neurology: 
n/N  
3/3 100 173/174 99 1 n/a 18/18 100 158/159 99 1 n/a 
Time to neurology 
review (months)^ 
4 (1 – 
n/a) 
n/a 4 (3 – 6) n/a 0.4 n/a 4.5 (3 – 6) n/a 4 (3 – 5) n/a 0.69 n/a 
Reviewed by Psychiatry: 
n/N 
1/2 50 90/169 53 1 0.9 (0.05-
14.3) 
10/17 59 81/154 53 0.80 1.3 
(0.47-
3.6) 
Time to psychiatry 
review (months)^ 
1 (1 – 1) n/a 4 (3 – 5) n/a 0.1 n/a 4 (3 – 10) n/a 4 (3 – 6) n/a 0.17 n/a 
Neurosciences centre 
(at point of referral): n of 
N documented 
1/3 33 102/174 59 0.32 0.3 (0.03-
3.9) 
11/18 61 92/159 58 0.35 1.1 (0.4 
– 3) 























Later referral: n /N 2/3 67 11/174 6 <0.001** 29.6 (2.5-
352.8) 
6/18 33 7/159 4 <0.001** 10.9 
(3.1-
37.5) 
Missed referral: n /N  2/3 67 4/174 2 <0.001** 85 (6.3-
1141.1) 
4/18 22 2/159 1 <0.001** 22.4 
(3.8-
133.4) 
n = number with feature N = number documented *Significant p <0.05 **Highly significant p <0.01 ^Median + IQR  1 For North region 
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b) Referral characteristics (older adults) 
Although the majority of older patients were referred from a neurologist there 
was an excess compared to younger patients of those referred from 
pathology. A strong association with later referral was demonstrated for both 
older age groups (Table 12). 
 
c) Clinical characteristics (older adults) 
When compared to younger referrals, there was a strongly significant 
association between age and presenting feature. In both older age groups this 
was due to an excess of patients presenting with rapid cognitive decline and 
fewer presenting with sensory disturbance (Table 13). 
 
There were no significant differences between groups and the presence of 
any clinical features. There was however an earlier onset of forgetfulness 
(and cognitive impairment) and a non-significant later time to onset of sensory 
disturbance in the older groups; both these findings in keeping with the 
presenting features described. In both older groups, cerebral MRI scan was 
significantly less likely to demonstrate typical changes (Table 14). 
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Table 13: Clinical characteristics – older adults (vCJD) 
 65 years old <65 years old  45 years old 
(n = 18) 
<45 years old 




n (of N1)  % N (of  N1) % p-
value 





1  33 88  51 
1 0.9 (0.8 – 0.9) 
7  39 82 52 
1 0.9 (0.2 – 4.1) 
Sensory 
disturbance 
0  0 38  22 
1 0.8 (0.7 – 0.8 
1  6 37 23 




0  0 22  13 
0.6 0.5 (0.04 – 5.5) 
2   11 20 13 
0.3 0.6 (0.2 – 1.6) 
Rapid cognitive 
decline 
2  67 13  7 
0.02* 24.8 (2.1 – 291)  
7  39 8 5 
<0.001** 12 (3.4 – 39) 
Unsteadiness 0  0 13  7 
1 0.9 (0.9 – 1) 
1  6 12 8 
1 0.7 (0.09 – 5.9) 
Overall     0.025* n/a     <0.001** n/a 




3/3 100 161/166 97 1 n/a 18/18 100 146/151 97 0.65 n/a 
Cerebellar 3/3 100 163/166 98 1 n/a 17/17 100 149/152 98 1 n/a 
Visual signs 0/3 0 21/157 1 n/a 2/17 12 19/143 13 1 0.9 (0.2-4.1) 
Oculomotor  0/3 0 65/155 42 0.27 n/a 6/17 35 59/141 42 0.80 0.8 (0.3-2.2) 
Pyramidal 2/3 67 113/162 70 1 0.9 (0.08-9.8) 9/18 50 106/147 72 0.06 0.4 (0.1-1.0) 
Extrapyramidal 0/3 0 19/152 13 1 n/a 1/15 7 18/140 13 0.70 0.5 (0.06-3.9) 
Primitive reflexes 1/3 33 73/146 50 1 0.5 (0.04-5.6) 6/14 43 68/135 50 0.78 0.7 (0.2-2.2) 
Seizures 0/3 0 9/165 6 1 n/a 0/17 0 9/151 6 0.60 n/a 
Myoclonus 2/3 67 106/156 68 1 0.9 (0.08-10.7) 15/18 83 93/141 66 0.18 2.6 (0.7-9.4) 
Other involuntary 
movements 
1/3 33 104/156 67 0.55 0.3 (0.02-2.8) 10/17 59 95/142 67 0.34 0.7 (0.3-2.0) 
Presence of symptom 
Headache 0/2 0 36/160 23 1 n/a 4/15 27 32/147 22 0.75 1.3 (0.4-4.4) 
Pain 1/3 33 89/164 54 0.60 0.4 (0.04-4.7) 9/16 56 81/151 54 0.53 1.1 (0.4-3.1) 
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Other sensory 
disturbance 
2/3 67 93/159 59 1 1.4 (0.1-16.0) 12/18 67 83/144 58 0.32 1.5 (0.5-4.1) 
Dizziness 0/3 0 23/163 14 1 n/a 3/18 17 20/148 14 0.47 1.3 (0.3-4.8) 
Pseudobulbar 
palsy 
0/2 0 16/121 13 1 n/a 1/10 10 15/113 13 1 0.7 (0.09-6.1) 
Muscle wasting 0/3 0 3/158 2 1 n/a 0/16 0 3/145 2 1 n/a 
Akinetic mutism 1/2 50 12/153 8 0.16 11.8 (0.7-199.9) 1/17 6 12/138 9 1 0.7 (0.08-5.4) 
Gait disturbance 3/3 100 170/174 98 1 n/a 18/18 100 155/159 98 1 n/a 
Speech 
disturbance 
2/3 67 138/166 83 1 0.4 (0.04-4.6) 14/17 82 126/152 83 1 1.0 (0.3-3.6) 
Visual 
disturbance 
1/3 33 48/156 31 1 1.1 (0.1-12.7) 6/18 33 43/141 31 1 1.1 (0.4-3.2) 
Forgetfulness 3/3 100 169/173 98 1 n/a 18/18 100 154/158 98 1 n/a 
Clinical 
depression 
1/3 33 91/141 65 0.55 0.3 (0.02-3.1) 9/17 53 83/127 65 0.42 0.6 (0.2-1.7) 
Social withdrawal 2/3 67 109/137 80 1 0.5 (0.05-5.9) 12/15 80 99/125 79 1 1.1 (0.3-4.0) 
Apathy 0/2 0 97/146 66 0.12 n/a 7/15 47 90/133 68 0.11 0.4 (0.1-1.2) 
Anxiety 0/2 0 86/147 59 0.18 n/a 6/14 43 80/135 59 0.27 0.5 (0.2-1.6) 
Delusions 1/2 50 56/152 37 1 1.7 (0.1-27.9) 8/15 53 49/139 35 0.26 2.1 (0.7-6.1) 
Hallucinations 2/3 67 56/152 37 0.60 3.4 (0.3-38.7) 9/17 53 49/138 36 0.19 2.0 (0.7-5.6) 
Aggression 1/3 33 72/155 47 1 0.6 (0.05-6.5) 5/18 28 68/140 49 0.13 0.4 (0.1-1.2) 




1 (1-n/a) n/a 3 (2-5) n/a 0.38 n/a 2 (0-5) n/a 3 (2-5) 
 
n/a 0.11 n/a 
Forgetful 1 (1-n/a) n/a 2.5 (1-4) n/a 0.15 n/a 1 (0-2) n/a 3 (2-4) n/a 0.007** n/a 
Cerebellar 4 (2-n/a) n/a 4 (2-6) n/a 1.00 n/a 5 (2-7) n/a 4 (2-5) n/a 0.24 n/a 





n/a 2 (1-4) n/a 0.86 n/a 4 (1-5) n/a 2 (1-4) n/a 0.29 n/a 
Pain 3 (3-3) n/a 1 (0-4) n/a 0.66 n/a 2 (1-5) n/a 1 (0-4) n/a 0.31 n/a 
Myoclonus 4 (2-n/a) n/a 5 (4-6) n/a 0.72 n/a 5 (4-6) n/a 5 (4-6) n/a 0.38 n/a 
Other movement  3 (3-3) n/a 4 (2-6) n/a 0.63 n/a 6 (3-14) n/a 4 (2-6) n/a 0.076 n/a 
Psychiatric 
symptoms 
3 (3-3) n/a 3 (1-7) n/a 0.93 n/a 4 (0-7) n/a 4 (3-6) n/a 0.81 n/a 
1Where N = number documented with clinical feature  *Significant p <0.05 **Highly significant p <0.01 
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Table 14: Investigation results - older patients (vCJD) 
Investigation 65 years old <65 years old  45 years old 
(n = 18) 
<45 years old 
(n = 159) 
 
 n (of N1)  % n (of N1) % p-value O.R (95% 
C.I.) 
n (of N1)  % n (of N1) % p-value O.R (95% 
C.I.) 
MRI 0/2 0 156/168 93 0.006** n/a 11/17 65 145/153 95 0.001** 0.1 (0.03-0.3) 
EEG 0/2 0 0/166 0 n/a n/a 0/16 0 0/152 0 n/a 0 
CSF 14-3-3 Nil done n/a 54/129 42 n/a n/a 4/11 36 50/118 42 0.76 0.8 (0.2-2.8) 
Codon-129 
genotype  
MM – 3/3 
MV – 0/3 




MM – 157/157 
MV – 0/157 




1 n/a MM – 17/17 
MV – 0/17 




MM – 143/143 
MV – 0/143 





1N = number documented with clinical feature   
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2.5 Discussion 
This review of vCJD provides an update to previously published series [80, 
82]. It is the first to review characterisation of later and missed referrals versus 
early referrals and the first to provide comparative review of older versus 
younger patients.  
 
Factors associated with later / missed referral include older age, male sex, 
rapid cognitive decline as a presenting feature, the presence of myoclonus 
and akinetic mutism and the relative absence of sensory disturbance. A 
negative cerebral MRI and referral from a non-neurosciences centre were 
also associated.  
 
Further review of older patients demonstrated a phenotype that overlapped 
with later referrals (with multivariate analysis demonstrating the confounding 
effect of age). A discrepancy between a shorter duration of illness with a 
longer time to diagnosis in older age groups was seen - an expected finding 
given the association with later diagnoses in these groups. 
 
Whilst this retrospective review has provided valuable insight into the referral 
and clinical characteristics of late and older referrals there are limitations to 
consider. The accuracy and full documentation of all clinical features that 
develop after the NCJDRSU neurologist’s review is likely to be incomplete. 
This is most notable for the over-representation of akinetic mutism in those 
referred later / missed with time for such patients to develop the full clinical 
spectrum of signs compared to earlier referrals. Conversely whilst those 
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referred later may be more likely to have a complete dataset, their data on 
clinical features was often collected retrospectively and although features are 
cross-checked / supplemented with contemporaneous medical records, recall 
bias cannot be excluded.  
 
Factors associated with the difficulties of a diagnosis of dementia in older 
patients, as discussed in section 1.2, may be important here; specifically, 
older patients may be less likely to have collateral histories. Similarly, the 
excess of male patients may be due to spousal survival with women less likely 
to have a surviving spouse to report concerns over new cognitive decline. It 
may also be that the shorter disease duration may lead to delayed referral in 
older patients with initial symptoms potentially attributed to age or another 
dementing condition, relatively more common in these older ages. However, 
as similar findings were seen in those  45 years old (i.e. young, particularly 
with respect to a diagnosis of dementia) this is unlikely to fully explain these 
observations.  
 
Included in this cohort are both probable cases and definite cases. Whilst the 
diagnostic criteria have been demonstrated to have a high specificity it is 
impossible to exclude CJD mimics (i.e. other forms of RPD) without 
neuropathological confirmation. It is unlikely however that if present such 
mimics would be in sufficient numbers to influence results in an important 
way. 
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Interpretation of retrospective review of missed cases is also limited by 
confirmatory and selection bias; later referrals had features recognisable for 
vCJD and those who reached post-mortem (which is, as per section 1.5, 
unusual in older patients with dementia) must have displayed features 
unusual enough to warrant pathological examination. Indeed, from review of 
medical notes it appeared post-mortem in some missed referrals was only 
undertaken as CJD was still under consideration.  
 
It may also be considered that there would be a longer time to diagnosis in 
early cases due to the novel nature of vCJD at this time. A post-hoc analysis 
of year of referral and time to diagnosis did not however demonstrate this 
association (p = 0.17), suggesting this is unlikely to be a significant 
confounding factor. 
 
Later and missed referrals were combined in order to improve statistical 
power. In order to exclusively review risk factors for missed cases it would 
have been more accurate to analyse those referred after death separately, as 
before, however this was not possible due to small numbers. Further to this, 
there may have been possible error introduced by using those referred after 
death as a surrogate marker of missed cases. Some may not have been 
referred in life due to family wishes / clinician choice despite a working 
diagnosis of CJD by the local team; analysis is therefore of later referral to the 
NCJDRSU rather than delayed diagnosis per se.  
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With regards investigation results, patients were dichotomously coded as 
cerebral MRI undertaken or not and MRI positive or not. If the MRI sequences 
most sensitive for the detection of prion disease (that is, DWI and FLAIR 
sequences) were not undertaken as part of a patient’s MRI protocol, changes 
would be missed with such scans documented as negative. It may be that 
those referred later or older were less likely to have full MRI protocols 
undertaken introducing a confounder not accounted for here. Indeed, a post-
hoc review demonstrated that of the 18 probable / definite cases of vCJD who 
had a negative MRI (and in whom sequences undertaken were known), only 
five (27.8%) had DWI and FLAIR sequences performed and a further two 
(11.1%) had FLAIR only sequences performed (data provided by Ms Jan 
Mackenzie).  
 
Despite these limitations the analysis provides evidence of differences, largely 
associated with age. There are no comparative studies of later / missed 
referrals in vCJD, however it is important to note that most patients presented 
with a rapidly progressive dementia (which, as demonstrated in chapter 1, is a 
relatively non-specific presentation of a number of neurodegenerative (and 
non-neurodegenerative) pathologies) with symptoms more suggestive of 
vCJD (i.e. sensory disturbance) not present until later in the disease course. 
Further to this, there was an excess of features unusual for vCJD (e.g. muscle 
wasting and, in later referrals, seizures). These factors, when combined with a 
lower sensitivity of MRI in the later groups, means it is perhaps not surprising 
that patients were less likely to be managed in a non-neurosciences centre 
and referred later / missed. 
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Results from review of older patients is consistent with el Tawil et al (2015) 
[23] description of older cases of vCJD. This is to be expected as patients 
reviewed here overlap with those previously described. Similar to above, 
however, as dementia is associated with increasing age it is not unexpected 
that diagnosis may be later / missed if older patients with vCJD have a non-
specific presentation of a rapid dementia, a negative MRI, and a later time to 
onset of features that normally help to distinguish CJD from more common 
forms of dementia. 
 
Whilst it is important to consider whether later / missed and older referrals 
look different to vCJD it is also important to review whether their illness could 
in fact be recognised as CJD, and specifically, as vCJD. Such review will 
allow for a greater understanding of where diagnostic confusion may lie prior 
to considering measures to identify later / missed referrals earlier.  
 
1) Fulfilment of diagnostic criteria. The vast majority of patients fulfilled 
internationally agreed diagnostic clinical criteria for vCJD, however there was 
a slight excess of cases who did not in both older ages and later diagnoses 
(although this did not reach statistical significance). In general, therefore 
patients did eventually look like vCJD, although as demonstrated the time to 
onset of diagnostic features in the later and missed referrals was longer, likely 
contributing to later diagnosis.    
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2) Consideration of CJD in life: In 4/5 missed referrals in whom information 
was available CJD was considered in life. In all cases however sCJD was 
considered the most likely form (with a diagnosis of CJD eventually 
considered less likely in most due to a lack of supportive investigation results 
for sCJD). A post-hoc analysis reviewed whether this diagnostic confusion 
was because later and older cases of vCJD presented in a sCJD-like manner 
(Appendix B).  
 
When comparing all cases, the criteria separate forms of CJD well with a 
significant difference in the presenting feature and presence of clinical 
features (that contribute towards respective diagnostic criteria) throughout 
illness. This was also seen in missed referrals. In those 65 years old, 
however, whilst sensory features and pain were more likely in vCJD, there 
was no difference when compared to sCJD for any other features and no 
difference in the presenting symptom between groups. Interestingly, at the 
other end of the age spectrum there were common features seen between 
young onset cases of sCJD and vCJD (Table D1). This suggests that the 
differences in age at onset between variant and sporadic CJD may be partially 
responsible for the phenotypic differences seen; this will be further discussed 
in chapter 3. 
 
Older patients may therefore present in a manner suggestive of sCJD. 
Sensory disturbances are less likely in older groups however their presence is 
an important marker of vCJD in older ages.  
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Direct comparison of the clinical features of vCJD with other forms of 
dementia has not been undertaken here. A comparative review of 
pathologically proven cases of vCJD and vCJD mimics (i.e. cases considered 
to be vCJD in life but subsequently diagnosed with an alternative pathology at 
post mortem) was undertaken by Heath et al (2010) [80]. This demonstrated 
that, consistent with findings here, pain was the least commonly documented 




This review has demonstrated that whilst later referrals could be recognised 
as vCJD there are key atypical features, which may limit case recognition. 
The most significant ‘atypical’ feature was older age. Older age presents 
unique challenges given the relative frequency of other more common forms 
of dementia.  
 
Evidence has therefore been provided here which is consistent with the 
possibility that the epidemiological characteristics of vCJD, and specifically 
the absence of cases in older ages, may be in part due to case under-
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Section 2.1 discussed that age may be a risk factor for late diagnosis of sCJD. 
An association between age and later / missed referral in vCJD was 
demonstrated in chapter 2 with clinical and referral characteristics potentially 
influential in this. The aim of the current chapter is to review whether such an 




3.21 Clinical features of sCJD  
sCJD is the most common form of CJD. It may present initially with non-
specific symptoms such as weight loss, sleep disturbance and mood changes 
[84, 85]. In the majority, a rapidly progressive dementia then follows 
associated with multifocal neurological decline.  
 
sCJD is clinically and pathologically heterogeneous and can be sub-classified 
into 6 categories according to clinical, biochemical, and pathological 
parameters [34, 35], mediated by the expression of either methionine or valine 
at codon 129 on PRNP and the subtype of the abnormal prion protein isoform 
(type 1 or 2).  The most common subtype, however, representing 57% of 
those cases for which information is available is MM1 [36, 86] (see Table 15 
[86, 87]).  
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In general, ataxia and myoclonus are seen in almost all patients, with visual / 
oculomotor disturbance, pyramidal and extrapyramidal features seen in most. 
As per all forms of CJD, patients typically converge on a terminal akinetic 
mute state.  
 
Table 15: sCJD subtypes (data from surveillance cohorts in Germany 
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3.22 Biomarkers of sCJD 
Unlike vCJD, CSF is the most sensitive and specific marker in sCJD. The 
presence of 14-3-3 is a marker of neuronal damage, which, in the correct 
context, is supportive of a diagnosis of sCJD with a sensitivity of 93% and a 
specificity of 80% [88, 89]. RT-QuIC is the most useful ante-mortem 
investigation with sensitivity in the UK of approximately 95% and a very 
favourable specificity approaching 100% [90]; it has recently been 
incorporated into the internationally agreed diagnostic criteria for sCJD (Box 
3). Cerebral MRI demonstrates high signal of the basal ganglia and cerebral 
cortex on DWI and FLAIR sequences. Overall specificity of basal ganglia 
restricted diffusion is unknown and dependent on local reporting variation, 
however previous reports have demonstrated this to be 93% within specialist 
units [91]. EEG typically evolves from slow changes into disorganised 
generalised triphasic periodic complexes at a slow rate of 1-1.5Hz, a feature 
seen in 64% of patients with sCJD [92].  
 
3.23 Epidemiology of sCJD: UK and worldwide 
As detailed in chapter 1, sCJD is a disorder of retirement ages, however, and 
at odds with other sporadic neurodegenerative conditions, the association 
between age and age specific mortality in older patients is not linear with a 
decline seen after the age of 79 years. There is a slight excess of cases in 
females. Similar to all forms of CJD, there is a significant excess, compared to 
the general population, of patients homozygous for methionine at codon-129 
on PRNP [7].  
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3.31 Study design/subjects/setting 
A retrospective review of sCJD diagnoses was undertaken. All work was 
undertaken by the author, unless stated otherwise All patients referred to the 
NCJDRSU between 1st January 2010 and 31st December 2015, resident in 
the UK at the time of onset and classified as either probable or definite sCJD 
according to internationally agreed diagnostic criteria by 30th April 2016 were 
included (n = 584). The time period chosen for sCJD was to define a 
contemporary period that incorporated recent changes in the diagnostic 
criteria in January 2010. This allowed for inclusion of MRI basal ganglia 
changes and therefore afforded a greater number of probable cases to be 
included.  
 
As per chapter 2, for the purposes of this thesis, data was extracted from the 
NCJDRSU database with this first pass of data collection undertaken by Ms 
Jan Mackenzie and Mr Nick Attwood.  
 
Data collection methods are as per those detailed in chapter 2.  All data were 
collected on the same standardised form over this shorter period of time and 
are therefore comparable. However, if questionnaires were missing 
(approximately 10% of cases), correspondence and medical notes were 
reviewed, the questionnaire retrospectively completed and data entered onto 
both the NCJDRSU and thesis database. In a small number of cases, 
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hospitals were re-contacted for medical notes if none had previously been 
made available.  
 
If, on database review, a patient had been referred late but contact had not 
yet been made with the patient’s relatives an invitation to participate in the 
NCJDRSU surveillance project was sent. Two invitations were sent; if no 
response was received no further contact was made. Only patients referred 
2 years of database review were included. In those referred prior to this 
time, it was considered too late for unsolicited contact to be made and entries 
were listed as missing. 
 
3.32 Data processing 
1) Basic demographics and referral characteristics 
Data fields are described in chapter 2.  
 
2) Clinical features  
Presenting feature, signs and symptoms occurring during the patient’s illness, 
time to onset of clinical features, investigation results, and diagnostic criteria 
were collected as detailed in chapter 2. Further detail specific for sCJD is 
provided in Table 16 
 
5) Diagnosis in life 
Case notes and death certificates from all missed referrals (as defined on 
page 83) were reviewed to determine the working diagnosis in life. As medical 
notes from later referrals of vCJD (as defined on page 45) were largely 
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unrewarding a sample of sCJD later referrals (as defined on page 83) were 
reviewed. These were also unrevealing of the initial working diagnosis and 
therefore data searching was limited to only those referred on or after the date 
of death. 
 
3.33 Data review 
Once data had been entered onto the thesis database, as per chapter 2, 
variables were checked for validity and consistency. Missing entries were 
entered as ‘missing’ and not included in analysis. 
 
3.34 Analysis approach 
a) Outcome variables 
As per chapter 2, the primary outcome variable was to determine the 
characteristics of patients not diagnosed in life. Here, again, patients were 
classified as ‘missed referral’ if they were referred on the day of their death of 
after or ‘later referral’ if they had been referred later in the disease course. In 
sCJD, later referrals included all patients referred within 14 days of their death 
or after. The shorter period was chosen here to reflect the shorter disease 
duration of sCJD and, specifically, approximately the last 10% of illness. 
Results are as compared to those referred before these respective cut-offs. 
 
b) Explanatory variables  
Explanatory variables are as described in chapter 2 and detailed in Table 16.  
 
c) Analysis  
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Statistical methods are described in chapter 2.  
 
Similar to vCJD, age was associated with timing of referral with multivariate 
analysis highlighting it as a confounding factor. A separate analysis was 
undertaken re-defining age as the outcome. Patients were classified as ‘older 
adults’ if they were aged 65 years old at time of onset of first symptoms. 
Reasons for using 65 years old are as detailed in section 2.33. A further sub-
group analysis was undertaken on the oldest 10% of cases; in sCJD this 
equated to patients aged 80 years old. 
 
A database was created in Excel (version 14.7.7). All data was then 
transferred to SPSS (version 22) and analysed with the aim of looking for 
factors associated with missed diagnoses of CJD. 
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Table 16: Explanatory variables (sCJD) 
Variable How recorded Range of values Completeness: 
n (%) 
Age Median years + IQR n/a 584 (100) 
Sex % male n/a 584 (100)  
IMD n/a 1-5 578 (99) 
Duration of illness Median months + IQR n/a 567 (97.1)  
Time to diagnosis Median months + IQR n/a 581 (99.5) 
Source of referral Neurology, psychiatry, 
pathology, general 
medicine, other 




Yes/no n/a 538 (86.1) 
Reviewed by 
neurology 
Yes/no n/a 507 (86.8) 
Time to neurology 
review 
Median months + IQR n/a 380 (65.0) 
Reviewed by 
psychiatry 
Yes/no n/a 544 (93.0) 
Time to 
psychiatry review  




Yes/no n/a 584 (100) 
Region of referral North U.K. / South U.K. n/a 569 (97.4) 
Presenting 
feature 





rapid cognitive decline, 
unsteadiness, visual 
disturbance, and other) 
n/a 484 (82.9) 
Presence of signs 
/ symptoms 
during illness  
Feature present since 
onset of illness 
Yes/no See Tables 19 
and 23 
Cerebral MRI Presence of basal 
ganglia restricted 
diffusion (DWI) or high 
signal (FLAIR) 
Positive/negative 284 (51.2) 
CSF 14-3-3 Presence of 14-3-3 Positive/negative 414 (70.9) 







triphasic sharp wave 
complexes 
Positive/negative 45 (7.7) 
Codon 129 + 
protein isoform 
Polymorphism / isoform 
recorded 
MM1 / MM2 
MV1 / MV2 
VV1 / VV2 
250 (42.8) 
 
The influence of age on case ascertainment in CJD 
 
Chapter 3: Factors associated with late referral of sporadic CJD 85
 
3.4 Results 
3.41 All cases sCJD 
a) Basic characteristics (all cases) 
584 patients were included who fulfilled internationally accepted surveillance 
criteria for probable or definite sCJD. Of these, 356 patients were definite 
cases (61%).  
 
283 patients were male (48.5%). The median age of onset was 68 years (50 – 
86 years). The median IMD was 3 (1 – 5). There was a long median time to 
diagnosis of 6 months (0 – 19 months; excluding those referred after death) 
compared to disease duration of 7 months (0 – 22 months).  
 
b) Referral characteristics (all patients) 
All patients were reviewed by a neurologist during their illness (n = 507). The 
majority of patients were referred by neurology (n = 341, 62.2%). 
Approximately 20% (n = 111) were referred by psychiatry specialities. 65.7% 
of patients (n = 360) were managed in a non-neurosciences centre (of which 
29% were from hospitals with in-house neurologists).  
 
c) Clinical characteristics (all patients) 
The majority of patients (approximately 60%) presented with either cognitive 
or cerebellar features and cognitive and cerebellar were the most frequently 
reported clinical features seen during illness. Involuntary movements were 
also commonly seen. CSF 14-3-3 was positive in 84% (n = 348), RT-QuIC 
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was positive in 90% (n = 278) and MRI demonstrated typical changes in 78% 
(n = 223).  
 
When reviewing the time to onset of symptoms, as expected, given the 
presenting symptoms, forgetfulness and gait change were early features. 
Although sensory and visual disturbances were uncommon features if they did 
occur they occurred early in the disease process.  
 
3.42 Later / missed referrals 
a) Basic characteristics (later / missed referrals) 
A total of 190 patients were referred within 14 days of death or after (32.5% of 
all referred cases of definite / probable sCJD). Of these, 42 patients were 
referred on or after the date of death (7.2% of referrals), however in almost all 
of these 42, sCJD had been considered in life. The most frequent diagnoses 
in life were CJD, a rapidly progressive dementia, or an encephalitis / 
encephalopathy. In those with a non-prion disease-specific working diagnosis, 
Alzheimer’s disease and vascular dementia were diagnosed most frequently 
(Table 17). 
 
Those referred later were significantly older (p <0.001 for later and 0.01 for 
missed referrals). In those referred in the later stages of their illness patients 
were more likely to be male and had a shorter duration of illness (Table 18).  
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Table 17: Missed referrals: diagnoses in life / CJD considered in life (sCJD) 
Rapidly progressive dementia 13 31.0
CJD 6 14.3
Encephalitis / encephalopathy 6 14.3
Vascular dementia 3 7.1
Alzheimer’s dementia 3 7.1
Parkinson’s plus 1 2.4
Delirium 1 2.4
Not clear 9 21.4
CJD considered Yes: 35 No: 3 Yes: 83.3 No: 7.1 
 
 
Table 18: Basic demographics - later referrals (sCJD) 
Patient 
characteristics  Later (referred 
14 days of 
death or after) 
Early (referred 
> 14 days of 
death) 
p-value O.R. (95% CI) Missed (referred 
on or after date 
of death) 
Referred in life p-value O.R. (95% CI) 
Median age: years^ 72 (66-78) 67 (62-73) <0.001** n/a 71 (66-79) 68 (63-74) 0.012* n/a 
Male: n of N 
documented (%) 
110/ 190 (57.9) 173/394 (43.9) 0.002* 1.2 (1.1-1.3) 22/42 (52.4) 261/542 (48.2) 0.63 1.0 (1-1.1) 
Median Index of 
Multiple 
Deprivation 
3 (2-4) 3 (1-5) 0.8 n/a 2 (1-4) 3 (2-4) 0.75 n/a 
Median duration of 
illness: months^ 
4 (2-7) 5 (3-10) <0.001** n/a 5 (2-11) 5 (3-9) 1.0 n/a 
Time to diagnosis: 
months^ 
4.4 (2.2-9) 3.9 (2.4-8) 0.82 n/a 9.2 (4.8-18.2) 3.8 (2.3-7.8) <0.01** n/a 
Fulfilled diagnostic 
criteria in life 
115/141 (81.5%) 
275/362 (76.0%)
0.19 1.4 (0.9-2.3) 13/23 (56.5%) 377/480 (78.5%) 0.02* 0.36 (0.15-0.83) 
*Significant p <0.05 **Highly significant p <0.01  ^Median + IQR 
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b) Referral characteristics (later / missed referrals) 
Later / missed referrals were less likely to be referred from neurology 
(although all were reviewed by a neurologist during their illness), and, as 
expected, there was an excess of patients referred from pathology. In general 
those referred later were less likely to be managed in a neurosciences centre 
and were more likely to be reviewed by psychiatry with a strong association 
seen with missed referrals (p = 0.005) (Table 19).  
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Table 19: Referral characteristics - later referrals (sCJD) 
Referral 
characteristic Later referrals 
( 14 days prior 
to death or after) 
Early referrals 
(>14 days prior 
to death) 
 Missed referrals 




date of death) 
 





























































































Neurology: n / N  




2 (1-4.5) n/a 2 (1-5) n/a 0.6 n/a 3 (1-8) n/a 2 (1-5) n/a 0.6 n/a 
Reviewed by 
Psychiatry: n / N  




3 (2-6) n/a 2 (1-5) n/a 0.8 n/a 3.5 (1.5-7.25) n/a 3 (2-7) n/a 0.8 n/a 
Neurosciences 
centre (at point of 
referral): n / N  
259/584  44.3 198/394  50.3 <0.001** 0.8 (0.7-0.9) 10/42 23.8 249/542 45.9 0.006* 0.9 (0.9-1) 
Region of 
residence: North 





































*Significant p <0.05 **Highly significant p <0.01  ^Median + IQR 1 For North region n = number with feature N = number documented 
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c) Clinical characteristics (later referrals) 
When compared to earlier referrals, later referrals demonstrated an 
association with presenting feature; this was due to an excess of patients 
presenting with rapid cognitive decline, visual disturbance, and behavioural 
changes and fewer than expected presenting with sensory disturbance and 
unsteadiness (Table 20).  
 
Cerebellar features were consistently less likely in both later and missed 
referrals. In missed referrals there was a general paucity of signs and 
symptoms other than delusions and hallucinations, which were seen more 
frequently (although not significantly so). 
 
In later referrals, again clinical features were less likely to be described 
compared to earlier referrals, although features associated with end stage 
CJD (akinetic mutism and cortical blindness) were significantly more likely. 
Forgetfulness and behavioural disturbance occurred earlier in later referrals, 
however no differences were seen with missed referrals. 
 
MRI was less likely to be positive in later and missed referrals; CSF was more 
likely to be positive with a significant association demonstrated with later 
referral. In later referrals there was a significant difference in the codon-129 
polymorphism / isoform subtype, with an excess of MM1 seen. 
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Table 20: Clinical characteristics - later and missed referrals (sCJD) 
Presenting 
features  Later referrals 
( 14 days prior 
to death or after) 
Early referrals 
(>14 days prior 
to death) 
 Referred on or 
after date of 
death 
Referred 
before date of 
death 
 




13/134 9.7 27/350 7.7 
0.16 1.5 (0.9 – 2.7) 
3/24 12.5 37/460 8.0 
0.2 2 (0.7 – 5.5) 
Sensory 
disturbance 
1/134 0.7 19/350 5.4 
0.02* 0.1 (0.02 – 1) 
0/24 0 20/460 4.3 




21/134 15.7 38/350 10.9 
0.5 1.3 (0.6 – 2.6) 
5/24 20.8 54/460 11.7 
0.4 1.6 (0.5 – 5.7) 
Rapid cognitive 
decline 
49/134 36.6 111/350 31.7 
0.3 1.2 (0.8 – 2.9) 
7/24 29.2 153/460 33.3 
0.8 0.8 (0.3 – 2) 
Unsteadiness / 
motor 
28/134 20.9 100/350 28.6 
0.1 0.7 (0.4 – 1.1) 
5/24 20.8 123/460 26.7 
0.6 0.7 (0.3 – 2) 
Visual 
disturbance 
16/134 11.9 29/350 8.3 
0.2 1.5 (0.8 – 2.9) 
3/24 12.5 42/460 9.1 
0.5 1.4 (0.4 – 5) 
Other 6/134 4.5 26/350 7.4 
0.3 0.6 (0.2 – 1.5) 
1/24 4.2 31/460 6.7 
1 0.6 (0.08 – 4.6) 
Overall     0.04* n/a     0.67 n/a 
Presence of sign 
Cognitive 
impairment 
123/152 80.9 322/375 85.9 0.16 0.9 (0.8-1.1) 17/27 63.0 428/500 85.6 0.002** 0.9 (0.8-1) 
Apraxia 33/87 37.9 126/245 51.4 0.03* 0.9 (0.8-1) 6/19 31.6 153/313 48.9 0.14 1 (0.9-1) 
Dysphasia 67/118 56.8 192/336 57.1 0.95 1 (0.9-1.1) 3/20 15.0 256/434 59.0 <0.001** 0.9 (0.9-1) 
Grasp reflex 54/121 44.6 180/364 49.5 0.36 1 (0.9-1.1) 1/21 4.8 233/464 50.2 <0.001** 0.9 (0.9-1) 
Cerebellar gait 
ataxia 
65/108 60.2 221/336 65.8 0.29 0.9 (0.8-1.1) 10/23 43.5 276/421 65.6 0.031 1 (0.9-1) 
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Cerebellar signs 84/187 44.9 266/394 67.5 <0.001** 0.7 (0.6-0.8) 11/41 26.8 339/540 62.8 <0.001** 0.9 (0.9-1) 
Lower motor 
neurone 
13/148 8.8 53/383 13.8 0.11 0.9 (0.8-1) 0/23 0 66/508 13.0 0.07 1 (0.9-1) 
Akinetic mute 80/146 54.8 103/384 26.8 <0.001** 1.4 (1.3-1.7) 8/24 33.3 175/506 34.6 0.90 1 (1-1) 
Pyramidal 
features 
79/148 53.4 217/381 57 0.46 1 (0.9-1.1) 5/24 20.8 291/505 57.6 <0.001** 0.9 (0.9-1) 
Extrapyramidal 
features 
69/146 47.3 178/375 47.5 0.97 1 (0.9-1.1) 7/24 29.2 240/497 48.3 0.07 1 (0.9-1) 
Cortical blindness 40/132 30.3 52/374 13.9 <0.001** 1.4 (1.1-1.7) 3/24 12.5 89/482 18.5 0.46 1 (0.9-1) 
Oculomotor palsy 15/143 10.5 43/374 11.5 0.75 1 (0.8-1.1) 1/26 3.8 57/491 11.6 0.22 1 (0.9-1) 
Dysarthria 39/132 29.5 108/357 30.3 0.88 1 (0.9-1.1) 2/24 8.3 145/465 31.2 0.02* 0.9 (0.9-1) 
Myoclonus 114/151 75.5 296/384 77.1 0.70 1 (0.9-1.1) 11/24 45.8 399/511 78.1 <0.001** 0.9 (0.9-1) 
Chorea 6/146 4.1 14/381 3.7 0.82 1 (0.8-1.4) 0/21 0 20/506 4 0.35 1 (0.9-1) 
Dystonia 33/147 22.4 82/380 21.6 0.83 1 (0.9-1.2) 0/21 0 115/506 22.7 0.01** 0.9 (0.9-1) 
Sensory signs 3/146 2.1 28/379 7.4 0.02* 0.8 (0.7-0.9) 0/23 0 31/502 6.2 0.22 1 (0.9-1) 
Presence of symptom 





71/148 48 188/372 50.5 0.60 1 (0.9-1.1) 10/27 37.0 249/493 50.5 0.17 1 (0.9-1) 
Language 
disturbance 
86/152 56.6 230/383 60.1 0.46 1 (0.9-1.1) 10/25 40 306/510 60 0.05* 1 (0.9-1) 
Psychiatric 
symptoms 
59/156 37.8 137/383 35.8 0.65 1 (0.9-1.1) 9/28 32.1 187/511 36.6 0.63 1 (1-1) 
Depression 36/154 23.4 85/379 22.4 0.81 1 (0.9-1.2) 6/28 21.4 115/505 22.8 0.87 1 (1-1) 
Anxiety 71/152 46.7 150/380 39.5 0.12 1.1 (1-1.2) 9/28 32.1 212/505 42 0.30 1 (0.9-1) 
Behavioural 
disturbance 
93/155 60 207/383 54 0.21 1.1 (1-1.2) 16/28 57.1 284/510 55.7 0.88 1 (1-1) 
Apathy / 
withdrawal 
61/151 40.4 160/378 42.3 0.68 1 (0.9-1.1) 11/26 42.3 210/503 41.7 0.96 1 (1-1) 
Delusions 33/149 22.1 98/384 25.5 0.42 1 (0.9-1.1) 9/26 34.6 122/507 24.1 0.22 1 (1-1.1) 
Hallucinations - 
visual 
88/155 56.8 205/384 53.4 0.48 1 (0.9-1.2) 17/28 60.7 276/511 54 0.49 1 (1-1.1) 
Hallucinations - 4/154 2.6 10/385 2.6 1.00 1 (0.7-2.3) 2/27 7.4 12/512 2.3 0.11 1.1 (0.9-1.4) 
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7/152 4.6 21/384 5.5 0.69 1 (0.8-1.2) 1/27 3.7 27/509 5.3 0.72 1 (0.9-1.1) 
Disturbance of 
gait 
135/157 86 337/383 88 0.52 0.9 (0.8-1.1) 22/28 78.6 450/512 87.9 0.15 1 (0.9-1) 
Bed-bound 135/156 86.5 221/385 57.4 <0.001** 1.4 (1.3-1.6) 21/27 77.8 335/514 65.2 0.18 1 (1-1.1) 
Speech 
disturbance 
104/153 68 256/381 67.2 0.86 1 (0.9-1.1) 12/27 44.4 348/507 68.6 0.009** 0.9 (0.9-1) 
Diplopia 27/153 17.6 53/384 13.8 0.26 1.1 (0.9-1.3) 0/27 0 80/510 15.7 0.026* 0.9 (0.9-1) 
Visual impairment 65/153 42.5 150/380 39.5 0.52 1 (0.9-1.2) 10/27 37.0 205/506 40.5 0.72 1 (1-1) 
Involuntary 
movements 
114/156 73.1 261/383 68.1 0.26 1.1 (1-1.2) 20/27 74.1 355/512 69.3 0.60 1 (1-1.1) 
Sensory 
symptoms (pain / 
numbness etc) 
20/153 13.1 73/382 19.1 0.1 0.9 (0.8-1) 2/27 7.4 91/508 17.9 0.16 1 (0.9-1) 
Seizures 17/153 11.1 25/384 6.5 0.07 1.2 (0.9-1.6) 4/28 14.3 38/509 7.5 0.19 1 (1-1.2) 
Time to onset of clinical feature 
Forgetful 1 (0-2) n/a 1 (0-3) n/a 0.03* n/a 1 (0-2) n/a 1 (0-3) n/a 0.2 n/a 
Rapid Cognitive 
Decline 
2 (1-4) n/a 3 (1-5) n/a 0.13 n/a 4 (1-11) n/a 2 (1-5) n/a 0.22 n/a 
Gait disturbance 1 (0-3) n/a 1 (0-4) n/a 0.37 n/a 2 (1-6) n/a 1 (0-3) n/a 0.16 n/a 
Cerebellar signs 2 (1-5) n/a 3 (1-5) n/a 0.23 n/a 4 (1-11) n/a 2 (1-5) n/a 0.12 n/a 
Visual symptoms 1 (0-4) n/a 2 (0-4) n/a 0.2 n/a 1 (0-6) n/a 1 (0-4) n/a 0.94 n/a 
Extrapyramidal 
signs  
3 (2-6) n/a 3 (2-6) n/a 0.62 n/a 4 (1-11) n/a 3 (2-6) n/a 0.56 n/a 
Pyramidal signs  3 (1-7) n/a 3 (2-7) n/a 0.13 n/a 7 (2-26) n/a 3 (2-7) n/a 0.22 n/a 
Myoclonus 2 (1-6) n/a 3 (2-6) n/a 0.19 n/a 4 (2-14) n/a 3 (2-6) n/a 0.21 n/a 
Akinetic mutism 3 (2-6) n/a 3 (2-5) n/a 0.95 n/a 5 (2-21) n/a 3 (2-5) n/a 0.18 n/a 
Behavioural and 
mood disturbance
0 (0-2) n/a 1 (0-3) n/a 0.04* n/a 1 (0-5) n/a 1 (0-3) n/a 0.27 n/a 
Psychiatric 
symptoms 
1 (0-3) n/a 4 (1-8) n/a 0.28 n/a 0.5 (0-
11) 
n/a 1 (0-3) n/a 0.92 n/a 
Sensory 
symptoms 
4 (1-7) n/a 1 (0-5) n/a 0.17 n/a 3 (3-3) n/a 1 (0-6) n/a 0.81 n/a 
1N = number documented with clinical feature  *Significant p <0.05 **Highly significant p <0.01 ^Median months + IQR 
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Table 21: Investigation findings - later and missed referrals (sCJD) 
 
Later referrals 
( 14 days prior 
to death or after) 
Early referrals 
(>14 days prior 
to death) 
 Referred date 
of death 
Referred before 
date of death 
 
 n (of N 
patients) 
% n (of N 
patients)
% p-value O.R. (95% CI) n (of N 
patients)
% n (of N 
patients)
% p-value O.R. (95% CI) 
Investigation             
MRI 50/67 74.6 172/217 79.3 0.4 0.9 (0.8-1.1) 3/6 50 219/278 78.8 0.09 n/a 
EEG 2/10 20.0 12/35 34.3 0.39 n/a 0/1 0 14/44 31.8 0.50 n/a 
CSF 14-3-3 97/106 91.5 251/308 81.5 0.04* 1.3 (1.1-1.4) 11/12 91.7 337/402 83.8 1.0 1 (0.9-1.1) 




(N = 87) 
MM1 - 62 
MM2 - 4 
MV1 - 2 
MV2 - 4 
VV1 - 1 








(N = 163) 
MM1 - 82 
MM2 - 13 
MV1 - 13 
MV2 - 23 
VV1 - 5 














(N = 20) 
MM1 - 11 
MM2 - 1 
MV1 - 1 
MV2 - 2 
VV1 - 1 








(N = 230) 
MM1 - 133 
MM2 - 16 
MV1 - 14 
MV2 - 25 
VV1 - 5 












*Significant p <0.05 **Highly significant p <0.01  ^Median + IQR
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Multivariate analysis 
An independent association with later referral was retained for being bed-bound (p = 
0.001, O.R. 4 (2.4 – 6.6)) / akinetic mutism (p <0.001, O.R. 2.9 (1.9 – 4.4)), 
cerebellar signs (p <0.001, O.R. 0.6 (0.4 – 0.9)), cortical blindness (p <0.001, O.R. 
(2.4 (1.5 – 3.8)), and being referred by a regional hospital (p = 0.03, O.R. 1.8 (1.2 – 
2.6)). All other findings were due to the confounding effects of age. 
 
In missed referrals, an independent association was retained for language 
impairment (p = 0.05, O.R. 0.4 (0.2 – 1)), speech disturbance (p = 0.008, O.R. 0.3 
(0.2 – 0.8)), cerebellar signs (p <0.001, O.R. 0.1 (0.05 – 0.4)) / ataxia (p = 0.05, O.R 
0.4 (0.2 – 1)), grasp reflex (p = 0.003, O.R. 0.05 (0.006 – 0.4)), pyramidal features (p 
= 0.001, O.R. 0.18 (0.07 – 0.5)), cognitive impairment (p = 0.002, O.R. 0.3 (0.1 – 
0.6)), dysphasia (p <0.001, O.R. 0.1 (0.03 – 0.4)), myoclonus (p <0.001, O.R. 0.2 
(0.1 – 0.5)), whether they were seen by psychiatry (p = 0.002, O.R. 3.5 (1.6 – 7.8)), 
and whether they were referred from a neurosciences centre (p = 0.023, O.R. 2.4 
(1.1 – 5)). Age was a confounding factor in all other associations.  
 
3.43 Older adults 
a) Basic characteristics (older adults) 
396 patients aged 65 years old were identified (67.8% of all cases of definite / 
probable sCJD). Of these, 62 patients aged 80 years old were identified (10% of all 
included cases). Older patients were more likely to be male. The duration of illness 
was shorter in both groups compared to younger patients with no shortening of the 
time to diagnosis to compensate for this more rapid progression (Table 22).  
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b) Referral characteristics (older adults) 
The source of referral was significantly associated with age. Older patients were less 
likely to be referred by neurology and were more likely to be referred by general 
physicians and pathology. All patients were however reviewed by a neurologist 
during their illness. Older patients were significantly less likely to be managed in a 
neurosciences centre at the time of referral. There was a strong association between 
older age and later referral with an excess of missed referrals in older patient groups 
(Table 23).  
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Table 22: Basic demographics - older adults (sCJD) 
Patient 
characteristics  
65 years old  
(n = 396) 
<65 years old 
(n = 188) 
p-value O.R (95% CI) 80 years old 
(n = 62) 
<80 years old 
(n = 522) 
p-value O.R (95% CI) 
Median age: years 
(median, IQR) 
72 (68-77) 60 (55-63) 
n/a 
n/a 82 (80-84) 67 (62-73) 
n/a 
n/a 
Male: n of N 
documented (%) 
202 (51%) 81 (43%) 0.07 1.2 (1-1.6) 31 (50%) 252 (48%) 0.8 1 (1-1.1) 
Median Index of 
Multiple Deprivation 
2 (2-4) 3 (2-4) 0.4 n/a 3 (1.8-4) 3 (2-4) 0.6 n/a 
Median duration of 
illness: months^ 
4 (3-8) 6 (3-12) <0.001** n/a 4 (3-7) 5 (3-10) 0.02* n/a 
Time to diagnosis 
(months)^ 
4 (2.3-7.7) 4.7 (2.4-9.6) 0.08 n/a 4.1 (2.4-6.5) 4.1 (2.3-8.3) 0.7 n/a 
Fulfilled diagnostic 
criteria during life 
268/342 (78.6%) 122/161 
(75.8%) 




0.48 1.4 (0.67-3.0) 
^Median months + IQR *Significant p <0.05 **Highly significant p <0.01 n/a = not applicable 
 
The influence of age on case ascertainment in CJD 
 
Chapter 3: Factors associated with late referral of sporadic CJD 98 
Table 23: Referral characteristics - older adults (sCJD) 
Referral 
characteristic  
65 years old  <65 years old  80 years old <80 years old  
















































































Neurology: n / N 




2 (1-4)  3 (1-6)  0.02* n/a 3 (1-6)  2 (1-5)  0.5 n/a 
Reviewed by 
Psychiatry: n / N  




3 (2-6)  4 (1.3-8.8)  0.2 n/a 3 (2-8)  3.5 (1.8-7)  0.9 n/a 
Neurosciences 
centre (at point of 
referral): n / N  
150/396 37.9 109/188 58.0 <0.001** 0.6 (0.5-0.7) 11/62 17.7 248/522 47.5 <0.001** 0.9 (0.8-0.9) 
Region: North 

















0.38 1.3 (0.7-2.5)1 
Later referral: n 
/N 
150/396 37.9 40/188 21.3 <0.001** 1.8 (1.3-2.4) 36/62 58.1 154/522 29.5 <0.001** 1.2 (1.1-1.2) 
Missed referral: n 
/ N 
33/396 8.3 9/188 4.8 0.1 1.5 (0.9-2.8) 8/62 12.9 34/522 6.5 0.07 1.1 (1-1.3) 
*Significant p <0.05 **Highly significant p <0.01 ^Median + IQR 1 For North region n = number with characteristic N = of number documented
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c) Clinical characteristics (older adults) 
In both older age groups there was an excess of patients presenting with 
rapid cognitive decline and an earlier onset of forgetfulness and cognitive 
impairment in keeping with this (Table 24).  
 
In both older groups, clinical features were less likely to be seen than in 
earlier groups. In particular, older patients were significantly less likely to have 
psychiatric features and in those 80 years old, cerebellar features. Older 
patients were however more likely to be bed-bound, akinetic and mute, and 
be cortically blind. Seizures were also significantly more likely in those 80 
years old. 
 
There was a shorter time to onset of forgetfulness in both older groups. A 
shorter time to onset was also demonstrated for a number of other clinical 
features in those 65 years old; this may simply reflect the significantly 
shorter duration of illness in this older group (an association seen to a lesser 
extent in those 80 years old). 
 
MRI was less likely to demonstrate the typical changes of sCJD in both 
groups (Table 25). In those 80 years old, EEG was more likely to 
demonstrate typical changes of sCJD.  
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% p-value O.R. 80 
years old 











24/328 7.3 16/156 10.3 0.5 0.8 (0.4 – 1.4) 2/49 4.1 38/435 8.7 0.8 0.8 (0.3 – 2.1) 
Sensory 
disturbance 
8/328 2.4 12/156 7.7 0.01 0.3 (0.1 – 0.8) 2/49 4.1 18/435 4.1 1 




37/328 11.3 22/156 14.1 0.3  0.7 (0.4 – 1.3) 5/49 10.2 54/435 12.4 0.4 0.4 (0.1 – 1.9) 
Rapid cognitive 
decline 
116/328 35.4 44/156 28.2 0.1 1.4 (0.9 – 2.1) 24/49 49.0 136/435 31.3 0.02* 2.1 (1.2 – 3.8) 
Unsteadiness 94/328 28.7 34/156 21.8 0.1 
1.4 (0.9 – 2.3) 
9/49 18.4 119/435 27.4 0.2 0.6 (0.3 – 1.3) 
Visual 32/328 9.8 13/156 8.3 0.7 1.2 (0.6 – 2.3) 5/49 10.2 40/435 9.2 0.8 1.1 (0.4 – 3) 
Other 17/328 5.2 15/156 9.6 0.08 0.5 (0.3 – 1.1) 2/49 4.1 30/435 6.9 0.8 0.6 (0.1 – 2.5) 




299/354 84.5 146/173 84.4 0.98 1 (0.7-1.4) 42/52 80.8 403/475 84.8 0.44 1 (0.9-1.1) 
Apraxia 111/215 51.6 48/117 41.0 0.07 1.3 (1-1.8) 10/28 35.7 149/304 49.0 0.18 1 (0.9-1) 
Dysphasia 187/304 61.5 72/150 48.0 0.006** 1.4 (1.1-1.9) 27/47 57.4 232/407 57.0 0.95 1 (0.9-1.1) 
Grasp reflex 169/325 52.0 65/160 40.6 0.02* 1.4 (1-1.8) 19/46 41.3 215/439 50.0 0.32 1 (0.9-1) 
Cerebellar gait 
ataxia 
189/293 64.5 97/151 64.2 0.96 1 (0.8-1.3) 19/38 50.0 267/406 65.8 0.05* 0.9 (0.9-1) 
Cerebellar signs 234/394 59.4 116/187 62.0 0.54 1 (0.8-1.3) 19/50 38 280/449 62.4 0.001** 0.9 (0.8-1) 
Lower motor 
neurone 
47/357 13.2 19/174 10.9 0.46 1.2 (0.8-1.7) 7/55 12.7 59/476 12.4 0.94 1 (0.9-1.1) 
Akinetic mute 138/356 38.8 45/174 25.9 0.003** 1.5 (1.1-2) 27/54 50.0 156/476 32.7 0.01** 1.1 (1-1.2) 
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Pyramidal 
features 
197/357 55.2 99/172 57.6 0.61 0.9 (0.7-1.2) 33/52 63.5 263/477 55.1 0.25 1 (1-1.1) 
Extrapyramidal 
features 
166/351 47.3 81/170 47.6 0.94 1 (0.8-1.3) 30/54 55.6 217/467 46.5 0.21 1 (1-1.1) 
Hemianopia 33/340 9.7 14/166 8.4 0.64 1.1 (0.7-1.8) 2/49 4.1 45/457 9.8 0.19 0.9 (0.9-1) 
Cortical 
blindness 
70/339 20.6 22/167 13.2 0.04* 1.5 (1-2.2) 14/50 28 78/456 17.1 0.06 1 (1-1.2) 
Oculomotor 
palsy 
37/345 10.7 21/172 12.2 0.61 0.9 (0.3-1.3) 3/50 6.0 55/467 11.8 0.22 0.9 (0.9-1) 
Dysarthria 103/324 31.8 44/165 26.7 0.24 1.2 (0.9-1.6) 12/44 27.3 135/445 30.3 0.67 1 (0.9-1) 
Myoclonus 283/360 78.6 127/175 72.6 0.12 1.2 (1-1.6) 41/56 73.2 369/479 77.0 0.52 1 (0.9-1.1) 
Chorea 14/353 4.0 6/174 3.4 0.77 1.1 (0.6-2.2) 3/54 5.6 17/473 3.6 0.48 1.1 (0.9-1.3) 
Dystonia 38/174 21.8 77/353 21.8 1.00 1 (0.7-1.3) 7/55 12.7 108/472 22.9 0.08 0.9 (0.9-1) 
Sensory signs 22/353 6.2 9/172 5.2 0.65 1.1 (0.7-2) 1/53 1.9 30/472 6.4 0.19 0.9 (0.9-1) 
Presence of symptom 
Forgetfulness 316/362 87.3 151/176 85.8 0.63 1.1 (0.8-1.5) 45/55 81.8 422/483 87.4 0.25 1 (0.9-1) 
Other higher 
function  
170/350 48.6 89/170 52.4 0.42 0.9 (0.7-1.2) 24/54 44.4 235/466 50.4 0.41 1 (0.9-1) 
Language 
disturbance 
215/360 59.7 101/175 57.7 0.66 1.1 (0.8-1.4) 33/55 60.0 283/480 59.0 0.88 1 (0.9-1.1) 
Psychiatric 
symptoms 
121/363 33.3 75/176 42.6 0.04* 0.8 (0.6-1) 12/56 21.4 184/483 38.1 0.01** 0.9 (0.9-1) 
Depression 68/358 19.0 53/175 30.3 0.003** 0.7 (0.5-0.9) 6/56 10.7 115/477 24.1 0.02* 0.9 (0.9-1) 
Anxiety 135/357 37.8 86/176 48.9 0.02* 0.7 (0.6-0.9) 15/56 26.8 206/477 43.2 0.02* 0.9 (0.9-1) 
Behavioural 
disturbance 
189/362 52.2 111/176 63.1 0.02* 0.7 (0.6-1) 27/56 48.2 273/482 56.6 0.23 1 (0.9-1) 
Apathy / 
withdrawal 
143/353 40.5 78/176 44.3 0.40 0.9 (0.7-1.1) 15/56 26.8 206/473 43.6 0.02* 0.9 (0.9-1) 
Delusions 85/358 23.7 46/175 26.3 0.52 0.9 (0.7-1.2) 6/56 10.7 125/477 26.2 0.01** 0.9 (0.9-1) 
Hallucinations - 
visual 
201/363 55.4 92/176 52.3 0.50 1.1 (0.9-1.4) 29/55 52.7 264/484 54.5 0.80 1 (0.9-1) 
Hallucinations - 
auditory 
8/364 2.2 6/175 3.4 0.40 0.8 (0.4-1.4) 0/56 0 14/483 2.9 0.20 0.9 (0.9-0.9) 
Other 
psychiatric 
15/361 4.2 13/175 7.4 0.11 0.7 (0.5-1) 1/56 1.8 27/480 5.6 0.22 0.9 (0.9-1) 
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320/363 88.2 152/177 85.9 0.45 1.1 (0.8-1.6) 44/56 78.6 428/484 88.4 0.04* 0.9 (0.8-1) 
Bed-bound 259/364 71.2 97/177 54.8 <0.001** 1.6 (1.3-2) 49/56 87.5 307/485 63.3 <0.001** 1.1 (1-1.2) 
Speech 
disturbance 
248/360 68.9 112/174 64.4 0.30 1.1 (0.9-1.5) 37/56 66.1 323/478 67.6 0.82 1 (0.9-1.1) 
Diplopia 54/361 15.0 26/176 14.8 0.96 1 (0.7-1.4) 5/55 9.1 75/482 15.6 0.20 1 (0.9-1) 
Visual 
impairment 
150/358 41.9 65/175 37.1 0.29 1.1 (0.9-1.5) 16/55 29.1 199/478 41.6 0.07 0.9 (0.9-1) 
Involuntary 
movements 
261/363 71.9 114/176 64.8 0.09 1.2 (1-1.6) 39/55 70.9 336/484 69.4 0.82 1 (0.9-1.1) 
Sensory 
symptoms  
53/359 14.7 40/176 22.7 0.02* 0.7 (0.5-0.9) 7/55 12.7 86/480 17.9 0.34 1 (0.9-1) 
Seizures 27/361 7.5 15/176 8.5 0.67 0.9 (0.6-1.4) 13/56 23.2 29/481 6.0 <0.001** 1.3 (1.1-1.6) 
Time to onset of clinical features^ 
Forgetful 1 (0-2)  1 (0-4)  0.01*  0 (0-1)  1 (0-3)  0.001**  
Rapid Cognitive 
Decline 
2 (1-4)  3 (1-7)  0.04*  2 (1-5)  2 (1-5)  0.40  
Gait 
disturbance 
1 (0-3)  2 (1-5)  0.001**  1 (0-3)  1 (0-3)  0.39  
Cerebellar signs 2 (1-4.5)  3 (1-7)  0.003**  3 (1-6)  2 (1-5)  0.52  
Visual 
symptoms 
1 (0-4)  1.5 (0-5)  0.30  1 (0-7)  1 (0-4)  0.88  
Extrapyramidal  3 (2-5)  4 (2-8)  0.024*  2.5 (2-
5.5) 
 3 (2-6)  0.38  
Pyramidal signs 3 (2-6)  4 (2-9)  0.08  3 (2-6)  3 (2-7)  0.28  
Myoclonus 2 (1-5)  4 (2-8)  0.003**  2 (1-5)  3 (2-6)  0.36  




1 (0-2)  1 (0-4)  0.15  1 (1-2)  1 (0-3)  0.92  
Psychiatric 
symptoms 
1 (0-3)  2 (0-4)  0.40  1 (0-8)  1 (0-3)  0.52  
Sensory 
symptoms 
2 (0.5-5)  1 (0-7)  0.79  2 (0-8)  1 (0-5)  0.95  
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*Significant p <0.05 **Highly significant p <0.01 ^Median months (+ IQR) 
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old (N = 
328)  
% <65 years 






(N = 49) 
% <80 years 
old 




MRI 141/191 73.8 81/93 87.1 0.01** 0.5 (0.3-0.9) 17/29 58.6 205/255 80.4 0.01* 0.9 (0.8-1) 
EEG 10/33 30.3 4/12 75.0 0.8 0.9 (0.3-2.5) 5/6 83.3 9/39 23.1 0.008** 1.5 (1-2.2) 
CSF 14-3-3 231/250 92.4 117/131 89.3 0.3 1.3 (0.8-1.9) 30/33 90.9 318/348 91.4 1.00 1 (0.9-1.1) 




(N = 170) 
MM1 - 104 
MM2 - 9 
MV1 - 9 
MV2 - 15 
VV1 - 1 








(N = 80) 
MM1 - 40 
MM2 - 8 
MV1 - 6   
MV2 - 12 
VV1 - 5 






















(N = 31) 
MM1 - 25 
MM2 - 1 
MV1 - 0 
MV2 - 2 
VV1 - 0 








(N = 219) 
MM1 - 119 
MM2 - 16 
MV1 - 15 
MV2 - 25 
VV1 - 16 
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3.5 Discussion 
This is one of the largest reviews of sCJD and provides an update to 
previously published series [34, 80]. It provides the first comparative review of 
late referrals and provides a further understanding of the clinical features, 
including their timing in older patients. 
 
Factors associated with later / missed referral were older age and male sex. 
In general clinical features were less likely to be documented, in particular the 
absence of cerebellar features was significantly associated with later and 
missed referrals. Features associated with end stage sCJD however were 
more likely. The MM1 subtype, a negative cerebral MRI but positive CSF 14-
3-3 and RT-QuIC were also associated with later / missed referral. 
 
Findings in older patients were largely consistent with a general paucity of 
clinical features demonstrated other than those associated with the later 
stages of sCJD. The MM1 subtype, a negative cerebral MRI but positive CSF 
RT-QuIC were also similarly associated with older age. 
 
The limitations described in chapter 2 also apply here with spousal survival, 
and possible later referral for investigation in older patients due to initial 
symptoms potentially attributed to age or another neurodegenerative 
condition, relatively more common in these older ages. Again, it would be 
unusual for older patients with dementia to reach post-mortem, with, similar to 
vCJD, correspondence suggesting that post-mortem was only undertaken in 
some missed referrals because CJD was a consideration. Confirmatory bias 
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is therefore likely a factor here. Recall bias however may be expected to be 
potentially lower in cases referred in life due to the shorter disease duration as 
compared vCJD; recall bias in missed referrals however cannot be excluded.  
 
As older patients and those referred after death were more likely to be under 
the care of general physicians it may also be that documentation of clinical 
features would be less than if managed in a neurosciences centre. Further to 
this, as older patients were more likely to be bed-bound, cerebellar signs may 
be missed. Indeed the discrepancy between the low frequency of signs in 
missed referrals with a higher frequency of symptoms recalled by family 
members may be suggestive of differing levels of examination, documentation 
and review at a more advanced stage in this group. Consistency was however 
seen in certain features such as cerebellar with fewer older patients having 
positive signs, symptoms, and a later time to onset of cerebellar dysfunction if 
present, consistent also with the literature [75, 76].  
 
In general missed referrals were also not investigated as thoroughly as those 
presenting earlier; MRI was undertaken in 14% of missed referrals compared 
to 51% presenting earlier (as defined by those coded by the NCJDRSU). This 
however was not replicated in older patients suggesting that although referral 
pathways differed in older patients the level of investigation did not. 
 
With regards investigation results, for the purposes of this thesis only those 
with basal ganglia changes were documented as ‘positive’. MRI findings 
however are influenced by sCJD subtype, with some subtypes demonstrating 
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more extensive cortical ribboning  (that is cortical high signal on DWI and 
FLAIR sequences) than basal ganglia changes, such changes would be 
missed here. 
 
Further to this, data collection did not include the type of MRI sequences 
performed, and it was therefore not possible to determine whether DWI 
sequences (i.e. the most sensitive sequences for changes of CJD) had been 
undertaken in those with negative scans. Further work (Dr Graeme 
Mackenzie, NCJDRSU research registrar, personal communication 
[04/12/18]) has since demonstrated that in those with possible, probable or 
definite sCJD, 9% (of 463 MRIs reviewed) had negative scans; of this 
number, 21 (65%) did not have DWI sequences performed. Similar to vCJD, it 
is therefore likely that completeness of MRI sequences performed / available 
to the NCJDRSU is a confounding factor; it is now known, however, whether 
this is influenced by age.  
 
In general clinical features present during the course of illness in older 
patients were consistent with the literature. Similar to Karch et al [75], those 
80 years old were more likely to have documented pyramidal and 
extrapyramidal features and less likely to have cerebellar signs or symptoms. 
Interestingly, those 80 years old were more likely to have seizures; a feature 
demonstrated to be more common in non-prion pathologies [64].  
 
The excess of cases of MM1 subtype in older groups (as compared to 
younger groups) is to be expected given the known older age of onset of this 
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subtype (see Table 15). An excess of cases of MM1 was also seen in later 
and missed referrals (as compared to earlier referrals). As sCJD subtype 
influences clinical and investigation findings a post-hoc analysis defining 
subtype as the outcome measure was undertaken to determine if there were 
factors beyond this later age of onset that may be relevant to later and missed 
referrals (Appendix C).  
 
Whilst MM1 were more likely to present with an atypical presentation of visual 
or behavioural disturbance than other subtypes, no statistically significant 
factors were noted otherwise - the majority still presented with rapid cognitive 
decline with no difference in features seen throughout illness. There was no 
association between subtype and MRI findings, which is at odds with previous 
observations [86]. This may however be a reflection of data collection 
methods as previously discussed. Association was demonstrated with CSF 
findings, in keeping with previous observations [93]. 
 
CSF was more likely to be positive in later and older cases with both 14-3-3 
and RT-QuIC demonstrating a more favourable sensitivity in older patients. 
The association between older age and RT-QuIC is contrary to previous 
studies where no association has been demonstrated. Association has 
however been demonstrated with disease duration, and those with a more 
rapid course (here, older patients) were more likely to have a positive result 
[93].  
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MRI was less likely to be positive in older cases, this is in keeping with 
findings by Karch et al (2014) who demonstrated that both cortical and basal 
ganglia changes were less commonly seen in patients with sCJD aged 75 
years. Isolated cortical changes were however more frequently seen in such 
older patients, which, contrary to previous reviews, was independent of sCJD 
subtype (although numbers were limited). Here, MRI findings were associated 
with age but not with sCJD subtype providing some support to Karch’s 
findings. Further review incorporating cortical changes would be helpful to 
further clarify this association.  
 
EEG, although undertaken regularly unfortunately was missing in the majority 
of cases from the NCJDRSU database with resultant small numbers and 
associations difficult to conclude. Despite this, the results are worth comment; 
in those 80 years old, EEG was more likely to demonstrate typical changes 
of sCJD. This finding however may be a reflection of the less specific nature 
of EEG, with similar findings seen in other dementias common in this older 
group. Further to this, as older patients were reviewed later in their illness 
they would be more likely to have developed the typical EEG changes of 
sCJD (which are known to be a relatively late finding). The potential 
confounding effect of EEG timing has not been reviewed due to small 
numbers. 
 
Similar to chapter 2, it is important not only to look for differences in later and 
older cases but also to consider whether cases were recognisable as sCJD: 
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1) Fulfilment of diagnostic criteria 
Missed referrals were less likely to fulfil diagnostic criteria. Older patients were 
however more likely to fulfil the internationally agreed diagnostic criteria for 
sCJD, predominantly due to an excess of late features (i.e. akinetic mutism, 
and to a lesser extent, myoclonus). This suggests that whilst patients 
eventually fulfilled the diagnostic criteria they are less helpful in the early 
stages of illness in older and missed referrals. 
 
2) Consideration of CJD in life 
In the vast majority of cases CJD was considered in life. When documented, 
sCJD was the considered form in all. Due to lack of detail in medical notes it is 
difficult to be certain of the reasons cases were not referred to the NCJDRSU 
prior to death. Some notes commented on mis-interpretation of MRI changes 
(e.g. restricted diffusion not initially recognised), lack of supportive 
investigations, or the patient dying prior to receipt of investigation results. 
 
As per chapter 2, it is important to have diagnostic criteria that separate CJD 
subtypes due to the differing public health implications. Although different 
forms of CJD were not confused here, during analysis of older patients it was 
demonstrated that there was an excess of younger patients presenting with 
psychiatric and behavioural disturbance, and in those <65 years old an 
excess presenting with sensory features (Table 24). A post-hoc analysis of 
younger cases of sCJD was undertaken to determine whether the merging of 
phenotypes in older vCJD cases and sCJD described in chapter 2 was also 
seen here in younger ages (Appendix D).  
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As demonstrated in Appendix D, sensory disturbance was still more likely in 
vCJD compared to sCJD however there was no difference in psychiatric 
features seen between groups. An association of younger age with psychiatric 
features has been previously noted [94]. Such presenting features are 
reminiscent of vCJD, which, as per chapters 1 and 2 is a disease of younger 
patients. This further raises the possibility that the phenotype of different 




The aim of this study was to review risk factors associated with later referral. 
Findings are similar to vCJD and although the majority of cases can be 
recognised as sCJD, atypical clinical and referral characteristics were seen 
and again older age was a significant factor associated.  
 
Further to the associations described in chapter 2, evidence is provided here 
for older age as a risk factor for later diagnosis of sCJD and therefore possible 
case under-ascertainment in older patients. 
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CHAPTER 4: ‘THE +65 STUDY’ – A PROSPECTIVE STUDY OF 
ENHANCED SURVEILLANCE OF OLDER ADULTS WITH CJD 
 
4.1 Introduction 
Chapter 1 discussed the possibility that cases of CJD are missed and that age 
may be a risk factor for this. Chapters 2 and 3 have demonstrated that cases 
of CJD diagnosed later in the disease process / after death are older. 
Differences were demonstrated in the clinical and referral characteristics of 
older patients although the majority eventually looked like CJD.  
 
It is important for public health protection to ensure comprehensive CJD 
surveillance systems exist. It follows from previous chapters that in order to 
look for ‘missed’ cases (that is, those not registered by the current 
surveillance systems), the older population is the most suitable group to 
consider.  
 
Whilst chapters 2 and 3 have provided insight into why age may influence 
timing of referral, conclusions are limited by selection bias. Unanswered 
questions still remain as to why and to what extent, older patients are missed. 
Possibilities include: 1) Cases are present and recognisable as CJD but they 
are not labelled as such, possibly in part due to a lack of differentiation of 
different sub-types of dementia within elderly services, 2) Cases of CJD in the 
elderly differ from younger cases and present with clinical features more in 
keeping with common forms of dementia (for example Alzheimer’s dementia), 
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or 3) Cases of CJD in the older population are very different and do not 
present like a dementia (that is unlike CJD or common forms of dementia).  
 
In order to address this and look for missed cases (that is, otherwise 
unrecognised CJD) there are different approaches dependent on the 
mechanism by which cases are missed: 
 
1) Cases of CJD are recognisable as CJD but not labelled as such 
A means of addressing this is to ask clinicians to refer all older patients with 
dementia but features which would be atypical for the more common forms of 
dementia to a project of ‘enhanced surveillance’. As will be further expanded 
on below, this was the clinical approach adopted here and the subject of this 
chapter. 
 
2) Cases of CJD in older patients present like common forms of dementia  
This is difficult to investigate with clinical surveillance due to the volume of 
cases required to be screened and followed up. The only feasible approach to 
this would be to screen for evidence of prionopathy amongst banked brain 
donations representing the more common forms of dementia.  
 
A separate study was established in 2015 screening all brain material 
received at the Edinburgh Brain Bank with referrals received via Alzheimer 
Scotland, the Scottish Motor Neuron Disease Register, the Lothian 
Intracerebral Haemorrhage Pathology, Imaging and Neurological outcome 
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study and the Fiscal Sudden Death Register. The details of this study are 
outwith this thesis and therefore will not be further considered here. 
 
3) Cases of CJD in the older population are very different and do not 
present like a dementia 
This is impossible to address in a systematic manner. It is unlikely this is the 
case and therefore efforts have been focused on the above 2 interventions.  
 
This chapter will provide an overview of the development of a protocol for 
enhanced surveillance of CJD in older patients (‘The +65 study’). Details of 
the first patients referred to the study will also be presented. Finally the 




4.21 Case definition 
As above, three possibilities for the case definition were reviewed: patients 
were typical of CJD but not labelled as such; patients were typical for other 
common forms of dementia; or patients were atypical for CJD and common 
forms of dementia. For the reasons stated above, the basis of the case 
definition for this study was patients who could be identified as CJD (that is, 
patients with dementia but with features considered atypical for the more 
common forms of dementia), with a separate neuropathology study to 
investigate patients with dementia who may not be recognised as CJD.  
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Chapters 1 – 3 were used to inform the case definition (see Box 5). Four 
specific parameters were included: older age, cognitive decline, neurological 
features, and speed of progression. 
 
1) Older age 
Older age was defined as 65 years old. As per chapters 2 and 3, 65 years 
classically separates unusual young onset dementias from the more common 
late onset dementias. It is also the age above which patients with dementia 
are generally seen by non-neurology services; such services are easily 
identified and, as highlighted from retrospective review, were more likely to be 
involved in later referrals. 
 
2) Cognitive decline 
Literature review demonstrated that, where clinical details were available, all 
patients who were diagnosed later had cognitive decline [59]. This was also 
demonstrated in chapters 2 and 3 with cognitive decline described in all later 
and older cases, and indeed dementia as a presenting feature was seen in 
excess in both groups. The presence of cognitive decline (and specifically a 
diagnosis of dementia) was therefore a pre-requisite for study inclusion. 
 
3) Neurological features 
Literature review highlighted that although older patients with sCJD were less 
likely to have focal neurological features the majority did still exhibit signs and 
symptoms that would be unusual in the more common forms of dementia [75, 
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76]. No comparative studies were available for vCJD, however a description 
of cases detailed that focal neurological features were seen [23]. 
 
Retrospective review of the NCJDRSU databases demonstrated similar 
findings. Although features associated with both forms of CJD (e.g. cerebellar 
dysfunction) were less likely, in the majority focal neurological features were 
seen. 
 
It therefore followed that any focal neurological features (the presence of 
which would be considered less typical for the common forms of dementia) 
were included.  
 
4) Speed of progression 
CJD is a rapidly progressive condition. Those who were older or referred later 
/ missed had a shorter duration of illness. A history of rapid progression was 
therefore included in the case definition. After discussion with the +65 
management group (a group of key stakeholders in neuropathology, clinical 
neurology, old age psychiatry, medicine for the elderly, and neuroradiology), a 
slowly progressive illness (beyond what would normally be expected for the 
common forms of dementia) was also included in order to capture the slowly 
progressive inherited prion diseases.  
 
As can be seen in Box 5, the inclusion criteria were kept relatively open. Such 
an all-inclusive approach was adopted: 1) as per section 4.1, selection bias of 
referrals to the NCJDRSU limits the understanding of the possible full clinical 
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spectrum of CJD in the older population. It is impossible to exclude the 
possibility that older patients with CJD may have a more atypical presentation 
than that seen to date in the NCJDRSU; 2) for ease of referral at the start of 
the study (the case definition was expected to become more focused after 
patient recruitment / feedback from clinicians). 
 
In order to be eligible for the study, patients were required to fulfil the inclusion 
criteria. An information sheet detailing these criteria was designed, listing the 
salient clinical features of the more common forms of dementia to aid 
identification of cases (Appendix E). 
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Box 5: The +65 study - case definition 
 
 
4.22 Size of population 
Lothian health board was selected as a discrete and local area serving a 
population of approximately 800 000 from which patients could be recruited. 
The health board local to this study was also chosen for practical reasons 
Inclusion criteria 
Aged 65 years or older and  
Have a new or established diagnosis of dementia and  
Have features considered to be atypical for the recognised forms of 
dementia (features considered to be atypical include a time course which 
is either rapid (over weeks to months) or slow (over a period greater than 
10 years), or focal neurological signs) and  
Have accessed secondary or tertiary care services for dementia (inclusive 
of medicine for the elderly (MFE), old age psychiatry (OAP), and 
neurology), or tertiary referral memory services, within Lothian (residents 




A non-progressive disorder or  
A very clear alternative explanation for their cognitive decline (inclusive of 
head injury, a clear / stable psychiatric disorder, demonstrable vascular 
insult which was temporally related to the cognitive deficit, significant and 
on-going alcohol / drug use as a cause, space occupying lesion, neuro-
inflammatory or neuro-infectious conditions) or 
A positive genetic result (including prion), which again could explain the 
features. 
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(such as travel distance, and familiarity of target clinicians to the study team 
and vice versa) [95].  
 
Having identified the target population, estimates of potentially eligible 
patients were required for study planning purposes: 
 
1) Establishing a denominator  
There are two sources of data from which to calculate a denominator of 
eligible patients in Lothian: i) Alzheimer Scotland data (using EuroCoDe data 
projected onto 2016 estimates from the 2012 census [96]) or ii) general 
practice quality and outcomes framework (QOF) registers for dementia (and 
other QOF compatible registers for dementia) [97]. 
 
a) Prevalence 
Using Alzheimer Scotland data, the prevalence of dementia in patients aged 
65 years in Scotland in 2016 is estimated to be 87,510. Lothian NHS health 
board covers approximately 16% of people residing in Scotland [98], and 
therefore c.14,000 patients with dementia would be expected in Lothian. Only 
50% of such patients are likely to be registered with dementia (and therefore 
eligible for this study) [2]; indeed using GP registers, the number of patients 
aged 65 years registered with a diagnosis of dementia in Lothian was 
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Using actual numbers of new diagnoses of dementia from health boards 
within Scotland and projected population demographics, in 2015, an 
estimated 2400 patients aged 65 years old in Lothian were diagnosed with 
dementia [99].  
 
2) Establishing predicted numbers 
The literature base regarding patients with dementia with less typical features, 
i.e. the group from which eligible patients for this study would most likely be 
referred, is limited. Surrogate estimates include those with ‘dementia due to 
unknown aetiology’ (i.e. those with atypical features precluding a diagnosis of 
a specific dementia type in life). Studies are small and include poorly 
phenotyped patients, however overall approximately 25% of patients would be 
expected to present with atypical features, with this number rising with age 
[100].  
 
Other studies have reviewed patients presenting with specific atypical 
features. These include a) rapidity of onset: Staekenborg et al (2015) found 
that 8.6% (of 4,500 patients with Alzheimer’s dementia (AD) referred to the 
Amsterdam Dementia Cohort) died within 2 years of 1st reported symptom 
[69], or b) focal motor features: Scarmeas et al (2005) found that 14% (of 533 
patients with AD) had motor features at onset, with 45% developing abnormal 
signs during their illness [73]. 
 
Using the above literature base and local expert opinion, we estimated 10% of 
patients seen in secondary and tertiary care would fulfil our criteria. This 
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4.23 Source of recruitment 
In order to be certain about full ascertainment of all eligible patients, recruiting 
patients from primary care would be recommended. In 2006 the NCJDRSU 
proposed a prospective study of enhanced surveillance of older adults. This 
was a feasibility study in Lothian to determine if older patients presenting to 
their general practitioner with cognitive decline may be missed cases of prion 
disease. Discussions with stakeholders in general practice in NHS Lothian 
highlighted that due to other time commitments and constraints recruitment 
from primary care would not be possible. The project was therefore closed as 
it was considered not feasible. 
 
A different approach was therefore considered here. Both the Scottish 
Intercollegiate Guidelines Network (SIGN) and the National Institute for 
Clinical Excellence (NICE) recommend that all patients with dementia should 
be assessed in a memory clinic [101, 102]. Secondary / tertiary care services 
were therefore selected as the most feasible option. The limitation that not all 
patients would fulfil this standard was acknowledged, however the benefit of 
discrete and easily identifiable clinical pathways as described below was 
considered to outweigh this limitation.  
 
Patients aged 65 years with dementia are generally diagnosed, admitted 
under and managed in the community by old age psychiatry, medicine for the 
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elderly (MFE), or less commonly, neurology [101, 103]. Chapters 2 and 3 
demonstrated that this is the experience also of those with CJD. Indeed, there 
was a trend towards earlier psychiatry input in older patients with vCJD, with a 
similar but non-significant association in the same age group in sCJD (despite 
older patients being less likely to have psychiatric features documented). 
Further to this, older patients with sCJD were less likely to be referred from 
tertiary neuroscience centres and more likely to be managed by general 
physicians, with medicine for the elderly expected to be the main providers of 
care in such circumstances. Focus was therefore placed on old age 






4.31 Study population and setting 
All consultants covering memory clinics and clinical leads in each speciality 
were contacted to discuss how best to approach their colleagues. Meetings 
were then arranged to disseminate information about the study. In order to 
ensure high ascertainment, patients were recruited from both inpatient and 
outpatient settings.  
 
1) Old age psychiatry (OAP) 
Within Lothian there is one hospital with in-patient beds for OAP (Royal 
Edinburgh Hospital), with a further six sites of outpatient clinics (Leith 
Community Treatment Centre, St John’s Hospital, Midlothian Community 
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Hospital, Herdmanflat Hospital, Royal Edinburgh Hospital, and the Memory 
Assessment and Treatment Service (MATS) Centre).  
 
Meetings were arranged at individual sites with consultant and trainee OAPs 
and community psychiatric nursing staff. Continuing Professional 
Development (CPD) sessions on CJD were provided with information 
disseminated on the +65 project. Separate meetings were also arranged with 
key consultants with active involvement in research with additional attendance 
at regional OAP research sessions to gain OAP input into the project prior to 
launching and to allow promotion of the project once started.  
 
ii) Medicine for the Elderly (MFE) 
Four hospitals within Lothian have MFE consultants based on-site; Liberton 
Hospital, Western General Hospital, Royal Infirmary of Edinburgh and St 
John’s Hospital. Meetings were arranged at individual sites. Similar to OAP, 
CPD sessions on CJD were provided along with promotional sessions on the 
study. Key consultants were also targeted separately.  
 
iii) Neurology 
Three hospitals within Lothian have neurologists based on site (Western 
General Hospital, Royal Infirmary of Edinburgh, and St John’s Hospital). All 
consultant and trainee neurologists in Lothian attend a weekly neurosciences 
meeting; this platform was used to present study information and updates.  
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The cognitive disorders clinic at the ARRNC (tertiary referral centre for 
cognitive disorders) was approached separately. Weekly attendance at this 
clinic ensured on-going study visibility with clinicians and research managerial 
staff.  
 
4.32 Patient recruitment 
Clinicians and community psychiatric nurses (CPNs) were encouraged to 
discuss any patient they considered may be eligible. Leaflets containing study 
information and contact details were provided to all key consultants and 
recruitment sites (Appendix F). A monthly e-mail was also sent out to all 
consultant and trainee old age psychiatrists, medicine for the elderly 
physicians and neurologists reminding them of the study and contact details 
for referral / discussion. Email reminders were generated by a research nurse, 
appointed to the study. 
 
An established research database of patients with dementia willing to 
participate in research was also available to the +65 study via the ARRNC. 
This database was regularly reviewed with study patient information leaflets 
and accompanying invitation to participate in the study sent out to eligible 
patients.  
 
For all referrals, basic details were documented on a standardised form. 
Patients (or their representatives: as defined below) were then contacted, 
and, if the patient / representative agreed, study information was sent 
(Appendix F) and a study visit arranged. 
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4.33 Study design / approach 
Assessing capacity 
Before recruiting any study participant, capacity was assessed and 
appropriate consent obtained. Capacity was defined, using the Adults with 
Incapacity (Scotland) Act 2000, as the ability to understand and retain the 
information relevant to the decision in question and to weigh that information 
in the balance to arrive at a choice [104]. Capacity was assessed at the 
beginning of all meetings by assessing the participant’s understanding of the 
project and their voluntary role within this. For adults who lacked capacity, 
consent was taken from a representative (either the patient’s legal 
representative [welfare attorney or welfare guardian] or, if none, their nearest 
relative) in accordance with the Adults with Incapacity (Scotland) Act 2000.  
 
If the participant lost capacity to consent during the study, their wishes whilst 
able to consent were respected in line with Scottish law. 
 
Ethics approval 
Ethics approval was granted by the local Scotland A Research and Ethics 
Committee on 19th January 2016.  
 
Clinical / epidemiology assessments 
The following assessment tools were developed: 
 
1) Clinical review 
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A detailed history of the dementia syndrome was taken. Specific illness details 
were taken for all in order to complete a symptom questionnaire 
encompassing disturbances of mood, cognitive domains, focal neurological 
disturbance and psychiatric features. Other details including initial prominent 
symptoms and evolution of symptoms were taken in order to phenotype the 
patient in as much detail as possible.  
 
b) Cognitive examination 
Formal neuropsychology is the gold standard in cognitive assessment. It is 
however time-consuming and arduous for patients to undertake and therefore 
a shorter screening test was sought. Multiple screening tests exist ranging 
from very brief tests (e.g. abbreviated mental test), brief tests (e.g. mini 
mental state examination and Montreal Cognitive Assessment), longer 
assessments which can still be undertaken in clinical practice (e.g. 
Addenbrooke’s cognitive examination-III), and longer / detailed assessments 
primarily reserved for research studies (e.g. clinical dementia rating scale). 
 
It was expected that participants may be at a more advanced stage of their 
dementia and as other assessments were to be undertaken it was considered 
that longer research orientated assessments would not be feasible. The mini 
mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), 
and Addenbrooke’s cognitive examination-III (ACE-III) were considered to be 
the most appropriate; they are of an acceptable length for patients and are 
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commonly used end points in dementia research studies. A summary of these 
tests is provided in Table 26. 
 
 Table 26: An overview of cognitive tests considered 
Test Overview Pros Cons Refs 










<10 minutes to administer.  
No special equipment 
required. 
Commonly reported in 
studies. 
High sensitivity for 
detecting dementia in 
general population. High 




of attention / 
memory. Poor 
assessment of 
frontal / visuospatial 
function 
Poor specificity. 
















Additional tests of 
executive function 
10-12 minutes to 
administer.  
Superior sensitivity 
compared to MMSE 


















No special equipment 
required.  
Well tolerated.  
High sensitivity (94%) to a 
favourable specificity (89%) 
(on well characterised 
patients).  
Addresses executive and 
visuospatial short falls of 
MMSE.  
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Overall, the ACE-III was considered to be the most appropriate assessment; it 
is validated, short enough to be acceptable to patients whilst detailed enough 
to provide a level of phenotyping, and was a familiar tool to the research 
team. 
 
Although the ACE-III incorporates tests of executive function it still lacks 
comprehensive assessment of frontal lobe functions. Such assessment was 
desired to ensure patients had global cognitive testing and were phenotyped 
in detail; the frontal assessment battery (FAB) was therefore added to the 
protocol. The FAB is the most commonly cited assessment of frontal lobe 
functions. It is quick and easy to administer. It is scored out of 18 (with lower 
scores reflecting increasing impairment), and includes assessment of mental 
flexibility and inhibitory control [107].  
 
c) Neurological examination 
The neurological examination consisted of the Edinburgh Motor Assessment 
Scale (EMAS).  
 
It has become increasingly recognised that there are motor manifestations of 
the dementias, however, no standardised generic (i.e. non disease specific) 
scales exist for documenting motor scores in dementia. The EMAS was 
devised for this role in research. It is scored out of 99, with a higher score 
representing a greater level of impairment. The validity of the EMAS is 
currently under assessment but thus far has been demonstrated to be a quick 
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and easy test to administer with high inter-tester reliability (personal 
communication from Dr T Bak), and good test-retest reliability [108]. 
 
d) Mood assessment 
Due to the association between mood and cognition and the presence of 
mood disturbance in (particularly variant) CJD, an assessment of mood was 
incorporated. The hospital anxiety and depression scale (HADS) [109] was 
selected due to its established validity in secondary care [110], with 
established validity in older patients [111, 112]. The HADS is a 14-item 
questionnaire scored out of 42, with higher scores representing more 
significant mood disturbance.  
 
e) Functional assessment 
In order to provide an overall assessment of impact of illness a functional 
assessment was incorporated. The Barthel Index (BI) is a 10-item 
questionnaire scored out of 20, with higher scores indicating lower disability 
[113]. Although the BI was originally devised to assess disability post-stroke, it 
has been widely adopted as a generic scale of functional ability.  
 
2) Ancillary investigations 
a) Codon-129 sampling 
All patients were asked to donate a 2ml blood sample for codon-129 
polymorphism typing. As discussed in previous chapters, allele expression at 
codon-129 has a modulating effect on population risk and phenotype of CJD. 
Due to this effect it is important to ensure codon-129 polymorphism was not a 
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significant factor in referrals of positive cases, particularly in vCJD where 
experience of the phenotype of cases beyond methionine homozygotes is 
very limited. 
 
b) Cerebral MRI scan 
As previously detailed, cerebral MRI is a highly sensitive investigation in CJD, 
and in particular in vCJD. If a cerebral MRI scan had not been performed 
during the patient’s illness then a research MRI scan was organised. Imaging 
protocol included sequences with the highest sensitivity for CJD (i.e. axial 
diffusion weighted imaging (DWI) and fluid attenuated inversion recovery 
(FLAIR)) in addition to standard T1 and T2 sequences. All images were 
reviewed by the NCJDRSU consultant neuroradiologist. A full MRI report was 
made available for the referring clinician on the standard Lothian radiology 
reporting service.  
 
If an MRI had been undertaken, a repeat was not organised unless there had 
been a 6 month period since the previous MRI or there had been significant 
decline since previous imaging.  
 
c) Neuropathology 
In the event of a study participant’s death a limited, head only post-mortem 
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CSF and EEG were discussed and excluded from the protocol. CSF, which as 
demonstrated in chapter 3 is particularly sensitive to the changes of sCJD in 
older patients, was discussed on a number of occasions within the 
management group and with referring clinicians in old age psychiatry and 
neurology. The decision not to pursue CSF testing at this stage in the study 
was agreed due to the invasive nature of the investigation which may limit 
referral and an inability to ensure on-going availability of a neurologist / 
facilities to undertake the procedure consistently and safely.  
 
EEG has been demonstrated to have a lower clinical utility in sCJD compared 
to other biomarkers and with no EEG marker of vCJD, EEG was not pursued. 
 
3) Epidemiology questionnaire 
An epidemiological questionnaire was designed to help generate hypotheses 
as to risk factors for disease, and, in the event of a positive case, to help 
identify the most likely route of infection and to inform any related public 
health actions. The questionnaire was based on the current iteration of the 
NCJDRSU questionnaire; additional questions on known risk factors for 
neurodegenerative conditions were included (e.g. vascular risk factors) and 
other questions removed to reflect an evolving understanding of the risk 
factors for CJD (e.g. details about dentist, occupation (beyond high risk jobs), 
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4.34 Analysis approach 
1) Study design / subjects / setting 
This was a feasibility study to assess enhanced surveillance approaches to 
ascertaining ‘missed’ cases of CJD.  
 
All patients referred to the study between 1st April 2016 and 31st September 
2016 (when data gathering undertaken for this thesis ended) were included (n 
= 62). All patients who were eligible for inclusion with assessments completed 
during this time period (n = 10) were included in this analysis. 
 
Methods are as described in the previous section with all patients undertaking 
an epidemiology / clinical questionnaire and clinical assessments (ACE-III, 
FAB, HADS, BI, and EMAS). Blood was taken for codon-129 polymorphisms, 
MRI was discussed and arranged as appropriate, and post-mortem 
provisional consent obtained (with consent for authorisation organised at time 
of post-mortem).  
 
Telephone contact was then scheduled at 3 monthly intervals thereafter to 
assess patient progression.  
 
In patients whose illness was consistent, or became consistent, with CJD (for 
example ataxia / involuntary movements and/or a more rapid course or acute 
terminal deterioration) a further visit was arranged for repeat clinical 
assessment and MRI. If there was sufficient suspicion of CJD, then the 
The influence of age on case ascertainment in CJD 
 
Chapter 4: ‘The +65 Study’  
 
133
treating clinician was informed with recommendation to refer the patient to the 
NCJDRSU / National Prion Clinic for assessment.  
 
Follow up continued for the duration of the patient’s illness (either until 
improvement or death) with post-mortem confirmation of diagnosis. 
 
All details collected were entered manually onto a secure electronic database. 
Correspondence files were also retained in paper format and filed securely. 
 
2) Data processing 
A) Data collection 
As above, all data was manually entered onto the study database and 
extracted for the purposes of this initial review. 
 
B) Basic variables 
Basic demographic variables included sex and age at time of onset of illness.  
 
C) Referral characteristics 
The following referral characteristics were documented:  
a) Source of referral. Neurology, old age psychiatry, medicine for the elderly, 
ARRNC cognitive disorders clinic, and other. 
 
b) Reason for referral. Thematic grouping was undertaken with the following 
groups emerging during data analysis: i) the presence of focal neurology; ii) 
the patient did not fulfil diagnostic criteria for recognised forms of dementia; iii) 
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the patient had an unusual rate of progression; and iv) the presence of 
psychiatric features. 
 
c) Time to review by neurology / psychiatry were calculated from onset of first 
symptom  
 
D) Clinical features 
The following clinical features were extracted: 
a) Presenting features. Presenting symptoms were grouped into similar as 
chapters 2 and 3, with patients presenting with one of: i) behaviour / 
personality change (consisting of any change which was not attributable to 
mood change); ii) sensory disturbance (consisting of pain or any other 
sensory modality); iii) mood disturbance or psychiatric features (consisting of 
delusions, anxiety, and depression); iv) cognitive impairment (any change in 
cognition); and v) unsteadiness (consisting of gait change or incoordination).  
 
b) Signs and symptoms occurring during the course of a patient’s illness. The 
presence of specific signs and symptoms were extracted. Clinical features 
were grouped into the following themes to improve statistical analysis: i) mood 
(anxiety and depression); ii) language (receptive and expressive); iii) 
behaviour (lack of empathy, disinhibited, aggressive); iv) hallucinations (visual 
and auditory); v) dystonia (inclusive of alien limb); and vi) visual symptoms 
(impairment and diplopia). 
 
c) Duration of illness was calculated from first symptom to time of death. 
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d) Working diagnosis (as provided by the referring clinician). 
 
e) Examination findings (ACE-III, FAB, Barthel index, HADS, and EMAS)  
 
E) Investigation results  
The following investigation results were documented:  
a) Cerebral MRI. MRI was documented as either positive (restricted diffusion 
of the medio-dorsal thalamus, basal ganglia or cerebral cortex) or negative (all 
other changes including normal) 
 
b) Codon-129 polymorphism  
 
c) Neuropathology: Histopathological diagnosis of the underlying dementia 
pathology and whether there was any evidence of prionopathy were 
documented. 
 
F) Missing data 
Where data were not available entries were classified as ‘missing’ and 
therefore not included in statistical analysis. 
 
3) Analysis approach 
An overview of basic demographic, referral characteristics, and working 
clinical diagnosis are as described for all patients referred to the study (n = 
62). Results are detailed for all patients eligible for inclusion in the study (n = 
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10). Due to the non-parametric spread of data, times are stated in median 





4.41 All referrals (n = 62) 
62 patients were referred or identified from research databases as eligible for 
inclusion in the study. 11 patients agreed to participate, 10 of whom had 
completed review by 31st September 2016. Reasons for exclusion are as 
stated in Figure 6. The age and sex of patients included did not differ 
significantly from those excluded (Table 27). 
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The majority of patients were referred from the cognitive disorders clinic at the 
ARRNC (CDC). The reason for referral to the study in most was failure to fulfil 
diagnostic criteria for recognised forms of dementia. Where information was 
available, all included patients had been reviewed by both neurology and 
psychiatry with a median time from symptom onset to review of 3 years and 








11 patient visits arranged 
10 patients included in data 
analysis 
  
Declined participation: 12 
Did not fulfill criteria: 6 
Did not reply after initial interest: 9 
Awaiting permission to contact: 13 
 
62 patients referred / identified 
from research databases 
Awaiting decision from patient: 9 
Awaiting confirmation of patient’s 
eligibility: 2  
Patient visits after 31/09/16: 1 
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Table 27: The +65 study - patient characteristics (all referrals, n = 62) 
Patient characteristics  Referred to 
study (n = 62) 
Included in 
study (n = 10) 
p-value 
Age at time of referral 
(median years + IQR) 
71 (67 – 77) 69 (66 – 75) 0.82 
Male: n of N documented 
(%) 
43 (69%) 7 (70%) 1 
Age at symptom onset 
(median years + IQR) 
u/k 62 (57 – 69) 
 
n/a 
Duration of illness 
(median years + IQR) 
u/k 7 (3.5 – 10.5) n/a 
Median time to referral 
(years) 
u/k 1 (0 – 2) n/a 
 
 
Table 28: The +65 study - referral characteristics (all referrals, n = 62) 
Referral 
characteristic 
Referred to study 
(n = 62) 
Included in study 



















Reason for referral: 
Did not fulfil 
diagnostic criteria 
Focal neurology 























neurology (n of N 
documented) 
u/k 8/8 n/a 
Time to review by 
neurology 
u/k 3 (3 – 7) n/a 
Reviewed by 
psychiatry (n of N 
documented) 
u/k 8/8  n/a 
Time to review by 
psychiatry 
u/k 2.5 (2 – 7) n/a 
CDC = Cognitive Disorders Clinic, Anne Rowling Regenerative Neurology Centre; OAP = Old age 
psychiatry; MFE = medicine for the elderly; u/k = unknown; n/a = not applicable 
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The majority of patients presented with cognitive decline (Table 29). 
Alzheimer’s dementia was the most frequent clinical diagnosis for patients 
both referred and those included in the study (Table 30), with an excess of 
patients with less common forms of dementia (as compared to Figure 2) seen 
also. There was no statistical difference between clinical diagnoses in the 10 
patients included in the study and all patients referred (p = 0.71). 
 
Table 29: The +65 study - patient characteristics (patients included in 
study, n = 10) 
Presenting symptom / sign n (of N = 10) % 
Cognitive impairment 7  70 
Behaviour change 1  10 
Unsteadiness 1  10 
Missing 1 10 
Sensory change 0 0 
Mood disturbance 0 0 
 
 
Table 30: The +65 study - clinical diagnoses (all referrals, n = 62) 




n (N = 
62) 
% n (N = 
10) 
% 
Alzheimer’s dementia  14  22.6 5 50 
Neurodegenerative condition not otherwise 
specified (NOS) 
7  11.3 1 10 
‘Parkinson’s plus’ 5 8.1 1 10 
Posterior cortical atrophy 4 6.5 2 20 
Frontotemporal dementia 3 4.8 1 10 
Frontotemporal dementia + Parkison’s disease 3 4.8 0 0 
No syndromic diagnosis 3 4.8 0 0 
Primary progressive aphasia 2 3.2 0 0 
No dementia 2 3.2 0 0 
Vascular dementia 1 1.6 0 0 
Mixed (AD + VaD) 1 1.6 0 0 
Missing 17 27.4 0 0 
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4.42 Study patients (n = 10) 
Table 31 details the clinical features of patients seen. As a group, all patients 
had language difficulties, with the majority also experiencing mood and 
behaviour change. Almost all experienced both executive dysfunction and 
visuospatial difficulties. Almost half experienced sensory symptoms.  
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Table 31: The +65 study - clinical features (patients included in study, n = 10) 
 
Patient n of N % 1 2 3 4 5 6 7 8 9 10 
Working diagnosis   AD PCA FTD PCA NOS PD+ AD AD AD AD 
Forgetful / repetitive 9/9 100 Y Y Y Y  Y Y Y Y Y 
Visuospatial / apraxia 8/9 89 Y Y  Y Y Y Y Y N Y 
Executive 
dysfunction 
9/9 100 Y Y Y Y Y  Y Y Y Y 
Language 10/10 100 Y Y Y Y Y Y Y Y Y Y 
Mood 8/10 80 Y Y N Y Y Y Y Y N Y 
Delusions 1/6 17   N N  N Y N N N 
Behaviour 7/10 70 Y N Y Y Y Y Y N N Y 
Apathy 4/7 57   Y N Y N N  Y Y 
Hallucinations 2/9 22 Y N N Y N N  N N N 
Gait 3/9 33 Y Y Y N N  N N N N 
Speech change 3/6 50  N Y N    N Y Y 
Visual symptoms 2/10 20 Y N N Y N N N N N N 
Tremor 5/8 63 Y Y Y  Y  N Y N N 
Myoclonus 4/9 44 Y Y N Y N  Y N N N 
Dystonia 2/7 29  N N  N Y Y  N N 
Clumsiness 3/3 100 Y  Y Y       
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6/8 75  Y Y N Y  Y Y N Y 
Sensory symptoms 4/9 44 N  Y Y N N Y N N Y 
Seizures 2/9 22 Y N N N N N  N Y N 
Akinetic mute 1/10 10 N N N N N N Y N N N 
Clinical 
examination 
            
ACE-III (/100)   0 5 71 71 11 29 0 45 39 87 
FAB (/18)   0 1 13 13 3 Unable Unable 7 7 17 
BI (/20)   4 6 18 19 12 2 0 20 19 16 
HADS (/42)   Unable Unable 6 10 Unable 31 Unable 14 9 11 
EMAS (/99)   86 60 15 19 22 77 69 17 15 2 
Study MRI 
undertaken? 
  N N Y N Y N N N Y Y 
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Clinical assessments demonstrated that the majority of the group had 
advanced dementia with a general association seen between the severity of 
cognitive decline and load of physical signs on EMAS. Additional motor 
features were common and seen in almost all patients.  
 
Of those undergoing cerebral MRI, no features of prion disease were detected 
(Figure 7). The majority demonstrated generalised atrophy with areas of focal 
predominance in keeping with a dementia process. One MRI demonstrated 
small vessel disease with no specific radiological markers of 
neurodegeneration (of note, although incidental findings were fed back to the 
referring clinician, as this is not an uncommon finding in patients with 
dementia no action was taken).  
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The initial results demonstrate that clinical and referral characteristics were 
heterogenous and whilst patients did have features seen in CJD, overall no 
patients had a clinical syndrome suggestive of CJD. Critically however no 
patients died and had a post-mortem performed during this initial study period 
and therefore confirmation of diagnosis is awaited in all.  
 
There are limitations to address. Due to small numbers of patients included it 
is not possible to draw robust conclusions about the phenotype or referral 
patterns of older patients with dementia and atypical features. Four of the ten 
participants were very impaired and had difficulty undertaking assessments 
further limiting characterisation. It is also possible that patients are being seen 
by other specialities not included in this study (e.g. acute medicine / palliative 
care). However it would be hoped that such patients would still come to the 
attention of OAP / MFE / neurology if such a relentless neurological 
presentation were encountered. Lastly whilst efforts have been made to 
reduce the confirmatory bias common to retrospective studies our case 
definition is based on knowledge from previous missed cases, thereby 
introducing an element of bias. The inclusion criterion has however been kept 
broad and with the additional pathology arm of recruitment it would hope that 
bias would be limited.  
 
There are no other identified studies of enhanced surveillance to compare the 
findings to. Of patients referred to the study there was an excess of patients 
with less common forms of dementia (as compared to Figure 2). This would 
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be expected, as it is in this group that diagnostic uncertainty would be 
expected to be greatest. The cognitive profile of patients (with both executive 
dysfunction and visuospatial difficulties) were consistent with the reasons for 
referral, with most patients referred to the study due to a mixed cognitive 
phenotype with features of an anterior and posterior dementia present. It is 
noteworthy that 5/10 patients seen experienced sensory disturbance; it is 
uncommon for patients with other (that is, non-vCJD) forms of dementia to 
experience sensory symptoms; <10% of patients with a diagnosis of a non-
CJD dementia who were referred to the NCJDRSU with suspected vCJD 
described sensory disturbance [80]. Further profiling of the nature of the 
sensory symptoms would be helpful to review features that distinguish 
between CJD and other forms of dementia. Additional motor features were 
seen in almost all patients, this is consistent with previous studies with motor 
features reported in up to 75% of patients with dementia (Table 3).  
 
4.52 Feasibility issues 
One of the most important considerations at this juncture in the study is 
whether this is a feasible means of enhanced surveillance. It is therefore 
necessary to review feasibility issues that arose and consider how they might 
be overcome prior to expanding the study to areas outwith Lothian. 
 
In order to systematically review the difficulties and potential solutions to 
these issues they have been grouped as ‘patient factors’, ‘clinician factors’ 
and ‘other’, as described below and as summarised in Table 32.  
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Table 32: A summary of feasibility issues and solutions 
Patient factors Problem Solution 
Advanced stage of 
illness 
Unable to complete 
assessments 
Substitute ACE-III for S-SIB, and 
HADS for informant mood 
screening questions 
Referral bias Older / more frail patients 
less likely to be referred 
Reassurance to clinicians / 
participants. New assessments 
less arduous. Telephone contact 
of non-responders to reassure. 
Other Lack of awareness of 
study 
Promotional events 
Involvement of patient groups in 
protocol development to try to 
reach as many as possible 
Clinician factors   
Case definition Difficulty applying case 
definition 
Change case definition to all 
patients without classical AD / 
DLB / VaD 
Work-load Time / clinical pressures 
limiting time to discuss 
research 
Remove / reduce onus on 
clinicians to discuss study 
(presence of study team on ward / 
clinic  + study information sheets 
provided) 
Lack of confidence 
discussing research 
Clinicians / CPNs felt out 
of their depth introducing 
study 
CPD sessions provided. Remove / 
reduce onus on clinicians to 




Concern discussing CJD 
may undermine 
diagnosis made 
Reassurance of clinicians. Update 





involved in a patient’s 
care; not clear who 
should take responsibility 
for referral to study 
Regular meetings arranged, 
particularly in areas of expected 
referrals (OAP) and sites of low 
referral. Regular e-mail contact to 
encourage referrals directly 
Other factors   
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Lack of research register 
outwith ARRNC 




Lack of specificity of 
functional rating scales 
Barthel Index substituted for MRC 
Prion Rating Scale 
Patient eligibility Patients seen by 
memory services <65 
years old included 
Limited referrals to patients with 
1st referral 65 years old 
 
 
1. Patient factors 
i) Clinical assessments 
After initial recruitment to the study it became apparent that patients who were 
most readily identified as eligible for the study were at a more advanced stage 
of their illness. Clinical assessments included in the protocol required a level 
of cognitive reserve and therefore were not appropriate for all.  
 
Three approaches to address this were considered: a) The use of a separate 
test in those perceived to be very impaired (with assessment of this by initial 
interaction with patient / highlighted from referring clinician); b) Change all 
assessments; or c) Attempt to undertake original assessments in all - if 
patients were unable to complete initial assessments, additional assessments 
for those with severe impairment would then be undertaken.  
 
A review of potential solutions, as summarised below, addressed this. Due to 
the ceiling effect of assessments designed for advanced dementia there is no 
universally acceptable alternative to use for all patients, and in some other 
aspects of clinical assessment no appropriate alternative was found. It is 
therefore proposed that the original assessments should be attempted in all, if 
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however patients were unable to complete such assessments then an 
alternative, if available, would be used:  
 
1) Cognitive assessments 
A floor effect was seen with the ACE-III in 4/10 participants. Cognitive 
assessments in those with advanced dementia were therefore sought; these 
may be either informant-based or involve direct assessment of the patient 
(Table 33). 
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Table 33: Overview of cognitive assessments in more severely impaired patients 
 Description Advantages Disadvantages Ref 
Informant 
based 
    
IQCODE  26-point screening tool. Compares current 
functioning to 10 years previously. 
Combination score out of 5 (1+2 indicate 
improvement, 3 = no change, 4+5 = 
deterioration) 
 Areas covered include learning, recall of 
recent and remote information and day-to-
day functioning 
 Identifies patients requiring further 
assessment (not a stand-alone diagnostic 
tool).  
 Most widely cited.  
 Questions are of ‘everyday 
relevance’.  
 IQCODE can be administered 
remotely and is less invasive to 
the patient.  
 Performs as well as MMSE 
 Significant heterogeneity of 
effectiveness and potential 
for investigator bias.  
 More useful for excluding 
patients without cognitive 
decline.  






 16-point screening tool.  
 All other features as per longer version. 
 Similar utility as long version. 
 Quicker to complete. 






    
Severe  40-item assessment scored out of 100  Most widely cited.   Takes 30 minutes.  [117, 
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(with lower scores indicating greater 
impairment). 
 Assesses social interaction, memory, 
orientation, language, attention, praxis, 
visuospatial, construction, and orientation 
to name 
 Allows a degree of phenotyping  
 Validated in longitudinal studies. 
High inter-rater reliability and 
test-retest reliability.  
 Sensitive to changes in 
moderate to severe dementia 
 Requires specialist 






 20-item assessment scored out of 200 
(with lower scores indicating greater 
impairment). 
 Based on the reverse Piaget’s theory  
 High test-retest reliability and 
validity (as compared to the 
CDRS and MMSE) 
 Rarely used.  
 Takes 40-50 minutes.  






 10-item questionnaire, scored out of 30 
(with lower scores indicating greater 
disability) 
 Correlates significantly with the 
CDRS and GDS, with good 
inter-rater reliability.  
 Addresses the floor effect of the 
MMSE. Quick and easy to 
administer  
 Acceptable to patients with 
advanced dementia 
 Relies on language (a 
highlighted area of difficulty 
for participants in this study). 
 Not validated in more 






 14-item test scored out of 28.  
 Assesses memory, motor function, 
language and recognition 
 High inter-rater reliability and 
test-retest reliability  
 Lacks a significant floor effect.  
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(SIRS)  Quick and easy to administer 
with no specialist equipment 
required. 
 Validated in advanced, 
institutionalised patients. 
Short form of 
the SIB (S-
SIB) 
 Developed for those with an MMSE <5 
who had difficulty completing the original 
SIB. 
 Covers same domains as SIB 
 Similar to the SIB it incorporates gestural 
cues to assist those with impaired 
language  
 Modest floor effects 
 Acceptable to patients  
 Validated in long-term 
institutional patients  
 Compares well to MMSE and 
the original longer SIB.  
 Quick to administer (10 minutes) 
 Ceiling effect seen in less 
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A direct assessment of the patient is desirable as it provides an element of 
cognitive phenotyping that is more comparable to assessments undertaken in 
less advanced patients. The SIB is a validated and reliable form of 
assessment based on the limited reviews available. The short-form (S-SIB) is 
a validated form of the SIB and, as it is of a more acceptable length to 
patients with advanced disease, the S-SIB is proposed if a patient was unable 
to progress through ACE-III.  
 
2) Mood assessment 
Patients with advanced disease had difficulty engaging with the HADS. 
Alternative scales, which could be employed as informant or observational 
assessments were therefore explored.  
 
Solution 
Few scales exist. The gold standard is the Cornell Scale for Depression in 
Dementia (CSDD) [125]. The CSDD takes approximately 20 minutes to 
administer and involves semi-structured interviews with both the patient and 
informant [126]. The inter-rater reliability is low, and the sensitivity / specificity 
again low when compared to old age psychiatry diagnosis. The same is true 
of other, less commonly used tests for depression in dementia (e.g. the 
Minimum Data Set Depression Rating Scale, and the Hayse and Lohse Non-
Verbal Depression Scale [127]).  
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As mood was not a primary outcome measure in this study and considering 
the limitations of assessments, it is proposed that mood symptoms, which 
currently form part of the symptom questionnaire, would be used as a primary 
informant-based outcome measure if a patient were unable to engage 
meaningfully with the HADS. 
 
ii) Other patient characteristics / factors 
As will be addressed below, the referral numbers to the study were lower than 
expected. There are general patient factors to consider which may impact 
referral patterns in any study of dementia in older patients; older age, more 
advanced stage of condition and the presence of co-morbidities have been 
demonstrated to negatively influence referral [128, 129], all of which were 
relevant to the study population here. 
 
Solution 
Undertaking additional tests when already at an advanced stage of illness can 
be a daunting prospect and therefore reassurance to both the referring 
clinician and participants / their representative is necessary.  
 
At time of initial contact with referring clinicians and during study update 
sessions, reassurance will be provided regarding the above changes to 
assessments, which will be more appropriate for the patients’ abilities. Further 
on-going reassurance will also be provided regarding the variable level of 
involvement each patient may wish to consent to.  
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2. Clinician factors 
 
ii.i) Case definition 
 
This was arguably the greatest feasibility issue in this study. A number of 
iterations of the case definition were proposed and developed with the +65 
management group but despite this it was raised most consistently as point of 
confusion. Some clinicians stated almost all their patients would fulfil this 
definition (a view which was encouraged) and others (with a similar patient 
load) felt that it was unlikely they would see any eligible patients.   
 
Solution 
Feedback suggested that the need to consider study eligibility at each patient 
encounter was both time-consuming and complex. In order to simplify matters 
3 possible options were considered: a) All patients without a typical 
presentation of a common dementia (defined here as Alzheimer’s dementia, 
dementia with Lewy bodies, and vascular dementia) should be referred; or b) 
All patients with non-typical Alzheimer’s dementia should be referred; or c) All 
patients with dementia should be referred.  
 
Option a) would increase prevalence figures to c. 2,300 and incidence to c. 70 
patients (based on the relative percentage of dementia subtypes in the UK, 
(Figure 1) [18]). Option b) would increase expected prevalence figures to 
c.5,000  and incidence to c.150 . Option c) would increase prevalence figures 
to c14,000 and incidence to c.400. For this option it would be envisaged that 
all patients fulfilling the inclusion criteria would have illness details taken and 
clinical assessment completed; if features were highlighted from the duration 
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of illness, the symptom questionnaire or the EMAS that were atypical then 
those patients would be followed up. If no unusual features were highlighted 
then data would be collected, patients signed up for post-mortem and no 
follow up otherwise arranged.  
 
Whilst options b) and c) are the most vigorous, reduce referring clinician 
workload the most and permit fewer assumptions about phenotype in older 
patients they are limited by their sheer number. Option a) was therefore 
considered the most feasible by the +65 management group with 
incorporation of this case definition into future protocol changes.  
 
ii.ii) Age eligibility 
A number of patients referred during this initial phase were seen in secondary 
and tertiary referral care clinics prior to turning 65 years old. As before, the 
prior probability of specific dementia syndromes is different in these groups 
and referral pathways differ. Insight into referral patterns of those 65 years 
old is therefore limited by their inclusion.  
 
Solution 
In conjunction with changes to the clinical eligibility, it is proposed that patient 
demographics should also be changed to include only patients seen who were 
aged 65 years and over at the time of referral and diagnosis to memory 
clinics. This would help to re-focus the study to only late onset dementias.  
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It was highlighted, particularly during meetings with OAP, that there was 
limited time and space in clinic for research to be discussed with patients. 
Additional workload is a common deterrent for referral to clinical studies [129, 
130]. Research is generally not regarded as integral or as important as clinical 
work [129] and can therefore be seen as an unwelcome extra in addition to an 
already busy clinical job.  
 
Solution 
As before, it would also be hoped that by widening the case definition that 
clinicians will not have to use time considering whether a patient is eligible 
and therefore any additional workload would be reduced. 
 
Referral workload was also reduced by the study research nurse attending the 
ARRNC cognitive disorders clinic with additional attendance on OAP ward 
rounds (REH) and proposal of attendance at OAP memory clinics (MATS). 
The presence of a research nurse can improve recruitment [128] and it would 
be hoped here to further improve study visibility and reduce referral workload 
for clinicians.  
 
Further efforts to remove responsibility of the clinician to introduce the study 
were also explored. During contact with referral sites it was emphasised that 
the role of the referring clinican was to obtain permission to refer the patient to 
the study rather than discuss the study in detail. Patient information leaflets 
were provided to clinicians in memory clinics to assist with this.  
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ii.iii) Clinician confidence in introducing research 
During meetings with MFE and OAP it was raised that clinicians had a general 
lack of confidence in introducing research (a common finding [129]). Specific 




Potential solutions include on-going involvement of clinicians in protocol 
amendments prior to progressing to a pilot study. Educational incentives have 
also been shown to improve recruitment [129]. CPD sessions on CJD were 
organised with consultants and trainees in OAP and MFE. As above, study 
information sheets were also available with contact details of the study team 
should patients have questions regarding the study or about CJD. 
 
Monthly meetings were arranged with OAP (at the Marchhall MATS Clinic, 
where c70% of all patients aged 65 years with dementia in Lothian are seen) 
to present an update on study recruitment and project developments. This 
was arranged to enable greater involvement of referring clinicians / CPNs / 
MATS nurses in the study and also enabled any difficulties experienced in the 
referral process to be addressed.  
 
ii.iv) Doctor-patient relationship 
Clinicians have reported an unwillingness to expose patients to study 
interventions [95], and have reported embarrassment at asking patients to 
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participate in studies. Discussing uncertainty may also negatively impact on 
the doctor – patient relationship [128]; raising the issue of another dementia 




During contact with referral sites it was emphasised that patients could 
consent to as little or as much as they wished of the study. It was highlighted 
that there would be potential benefit to the referring clinicians / CPNs with 
information sharing of cognitive assessments and MRI results, limiting 
clinician’s time and resources and limiting any additional or duplicate 
assessments of patients.  Whilst it was felt important to address this and 
ensure reciprocal benefit from patient involvement in the study, at odds with 
the above, studies have highlighted that benefits to the referring clinician have 
not been shown to influence the likelihood of referral. These methods may 
therefore realistically only assist those who would likely refer anyway. 
 
ii.v) Lack of accountability for enrolment to study 
As it was not initially clear, particularly within community OAP, who would be 
best placed to refer patients and when (e.g. old age psychiatrist at diagnosis 
or CPN at follow up), there was a lack of accountability resulting in no 
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Regular contact was made with all OAP, MFE and neurology clinicians and 
CPNs to remind them of the study and to give opportunity to refer patients by 
return of e-mail. 
 
In particular areas where either the majority of patients were seen (MATS), or 
areas where recruitment of the referral site was slow (e.g. non-MATS 
community OAP memory clinics), separate meetings were arranged to clarify 
in each individual area who should refer patients and when in order to 
improve local accountability for referral. 
 
3. Other  
iii.i) Research databases 
Other than the ARRNC there were no accessible databases for researchers. 
Local and national databases of patients interested in participating in research 
have been found to be the greatest strategy for improving recruitment to 
studies on dementia [131]. It was also known from the ARRNC database how 
often information sheets were provided for researcher follow up, thus 
providing numbers of patients enrolled from those approached (to assess if 
there were any barriers at this level). There was no such system in other 
recruitment sites.  
 
Solutions  
Separate to this study but using this study as an impetus for change, OAP 
have committed to a research database, initiating monthly research meetings 
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to discuss studies and recruitment, and adapting clinic introduction letters to 
include mention of research to ensure research becomes an integrated part of 
patient management.  
 
Whilst these solutions will not impact this study it was hoped they might 
provide benefit to future studies. Realistically however, although they provide 
an effective means of contacting patients, the recruitment rate from the 
ARRNC database was low from patients contacted and therefore it is not clear 
whether such changes would yield significant improvement in numbers 
recruited. 
 
iii.ii) Miscellaneous - 2 
Feedback from the +65 management group highlighted the importance of 
utilising specific prion rating scales when assessing functional ability. 
 
Solution 
The Barthel Index was substituted with the MRC Prion rating scale: a specific 




Comprehensive case ascertainment of CJD is important in older patients. A 
protocol for enhanced surveillance of CJD in the older population has been 
designed and piloted here. Of the initial patients recruited there was no 
evidence of CJD clinically, however, no patients reached post-mortem. 
Barriers to referral likely impacted numbers recruited and further review of the 
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feasibility of this study is necessary after protocol changes have been 
incorporated.  
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CHAPTER 5: OVERALL DISCUSSION 
 
5.1 Introduction 
This thesis has considered CJD with a focus on older patients, specifically on 
their detection through disease surveillance activities and the possibility that 
cases may be missed.  
 
CJD continues to be an important concern to public health and disease 
surveillance remains as relevant now as it has ever been. There is caution 
that there may potentially be more cases of vCJD to come with the first 
pathologically confirmed case of a codon-129 heterozygote, and the appendix 
III study demonstrating a potentially larger at risk population. Further to this, 
the first case of chronic wasting disease (a prion disease of deer and elk) in 
Europe has been confirmed; whilst the zoonotic potential is not clear, it further 
emphasises the importance of on-going surveillance. 
 
The epidemiological characteristics of CJD, and in particular sCJD, are 
suggestive of possible case under-ascertainment, and specifically in older 
ages. This thesis has demonstrated that age is a risk factor for later referral to 
surveillance systems and that clinical and referral characteristics may be 
influential in this. It has done this by: 
 
1) Literature review  
This demonstrated that missed cases do occur with older age a possible risk 
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for this. It was however unclear whether this was due to a different 
presentation of CJD in older patients or whether there was a tendency for 
cases of CJD in the older population to become lost in the more common 
dementias. Given the rapid neuropsychiatric presentation of CJD it would 
seem unlikely that many cases would be missed, however as has been 
demonstrated, the features most suggestive of CJD (that is rapidity of decline 
and focal neurological features) are not unique markers of CJD.  
 
2) NCJDRSU database retrospective review  
In general, for both vCJD and sCJD, older age was significantly associated 
with later / missed referrals and indeed older age was a confounding factor in 
most associations seen in cases referred later. It further demonstrated that 
clinical features and referral characteristics were associated with later referral 
and older age with the following findings noted:  
 
A) vCJD 
In both later and older cases: 1) patients were more likely to present in a 
relatively non-specific manner with rapid cognitive decline; 2) symptoms more 
suggestive of vCJD (e.g. sensory symptoms) presented later in the disease 
course. Sensory symptoms were the only consistent differentiating feature 
between later / older cases of vCJD and sCJD with late diagnoses confused 
with sCJD, possibly related to the later onset of such symptoms; and 3) 
cerebral MRI was a less sensitive investigation.  
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In both those 80 years old and those referred later: 1) cerebellar features 
were less likely throughout illness with a later time to onset of such features 
also; 2) atypical features at onset (e.g. visual disturbance in those referred 
later in their illness) and during illness (e.g. seizures in those 80 years old) 
were noted; 3) MRI was less sensitive in later referrals; a product of the 
confounding effect of the older age of such cases (in keeping with previous 
review [75]); and 4) patients were less likely to be referred by a neurologist or 
be managed in a neurosciences centre.  
 
Following these findings a protocol for enhanced surveillance was proposed 
to manage this unmet need. A system of enhanced surveillance in the older 
population is required as: 1) All cases of CJD have potential implications for 
public health; 2) The elderly are more likely to require surgery / blood 
transfusions and are therefore at a greater risk of not only contracting iCJD 
but also of transmitting to others; and 3) To phenotype in detail cases missed 
in life who would not have otherwise been referred to the NCJDRSU 
surveillance system or reached post-mortem. Another potential benefit of this 
study is to produce the first prospective clinicopathological study of dementia 
with atypical features in the older population.  
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5.2 The next steps in ‘The +65 Study’ 
No conclusions can yet be drawn about the characteristics of additional, 
previously undetected cases from enhanced surveillance. Recruitment is 
continuing and protocol feasibility issues are being addressed. Further to the 
necessary protocol changes an area that requires additional consideration is 
the lower than expected referral numbers. It is difficult to know at this stage 
whether the low study recruitment is reflective of feasibility issues, or because 
such numbers are an accurate reflection of eligible patients.  
 
As previously discussed there is limited literature from which to predict 
accurate patient numbers. Estimates are based on small cases series with 
larger cohorts focusing specifically on older age groups making 
generalisability / applicability specifically to this study difficult [26]. In addition 
to this it has been previously observed that: “The number of patients who are 
actually available for a trial is about 1/10 to 1/3 of what was originally 
estimated” (‘Lasagna’s Law’ [132]). Without clear predicted recruitment 
estimates for the +65 study it is difficult to know whether ‘Lasagna’s Law’ has 
been a significant factor here.  
 
In order to clarify this, a two part approach is proposed: 1) A survey of 
potentially eligible patients to determine accurate numbers; and 2) Assuming 
numbers could be improved, a survey of clinicians to understand in greater 
detail the barriers to recruitment that may be most important here (and 
therefore how best to re-focus efforts to improve recruitment). 
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a) Audit of potentially eligible patients 
Ideally an audit would involve a coded outcome measure (e.g. ISD coded 
diagnosis of dementia, number who had died or had required long-term 
institutional care within a defined, short period of time). As became apparent 
when this was further explored, there are no clear outcome codes that could 
be utilised. The certainty of diagnosis is not coded, and whilst those dying 
within a short period of time could be coded, a great number of other 
potentially eligible patients would be missed. The only way to reliably audit 
this was to review medical notes of all patients seen within a time period over-
lapping with the study to determine whether eligible patients were missed. 
Such an audit is proposed in Appendix G.  
 
Accepting the limitations of this approach (for example, neurological features 
may not be detailed outwith a neurology appointment), the potential insights 
into the clinical and referral characteristics of patients seen through, 
particularly community OAP, would outweigh any such limitations.  
 
b) Survey of referring clinicians 
A survey of clinicians / CPNs at recruitment sites should be quick, accessible, 
and anonymous (beyond job title). An electronic ‘doodle poll’ is proposed for 
these reasons. The aim of this survey is to determine how strongly 
participants feel about certain potential barriers to referral (identified both from 
literature review and those identified during discussions with local clinicians). 
Such a survey would not only assist study development but also add to 
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the literature base, as currently assessment of recruitment of cohort studies 
are lacking. Such a survey is proposed in Appendix H. 
 
Whilst the clinical arm of this study has been a little slow to recruit, the 
concurrent pathology arm (to capture additional cases missed through clinical 
screening) has been successful. During the same first 6 months of the study 
49 cases were referred with 36 cases fully analysed during this time (84%); no 
cases of prion disease were detected.  
 
As a final consideration, whilst measures to improve feasibility are still 
required, assuming difficulties can be overcome, the next step beyond this is 
to consider how to roll this study out as a standard add-on enhanced 
surveillance service in the UK. In order to do this, two areas would require 
consideration: 1) How to reach all relevant referring clinicians and to ensure 
on-going study visibility and; 2) How to manage numbers. 
 
1) How to reach all relevant referring clinicians  
Possible means of reaching trainee and consultants in OAP / MFE / neurology 
would be via national societies. All trainee and consultant neurologists are 
members of the Association of British Neurologists (ABN) - likewise all OAP 
clinicians and the majority of MFE clinicians are members of the Scottish 
branches of the Royal College of Psychiatrists and British Geriatrics Society 
respectively. It is proposed that an e-mail alert could be generated from these 
societies with later inclusion in society news update emails to maintain study 
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visibility.   
 
2) How to manage numbers 
This will be managed by the case definition. At present the inclusion criteria 
are too broad. This has been beneficial for this stage of the study in order to 
minimise any preconceptions / bias about the presentation of older patients 
with CJD and to ensure confidence that surveillance has been as 
comprehensive as possible whilst the case definition is developed. It will not 
however be possible to ensure all patients are seen and followed up 
adequately if such an all-inclusive case definition is rolled out. Refinement of 
the inclusion criteria will be required following analysis of the 
clinicopathological features of the first patients recruited and feedback from 




This thesis has demonstrated a relationship between age and timing of 
referral in both variant and sporadic CJD. Further to this it has addressed this 
association with description of the first study of enhanced surveillance of CJD 
in the older population. Results are awaited to determine the characteristics of 
otherwise missed cases and whether this is an on-going feasible means of 
enhanced surveillance. 







Appendix A: An overview of the most common dementias 
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As per dementia 
















1CSF – cerebrospinal fluid; 2SPECT – single photon emission computerized tomography; 3FDG-PET – fluorodeoxyglucose-positron emission tomography; 4MRI – magnetic resonance imaging; 5CT: 
computed tomography; 6DaT: Dopamine transporter imaging  





APPENDIX B: vCJD VERSUS sCJD 
Table B1: Clinical features vCJD compared to sCJD (all cases) 
Clinical feature vCJD  sCJD p-value 






Gait change 173/177 472/540 <0.001** 
Cerebellar features 166/169 350/581 <0.001** 
Pyramidal 115/165 296/529 <0.001** 
Extrapyramidal 19/155 247/521 <0.001** 
Visual symptoms 49/159 268/536 <0.001** 
Myoclonus 108/159 410/535 0.027 
Sensory 133/169 93/535 <0.001** 
Pain 90/167 40/535 <0.001** 
Hallucinations 58/155 293/539 <0.001** 
Anxiety 86/149 221/533 <0.001** 
Depression 92/144 121/533 <0.001** 
Social withdrawal + 
apathy 
97/148 221/529 <0.001** 
Delusions 57/154 131/533 0.002** 
Grasp / primitive 
reflexes 
74/149 234/485 0.76 
Seizures 9/168 42/537 0.28 
Other movements 
(chorea / dystonia) 
105/159 130/528 <0.001** 
Akinetic mutism 13/155 183/530 <0.001** 
*Significant (p <0.05) **Highly significant (p <0.01) 






Table B2: Clinical features vCJD compared to sCJD ( 65 years old) 
Clinical feature vCJD  sCJD p-value 
Forgetful 3/3 316/362 0.51 
Rapid cognitive 
decline 
3/3 342/362 0.68 
Gait change 3/3 320/363 0.53 
Cerebellar features 3/3 234/394 0.15 
Pyramidal 2/3 197/357 0.69 
Extrapyramidal 0/3 166/351 0.10 
Visual symptoms 1/3 184/361 0.54 
Myoclonus 2/3 283/360 0.62 
Sensory 2/3 53/359 0.013* 
Pain 1/3 22/359 0.054 
Hallucinations 2/3 201/363 0.70 
Anxiety 0/2 135/357 0.27 
Depression 1/3 68/358 0.53 
Social withdrawal + 
apathy 
0/2 143/353 0.24 
Delusions 1/2 85/358 0.39 
Grasp / primitive 
reflexes 
1/3 169/325 0.52 
Seizures 0/3 27/361 0.62 
Other movements 
(chorea / dystonia) 
1/3 86/354 0.72 
Akinetic mutism 1/2 138/356 0.75 
*Significant (p <0.05) **Highly significant (p <0.01) 





APPENDIX C: POST-HOC ANALYSIS OF sCJD SUBTYPE 
Introduction 
As per chapter 1, sCJD may be sub-classified into 6 sub-types according to their 
allele expression at codon-129 (M or V) and the isoform of prion protein (type 1 or 
type 2).  
 
Methods 




There was no association with gender (p = 0.78). The age at onset however was 
significantly associated (p = 0.002) with MM1 and VV2 seen more frequently in older 
patients. The duration of illness was also strongly associated (p <0.001), with MM1 
having the shortest duration at 3 months (1-25), and MV2 with the longest duration at 
15 months (3-63) (Table D1)  
  
Table C1: Basic demographics and sCJD subtype 
 MM1 
(n = 144) 
MM2 
(n = 17) 
MV1 
(n = 15) 
MV2 
(n = 27) 
VV1 
(n = 6) 
VV2 
(n = 41) 
































There was a significant association between presenting feature and sub-type (p = 
0.02). Those presenting with behavioural / visual symptoms were over-represented 





by MM1, those with rapid cognitive decline were over-represented by MM2 and MV2, 
and those with an ataxic onset were over-represented by VV2 (Table D2).  
 




(n = 120) 
MM2 
(n = 15) 
MV1 
(n = 14) 
MV2 
(n = 22) 
VV1 
(n = 5) 
VV2 
(n = 34) 
Behavioural 14.2 20.0 14.3 13.6 20.0 8.8 
Sensory 4.2 0 7.1 0 0 0 
Mood / 
psychiatric 




32.5 53.3 28.6 45.5 60.0 29.4 
Unsteady / 
motor 
20.8 6.7 21.4 27.3 20.0 50.0 




4.2 0 0 9.1 0 11.8 
 
When analysed with grouped clinical features, there was no statistically significant 
association with cognitive decline (p = 0.76), psychiatric symptoms (p = 0.38), 
cerebellar (0.09), extrapyramidal (p = 0.12), pyramidal (p = 0.39), sensory symptoms 
(p = 0.17), and seizures (p = 0.63). Furthermore there was no statistically significant 
association with fulfilment of the diagnostic criteria (p = 0.69). There was however a 
significant association with vision p <0.001 (more likely in MM1 and MV1), and 
features of lower motor neurone involvement p = 0.007 (more likely in MV2 and 
VV2).  
 
There was no statistically significant difference in MRI findings (p = 0.70), and EEG 
result (p = 0.31), however there was a statistically significant association with CSF 
14-3-3 results (p = 0.03) and RT-QuIC results (p = 0.001).  





APPENDIX D: YOUNG ONSET sCJD VERSUS vCJD 
 
Table D1: Clinical features vCJD compared to sporadic CJD: <45 years old 
Clinical feature vCJD  sCJD p-value 
Forgetful 154/158 2/4 <0.001** 
Rapid cognitive 
decline 
146/151 2/4 <0.001** 
Gait change 155/159 2/4 <0.001** 
Cerebellar features 149/152 2/4 <0.001** 
Pyramidal 106/147 2/4 0.33 
Extrapyramidal 18/140 0/4 0.44 
Visual symptoms 43/141 0/4 0.19 
Myoclonus 93/141 1/4 0.09 
Sensory 119/152 1/4 0.013* 
Pain 81/151 1/4 0.26 
Hallucinations 49/138 1/4 0.66 
Anxiety 80/135 1/4 0.17 
Depression 83/127 2/4 0.53 
Social withdrawal + 
apathy 
90/133 1/3 0.21 
Delusions 49/139 1/4 0.67 
Grasp / primitive 
reflexes 
68/135 1/4 0.32 
Seizures 9/151 0/4 0.62 
Other movements 
(chorea / dystonia) 
95/142 0/4 0.006** 
Akinetic mutism 12/138 1/4 0.27 


















1. Aged 65+ (at time of contact, not onset)  
 AND 
2.  Progressive cognitive impairment (memory, language, behaviour 
change)  
 AND 
3. Atypical features for the known types of dementia (typical features 
detailed  overleaf) 
 AND 
4.  No clear alternative demonstrable pathology (inherited dementia, 
psychiatric diagnosis, space occupying lesion, 
neuroinflammatory/neuroinfectious condition, related cerebral insult) 
 
Atypical features may include: 
1. Unusual rate of progression (e.g. rapid – this would be over weeks to 
months) 
 AND/OR 
2. Focal neurological symptoms including unsteadiness, 
jerking/involuntary  movements, painful sensory symptoms, visual loss, 
seizures 
 AND/OR 
3. Neuropsychiatric symptoms including psychosis, hallucinations, 
significant new  onset mood disturbance 
 
Please note that the above has been developed to offer guidance for 
identifying atypical features of dementia.  
Any patient who you feel is presenting with atypical features but you 
would like to discuss further, or confirm their eligibility, please do not 
hesitate to contact a member of the 65+ Dementia Study team on the 
contact details below.  
 
 
Mrs Gemma Logan (Research Nurse): 0131-537-1980 / 07464-677-117 
gemma.logan2@nhs.net 





Typical Features of Main Dementia Sub-Types 
The 65+ Dementia Study 
Case Definition Tool 







- Initial / prominent features: impairment in learning and recall of recently 
learned information 
- Progression: Insidious onset, typically over 8-10 years 
 
Frontotemporal Dementia 
- Initial / prominent features: behavioural disturbance which can include 
behavioural disinhibition, apathy, loss of sympathy or empathy, and/or 
compulsive/ritualistic behaviour 
- Progression: Insidious onset, typically over 6-8 years  
 
Dementia with Lewy Bodies 
- Initial / prominent features: fluctuating cognition with pronounced 
variations in attention and alertness. Recurrent visual hallucinations 
that are typically well formed and detailed, in the presence of 
parkinsonism 
- Progression: Insidious onset, typically over 6-12 years 
 
Vascular Dementia  
- Initial / prominent features: evidence from the history, examination, or 
tests, of a significant cerebrovascular disease, which may reasonably 
be judged to be aetiologically related to the dementia 
- Progression: May be abrupt onset or insidious, with a variable rate of 
progression 
 













National CJD Research & Surveillance Unit 
Western General Hospital, 
Edinburgh, EH4 2XU 
 
Enhanced CJD surveillance in the older population (Scotland A REC ref:15/SS/0196) 
Participant Information Sheet & Consent Form  (Participants) version 1.2, 28/06/2016 
 
Study Principal Investigator: Dr Anna Molesworth, PhD 
Telephone: 0131 537 1980 
Email: anna.molesworth@ed.ac.uk 
 
THE 65+ DEMENTIA STUDY  
INFORMATION   
FOR PATIENTS 
 
We understand that you have been diagnosed with a type of dementia. We 
would like to invite you to take part in our research study on dementia in 
people aged 65 and above.  
 
Before you decide, we want you to understand why this research is being 
done and what it would involve.  Please take time to read the following 
information carefully. Ask us if there is anything that is not clear or if you 
would like more information.  
 
The 65+ Dementia Study Team 
 
We are doctors, scientists and nurses from University of Edinburgh and NHS 
Lothian who have a special interest in patients with dementia, including a 
particular type of dementia due to prion disease. Prion diseases are a very 
rare group of diseases that affect nerve cells in the brain and spinal cord. 
Prion disease can exist in different forms, but the most common is 
Creutzfeldt-Jakob Disease (CJD). We provide doctors with information about 
prion disease, and advice on how to look after their patients. We also do 
research into some of the causes of prion disease. This research project may 
help us to find out what caused your dementia. 
 





If, having read this leaflet, you are interested in the research, then we can 
arrange a meeting either in the clinic or at your home at a time that is most 
convenient for you and any family members you wish to be present. The 
purpose of this visit is to discuss the study and what is involved. One of our 
research team will go through this information leaflet with you and 
answer any questions you have. 
 
What is the purpose of this study? 
There are about 850,000 people living with dementia in the UK, the majority in 
people aged 65 year or over.  Around 100 people in the UK are diagnosed 
with prion disease every year, however we think that more might be infected 
but their illness may not have been recognised, perhaps because the signs 
and symptoms are similar to different forms of dementia. This research will 
use patient assessment, blood samples, brain scans and samples of 
brain tissue from people in Lothian when they die, to find if prion 
disease is being missed and why. 
 
Why have I been asked to take part? 
 
We understand that this is a difficult time for you. All patients aged 65 and 
over who have recently had a diagnosis of dementia are being considered. 
There are many different types of dementia, and in the majority of patients the 
diagnosis can be made with confidence. However, because the signs and 
symptoms of dementia vary from patient to patient, we find that some 
characteristics are less common than others. You are being invited to join this 
study because you have some of these less common features and studying 
them may help us understand your type of dementia, why you developed your 
current illness and if it might be due to prion disease. This could benefit others 
in the future.  
 
Do I have to take part? 
 
No. It is up to you to decide whether you wish to take part in the research or 
not. If you do wish to participate, we will ask you to sign a consent form. You 
are still free to withdraw at any time, without giving a reason. Deciding not to 
take part or withdrawing from the study will not affect the healthcare that you 
receive, or your legal rights.  
If you lose your capacity to make an informed decision about participation in 
the study after you have joined, then your previous wishes will be respected 
and the study will continue under existing consent arrangements. In these 
situations we will check with your representative that they are happy with 
these arrangements. We will then ask you to renew your consent when 
capacity is regained. 
What will happen to me if I take part? 
 
There are five parts to the research and you can contribute to any of them. 






1. Assessment by the 65+ dementia study team 
 
We would like to ask you some questions about your current illness and your 
memory and mood, and examine your ability to move. This will take about 1 
hour, and will help us better understand your illness and if you have any 
symptoms or signs that might be due to prion disease. We will also review 
your medical notes to help investigate what may have caused your illness. 
 
In some instances we may offer you the opportunity to undertake a magnetic 
resonance imaging (MRI) brain scan at a brain research imaging centre for 
research purposes, if you have not already had one organised by your doctor 
as part of your standard patient care.  This scan might help identify a cause of 
your dementia.  
 
MRI is a safe and painless procedure that uses a combination of powerful 
magnets and radio waves to create detailed pictures of your brain, which are 
then reviewed by a doctor qualified in medical imaging to help us in our 
research.  
 
MRI will take approximately 30 minutes to one hour to complete. It does not 
involve any exposure to x-rays or other forms of radiation, and there is no 
evidence that the scanning poses any risk to the body. However, because not 
everyone can have an MRI scan, for example they are not always possible for 
people who have had certain types of implants fitted, we will check 
beforehand that it is perfectly safe for you to be scanned.  
 
The research team will be able to explain more about this process when you 
meet with them, so you will have the opportunity to discuss this and the 
investigation will not proceed without your agreement. 
 
2. Medical history questionnaire 
 
We would also like to ask you some questions about your past medical history 
and any family history of dementia, the answers to which will be recorded on a 
questionnaire form. This will take about 30 minutes.  The information you 
provide, together with a detailed review of your medical notes, may help us 
identify possible causes for dementia.  
 
3. Blood sample 
 
If you agree, we will also ask whether you wish to donate 2ml (just under half 
a teaspoon) of your blood, so we can study genetic influences on neurological 
conditions.  Some of your genetic material (DNA) will be extracted from the 
blood sample. This helps us to understand the different forms of prion 





disease. It may also help us identify genes that may make an illness more 
likely, sometimes when someone has other risk factors too. 
 
4. Checking how you get on in the future 
 
We would like to follow your progress on the hospital patient management 
system and will contact you on a regular basis by telephone in order to assess 
your illness and answer any questions you may have. How often we call you 
will vary from person to person according to the nature of your illness, but is 
likely to be within 1 month of joining the study and every 3 months thereafter. 
You may also contact us with questions and concerns any time you would 
like. A follow-up home visit may be suggested, with your agreement, if we feel 
a further clinical assessment or MRI scan could be helpful. 
 
5. Examination of brain tissue 
 
With all forms of dementia, the only way to be certain as to the exact cause of 
someone’s symptoms is to perform a post-mortem examination. This means 
that we therefore are inviting you to consider donating samples of your brain 
to the Edinburgh Brain & Tissue Bank when you die, to assist us in this and 
future research. More information will be provided in relation to this in a 
separate information sheet.  
 
What if we think you may have prion disease? 
 
It is very unlikely that you have prion disease, however, if prion disease is 
suspected then, with your clinician’s approval, you would be offered an 
immediate onward referral to the National CJD Research & Surveillance Unit 
(NCJDRSU) for further assessment. 
 
Will my taking part in the study be kept confidential? 
 
Yes. There are strict laws which safeguard your privacy and your identity is 
totally confidential. No identifying details will ever be made public. The 
NCJDRSU has a policy for data protection, confidentiality and information 
security and regular training is required for all staff and research partners.  
 
How will information about me be handled? 
 
The study is run by a team from the NCJDRSU working with colleagues from 
the University of Edinburgh and NHS Lothian. Information is processed by this 
team with the help of medical statistics, computing and administrative staff, 
and all staff have a professional duty of confidentiality. All information is held 
in secure, password-protected databases at NCJDRSU, the Brain Research 
Imaging Centre and Edinburgh Brain & Tissue Bank; paper records are kept 
locked up when not in use. Access to your personal information is for the 
purpose of this study only and is restricted to authorised personnel on a need-
to-know basis.   
 





To ensure that the study is being run correctly, we will ask your consent for 
responsible representatives from the Sponsors (University of Edinburgh and 
NHS Lothian) to access your medical records and data collected during the 
study, where it is relevant to you taking part in this research. The Sponsors 
are responsible for overall management of the study and providing insurance 
and indemnity.  
 
What happens to the results of my assessment and brain scan? 
 
You would not normally be told the outcome of the research investigations. 
However, for any person having a MRI scan there is the possibility that an 
abnormality may be found that was previously unknown about that could have 
an impact on your care. If this was to occur or if, as a result of the clinical 
assessment or MRI, we encounter evidence of prion disease, then we would 
discuss the findings with the local medical consultant in charge of your care 
and your GP, and either ourselves or your doctor will then discuss these 
findings with you. 
 
What gene is being tested for and why? 
 
Your genes can affect your health in different ways. Firstly, an abnormality in 
a  gene may directly cause illness or secondly, a normal variation in a gene 
may make illness more, or less, likely, in combination with other factors.  
 
We are looking at the prion protein gene and at one part in particular, called 
the  “codon-129 genotype”, which falls into the second group. We all have a 
codon-129 genotype. It does not cause prion disease, but variations in the 
codon-129 genotype, in combination with other risk factors, may make prion 
disease more likely. The codon-129 genotype also helps us identify the 
different types of illness in people who are known to have prion disease. To 
find out the  codon-129 genotype, some of your genetic material (DNA) will be 
extracted from the blood sample and tested in our laboratory.  Any remaining 
blood and genetic material will then be disposed of after the study has ended. 
Alternatively, if you agree, rather than disposing of the genetic material it can 
be stored by us for use in future genetic research into prion disease and other 
neurological conditions.  
 
What do you mean by future genetic research? 
 
Current knowledge of the genetics of neurological conditions is limited but as 
understanding increases there may be new studies that we can undertake to 
have a better understanding of these disorders. These new studies may, for 
example, involve genetic testing for individual genes or looking at all your 
genes - a process called whole genome scanning. In turn this could help 
prevent disease, develop diagnostic tests or lead to new and better 
treatments.  
 
What are the possible benefits of taking part? 
 





You may not get a direct benefit from taking part in this study, however if we 
suspect prion disease there may be the possibility of you and your family 
receiving additional care and emotional and practical support through the 
National CJD Care Package. 
 
By participating in this research you will be helping us better understand the 
symptoms of dementia, and the reasons why people may develop less 
common symptoms and how a diagnosis of prion disease can be missed. This 
may help us to learn how we can improve the detection of prion disease in 
those aged 65 and over. This has potential benefits for the diagnosis of other 
NHS patients, their management and care, and in protecting public health. 
This could in the future inform routine practice in Lothian and elsewhere. 
 
What are the possible disadvantages and risks of taking part? 
 
Our initial visit will take between two to three hours – this may seem a long 
time but it will enable us to discuss the study fully with you, and for you to ask 
any questions you may have. This also allows time for the assessment and 
review, if you agree. The process of taking of blood may be a little 
uncomfortable or leave some bruising. Some patients may find the MRI 
scanning process claustrophobic – but the radiology staff who will be running 
the scan will be watching out for this and if this happens to you, the scan 
would not have to continue.  
 
We will do our best to deal with any issues that worry you. You will also be 
given our contact details so you can speak to us at any point in the study if 
you have concerns. 
 
What happens to the samples I have donated for future research? 
 
The genetic material and samples of brain tissue will be retained indefinitely in 
a secure laboratory and used in an anonymised form for future medical 
research to benefit human health. They will then be disposed of lawfully when 
they have served this purpose. This may mean that we may work with other 
national and international research centres, sometimes including commercial 
organisations. We cannot predict every type of project but all research that we 
support is ethically approved. The samples are donated to researchers freely 
and neither you nor your relatives would benefit financially from any 
developments of this kind, even if the research results in the development of 
new treatments or diagnostic tests. 
 
We may share with researchers information we have collected as part of the 
research, but no information that could identify you personally will be made 
available to research staff and your samples will be coded so that researchers 
who analyse these samples will not know who you are. This also means that 
you will not be told your results. 
 
What happens when the study is finished? 
 





The study will run until March 2018, with the possibility of an extension if we 
need time to continue follow-up. Samples will be retained until the end of the 
study, after which arrangements will be made for the disposal of any material 
not destined for long-term storage. Tissue samples that are suspected to be 
CJD or any other prionopathy will routinely be retained in the CJD Brain and 
Tissue Bank (part of the Edinburgh Brain Bank).  
 
Information about you will be retained for a minimum of 5 years past 
completion of the last date of testing of samples for the final participant, and 
then it’s retention will be reviewed with a view to permanent disposal or long-
term archiving for future research, audit or as part of your medical record.  
 
 
Will my doctors be informed about my participation? 
 
Yes. We will contact your GP and the consultant in charge of your care to let 
them know, as a professional courtesy, that you have agreed to take part in 
this study and to request to see your medical notes. We will also discuss the 
results of our investigations with them if this is relevant to your treatment and 
care.  
 
Can I agree now and change my mind later? 
 
Yes. It is possible to withdraw from any or all parts of the study if you change 
your mind later on. The information we hold about you can be deleted to the 
minimum required for audit purposes and where relevant to your medical 
record, and will not be used in research. You can also withdraw permission for 
any samples to be tested up until the time they are tested and your sample 
will be destroyed. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should speak to a 
member of the 65+ dementia study research team who will do their best to 
answer your questions. If you wish to make a formal complaint, please contact 
the NHS Lothian Patient Experience Team by calling 0131 536 3370, or 
emailing feedback@nhslothian.scot.nhs.uk.  
 
What will happen to the results of the study? 
 
The results of the study will be written up for publication as journal articles and 
presented at national conferences and worldwide. We will also report our 
findings to the funding bodies, relevant expert panels and other stakeholders. 
Summary information will also be available through information published on 
the NCJDRSU website and we can send this to you directly if you wish. You 
will not be identifiable in any reports or published results. 
 





Who is overseeing the research? 
 
This study is lead by the NCJDRSU with oversight from an external steering 
committee and is co-sponsored by the University of Edinburgh and NHS 
Lothian. All research in the NHS is looked at by an independent group of 
people, called a Research Ethics Committee (REC). A favourable ethical 
opinion has been obtained from Scotland A REC.  
 
Thank you for taking the time to read this information leaflet. 
 
If you would like further information please contact one of the study 
team: 
 
Mrs Gemma Logan (Research Nurse) 
Dr Briony Waddell (Research Registrar) 
Dr Anna Molesworth (Principal Investigator) 
 
National CJD Research & Surveillance Unit, 
University of Edinburgh 
Centre for Clinical Brain Sciences, 





Telephone: 0131 537 1980 
Email: gemma.logan2@nhs.net 
 
Independent advice about the study is available from: 
 
Mrs Chris Lerpiniere (Research Nurse) 
Centre for Clinical Brain Sciences 
Chancellors Building 




Telephone: 07872 416010 
Email: chris.lerpiniere@nhslothian.scot.nhs.uk 
 













The prevalence of dementia in Scotland is 87,000 with 13,000 of such 
patients residing in Lothian. Approximately 97% of these patients are over the 
age of 65 years. With the ageing population, this figure is expected to rise. 
The National Institute of Clinical Excellence states that all patients with 
dementia should be diagnosed by a ‘specialist assessment service’. The 
integrated care pathway in Lothian further defines standards and states that 
all patients should be diagnosed by a ‘specialist diagnostic service’, also 
referred to as ‘memory clinics’, the vast majority of which are managed by old 
age psychiatry.  
 
With increasing age the correlation between clinical and pathological findings 
in dementia dissociate with an increasing number of patients who do not fulfil 
diagnostic criteria for syndromic diagnoses (e.g. Alzheimer’s, frontotemporal 
dementia, dementia with Lewy bodies etc). It is therefore expected that a 
number of elderly patients with dementia will be reviewed by old age 
psychiatry each year where the cause for their cognitive decline is not clear.  
 
The +65 study is seeking to answer whether there are missed cases of CJD in 
the population over the age of 65 years old. There is concern that there may 
be an under-ascertainment of cases of CJD in the older population; similar to 





other forms of dementia, the clinical utility of diagnostic criteria reduces with 
increasing age.   
 
Recruitment for this study relies on referrals from specialist memory services. 
Since initiation of this project there have been a lower than expected rate of 
referrals. One reason for this may be that original estimates of predicted 
numbers of eligible patients were inaccurate or that patients are not being 
referred. In order to answer whether cases are being missed we propose an 
audit of referrals to old age psychiatry and the syndromic classification of 
patients seen. 
 
Results from this audit could also assist service planning. There are very few 
studies reviewing the proportion of patients with dementia in the older 
population in whom diagnoses cannot be made with confidence. Accuracy of 
syndromic diagnoses allows more accurate prognostication, future care 
planning and helps to identify suitable therapeutic options, all of which are 




To determine the proportion of patients seen in old age psychiatry memory 
clinics over the age of 65 years diagnosed with dementia  
 
To review the sub-classification of dementia diagnoses  
 









The period of evaluation will be 1st April 2015 to 30th April 2016 inclusive. 
This will provide data reflecting very recent referral patterns, whilst also 
allowing for time for investigations to occur (which may increase diagnostic 
certainty of syndromic classification).  
 
We propose undertaking a review of coding data with the following information 
collected: 
1) The number of patients seen in an old age psychiatry memory clinic 
2) How many appointments were new appointments 
3) The number of patients coded with a diagnosis of dementia 
4) The number of patients where diagnosis could not be reached with 
confidence 
5) Basic demographic data will be collected on all (age and gender) 
 
Dissemination of results 
Results will be fed back to old age psychiatry / discussed at the NCJDRSU 
+65 study steering group meeting 





APPENDIX H: SURVEY OF CLINICIANS / CPNS 
Table H1: Survey of clinicians / CPNs 
Job title  
Old age psychiatry consultant  
Old age psychiatry trainee  
Community psychiatric nurse  
Consultant medicine for the elderly  
Medicine for the elderly trainee  
Consultant neurologist  









I have seen eligible 
patients for this study 
      
I know who to refer to 
this study 
      
I know how to refer to 
this study 
      
Study referral is time 
consuming 
      
The study referral 
process is easy 
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